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Chapter 1. 
General introduction 
6Breast cancer is the most common type of cancer in women globally.1 In a continuous 
process of clinical research new treatments options are evolving, leading to improved 
survival. However, each medical treatment may have its adverse effects on quality of 
life. In general, both cancer and cancer treatment can result in fatigue, reduced 
physical fitness, and emotional disturbances.2 Furthermore, in breast cancer, specific 
effects on arm and shoulder function are commonly observed, for which physical 
therapy treatment can be indicated. 
In this chapter, I will first explain my motivation to start the studies described 
in this thesis. The chapter continues with a brief summary of the epidemiology of 
breast cancer, adverse effects of medical treatment, the use of the International 
Classification of Functioning and Health (ICF) for communication between health care 
providers, the role of the physical therapist, measurement instruments available in 
physical therapy practice, and guidelines on rehabilitation and follow-up care of 
patients with breast cancer. This chapter finishes with the aim and outline of this 
thesis.  
As physical therapist, specialized in treatment of patients with breast cancer 
and lymphedema, I have observed many health problems related to swelling or 
lymphedema in the arm. Limitations in performing arm and shoulder tasks are 
common in these patients.3,4 These limitations have impact on activities in daily life 
and participation in social activities, sports, work and on quality of life.5-7 When I 
started my master thesis in 2000, little was known about the effect of physical 
therapy treatment on arm and shoulder activities. In clinical practice, I experienced 
the benefits of early detection and treatment of arm and shoulder problems, and - 
more specifically - lymphedema. I was very happy with the opportunity to participate 
in the development of the Dutch Evidence Statement on Breast Cancer, published by 
the Royal Dutch Society for Physical Therapy (KNGF) in 2011.8 This statement was the 
first step to support evidence based physical therapy treatment for patients with 
breast cancer. The statement is incorporated in the Dutch multidisciplinary guideline 
on breast cancer, as well as in the guideline on lymphedema.9,10 Based on discussions 
in the guideline development groups, I felt the need to broaden our insights in arm 
and shoulder problems in patients with breast cancer in all aspects, especially in 
relation to lymphedema.  
To support evidence-based choices in clinical decision making, knowledge of 
potential adverse effects of each medical breast cancer treatment modality on arm 
and shoulder problems is important. Insight in adverse effects - which can be related 
to specific medical treatments - in interaction with specific personal and disease-
specific risk factors, is important to inform the patient adequately, as well as to tailor 
person-centered interventions by physical therapists and other health care providers. 
There is some evidence that such tailored interventions improve quality of life.11,12 
Knowledge of normal patterns of recovery after treatment and risk factors for long-
lasting shoulder and arm problems, can help to guide care providers in treatment 
7
strategies and prevention, such as referral to a physical therapist, instructions for 
self-care, or for further diagnostic tests to rule out recurrence of cancer. Taken 
together, it is relevant to recognize patients at risk for arm and shoulder problems, 
and to indicate patients that need specific attention to prevent inadequate use or 
underuse of arm and shoulder. An important prerequisite for identifying and 
monitoring adverse effects and health problems are the use of objective, reliable and 
valid measurement instruments. 
Epidemiology 
Approximately 25% of all women diagnosed with cancer have breast cancer. Highest 
incidences of breast cancer have been reported in the developed world.1 In 
developed countries, five-years survival is over 80%. In the Netherlands, heart 
diseases and cancer are the major causes of death in women. For women, breast 
cancer ranks third as a cause for cancer mortality, directly after colorectal cancers 
and lung cancers.1 In less developed countries, breast cancer is the most common 
cause of cancer death in women.1 In 2017, in the Netherlands 14.890 patients were 
diagnosed with invasive breast cancer, of which 125 were male. Mean age at 
diagnosis is 61 years. In 2016, 3.150 women and 25 men died because of breast 
cancer.13  
Medical treatment and adverse effects 
Current treatment of breast cancer generally consists of surgery, often combined 
with radiotherapy, systemic therapies and breast reconstruction (directly or in a later 
stage).9 Literature on adverse effects of breast cancer treatment and risk factors is 
ample, although not always evaluated in relation to specific modalities of the 
treatment as a whole.3,14-18 Each treatment modality has its specific adverse effects, 
mostly occurring during or directly after treatment. Specifically with respect to arm 
and shoulder problems in studies on patients with breast cancer, reduced range of 
motion, reduced muscle strength, stiffness, numbness, tingling, pain, and 
lymphedema are frequently mentioned after surgery and radiotherapy,8,14-21 resulting 
in poorer quality of life.22 The number of patients with arm and shoulder complaints 
reduced significantly by the introduction of the sentinel node biopsy.23 Recently, in 
case of positive lymph nodes, axillary radiotherapy is more common than axillary 
lymph node dissection. The AMAROS-study showed, that the incidence of 
lymphedema was significantly less in patients treated with radiotherapy to the axilla 
compared to patients treated with axillary lymph node dissection.21 However, no 
significant differences between groups were observed on range of motion and quality 
of life.21 By introducing neo-adjuvant chemotherapy, more patients received breast-
sparing surgery and less invasive axillary treatment.9 Physical problems in arm, 
shoulder, and hand related to chemotherapy are reduced muscle strength, 
chemotherapy induced polyneuropathy, arthralgia and myalgia.24-27 It has been 
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8suggested that regimens containing anthracyclines, as the nowadays frequently used 
course with docetaxel, doxorubicin and cyclophosphamide (TAC), trigger 
lymphedema.28,29 Anti-hormonal therapy is related to arthralgia, which is more 
reported when tamoxifen was used.9,30,31 Physical problems may persist long after 
breast cancer treatment: up to 60% of women with breast cancer reported at least 
one problem three years or longer after treatment.21,32,33 
Lymphedema 
In patients with cancer, lymphedema is associated with decreased lymph-flow as a 
result of the medical treatment, especially after surgery or radiotherapy.34 Many 
diagnostic studies on lymphedema focus on swelling, but other health problems are 
also described.35,36 Prevalence of lymphedema after breast cancer treatment differs 
among studies. In two studies, prevalence of chronic or progressive lymphedema was 
reported to be between 30% and 40% , while in 15 to 22% of these patients 
lymphedema was transient.37,38 In a previous meta-analysis, 14.8 - 16.4% of the 
patients with breast cancer were reported to develop lymphedema.39 It should be 
noted that the prevalence depends on what measurent method is used. In fact, the 
prevalence increases when different measurement methods are used together, or 
when patient self-reports are used.39 Multi-morbidity may play a role in the onset of 
lymphedema.40 In patients treated with axillary lymph node dissection, prevalence of 
lymphedema is four times higher than after sentinel node biopsy only.38 Other risk 
factors for the development of lymphedema are mastectomy, higher number of 
dissected lymph nodes and higher body mass index.38 Lymphedema in the arm is a 
chronic condition and requires lifelong selfcare such as bandaging and skin care to 
prevent wounds and infection, exercise and healthy diet.10  
Classification of limitations in shoulder and arm function 
In general, patients with breast cancer need a multidisciplinary approach for their 
health problems. Ideally, all health care providers use the same language to assess 
the functioning, health and disability of patients with breast cancer. The International 
Classification of Functioning, Disability and Health (ICF) provides a uniform 
framework to describe health problems and the interaction between the different 
aspects of functioning and environmental and personal factors in a systematic way.41 
In using the ICF classification in international communication, disease-specific health 
data can be compared without language barriers. The ICF consists of two parts. The 
first part addresses functioning, and has three components: ‘body functions’, ‘body 
structures’ and ‘activities and participation’. The second part addresses 
‘environmental factors’ and ‘personal factors’. Examples of environmental factors are 
support and relationship, architectural characteristics, legal and social structures, 
climate and products, and technology. Examples of personal factors are gender, age, 
coping styles, social background, education, profession, and other factors that 
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influence how disability may be experienced by the individual. Using the ICF, a 
person’s health can be described by body functions, anatomical characteristics, 
activities and participation. Environmental and personal factors can be described as 
barriers and facilitators in functioning. See figure 1 for an overview of the ICF-
concept.41 
 Within each ICF component, categories are described. Each category consists of a 
letter and one or more numbers. The letter refers to the classification component: ‘b’ 
for body functions, ‘s’ for body structures and ‘d’ for activities and participation. Each 
letter is followed by one or more numbers, starting with the first level (the ICF 
chapter), followed by second-, third- and fourth-level specifications, when applicable. 
Environmental factors are classified with ‘e’.41
Figure 1. ICF-scheme.41 
The ICF contains over 1400 categories, which makes it difficult to use in daily practice. 
Therefore, ICF Core Sets have been developed for specific diagnostic groups. In the 
development process of the Core Sets, meaningful concepts are derived from 
literature and measurement instruments, by experts and patients. These concepts 
are coded with the ICF, thereby creating a common language. These Core Sets can be 
used in multidisciplinary assessments (Comprehensive Core Sets) or in 
monodisciplinary assessments (Brief Core Sets).42  
Role of the physical therapist on arm and shoulder function 
Physical therapy treatment plays an important role in the multidisciplinary care of 
patients with breast cancer. The role of physical therapy treatment is to reduce the 
impact of cancer and the adverse effects of medical treatment on functioning in daily 
body functions 
and structures 
(impairments) 
Activities 
(limitations) 
Participation 
(restrictions) 
environmental factors 
(positive and negative) 
personal factors 
(positive and negative) 
disease/disorder/trauma 
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life. Goals of physical therapy treatment in patients with breast cancer are related to 
monitor and treat limitations in arm and shoulder function, and to improve activities 
of daily living. Exercise improves overall quality of life in breast cancer survivors, and 
improvements of breast and arm symptoms are observed.43 Early start (5 to 7 days 
after surgery) of physical therapy treatment after axillary lymph node dissection or 
mastectomy will restore functions sooner, and minimizes the risk of development of 
lymphedema.8,10,44,45 Early detection and early treatment of lymphedema minimizes 
long-term effects of swelling and its accompanying functional problems.10 Early start 
of muscle strength training of the large muscle groups has been shown to decrease 
the risk of development of lymphedema.46 Early treatment of lymphedema results in 
less swelling, and stabilizes lymphedema within 3 months.47 Up till now, no evidence 
was found on the preventive effect of stretching of the pectoralis muscle during and 
after completion of radiotherapy prevents loss of range of motion of the shoulder.48
When differences of 7-10% in volume between both arms are detected, 
treatment of lymphedema consists of exercises and a compression sleeve. When 
differences between both arms exceed 10%, a more intensive treatment is required 
with manual lymphatic drainage and bandaging, in combination with exercises.10 
Exercises consist of improvement of range of motion, coordination and functional 
training of the shoulder and arm, and strength training of both the shoulder muscles 
and large muscle groups.10,47 When a maximum reduction of lymphedema is 
achieved, a compression sleeve is provided and the patient is encouraged to continue 
self-management with compression, skin care and daily exercises. 
Measurement instruments in physical therapy 
Arm and shoulder problems should be identified and monitored by the physical 
therapist using objective measurement instruments as well as by self-report of 
patients. The patient has to be informed about expected health problems based on 
the risk profile, and where possible be instructed to monitor and measure by herself. 
Ideally, a measurement instrument should be easy in use and cheap. A core set of 
measurement instruments for physical therapy diagnosis and treatment in patients 
with breast cancer, is advised in the Evidence Statement on Breast cancer and in the 
Dutch multidisciplinary guideline on lymphedema. See table 1 for an overview of 
recommended measurement instruments.8,10 To evaluate the impact of 
lymphedema, two questionnaires have been validated in Dutch settings: the Upper 
Limb Lymphedema questionnaire (ULL27) and the Lymph-ICF questionnaire.49,50 
These questionnaires support in broadening the scope of the physical therapist, as 
they do not only cover physical functions, but also limitations in activities of daily 
living. In lymphedema, the severity of swelling determines the choice for start of 
compression therapy, but - as a variety of health problems are mentioned in the ICF 
Core Sets of Lymphedema - the attention of the health care providers during 
diagnosis and treatment has to cover all domains of the ICF.10  
Table 1. Measurement instruments as advised in the Dutch Evidence Statement on Breast 
cancer and the Dutch multidisciplinary guideline on lymphedema.8
ICF 
code Measurement instrument 
Range of motion b710 Goniometer 
Muscle strength b730 Microfet 
Hand dynamometer 
Pain b280 NPRS/ Visual Analogue Scale 
Lymphedema b435 Tape measure 
Water volume meter 
Fatigue b455 Visual Analogue Scale 
Emotional problems 
Intimacy 
b152 
b640 Distress thermometer and problem list 
Body mass index b530 Length/weight 
Shoulder-/arm function d445 Disabilities of Arm Shoulder and Hand - DLV 
Activities d230 Patient Specific Complaints list 
Quality of life ns Upper Limb Lymphedema Questionnaire (ULL27) 
Lymph-ICF upper extremity 
DLV: Dutch Language Version; ns: not specified 
For the assessment of lymphedema, several reliable and valid instruments for the 
measurement of swelling are available. Swelling can be measured by water 
volumetry, perometry, or a tape measure. Using a tape measure, several methods 
are used, generally incorporating multiple measurement points of arm 
circumference. No clear gold standard for measurement of lymphedema has been 
established.8 Furthermore, self-measurement by the patient or caregiver has been 
described scarcely.51-53 For self-measurement of lymphedema, up to now no simple 
feasible tool is available. 
Guidelines on follow-up of patients with breast cancer 
The aim of guidelines is to assist in clinical decision making, to stimulate uniformity in 
measurement, diagnosis and treatment, and to support in choosing interventions 
through shared decision-making. In the Netherlands, evidence based 
multidisciplinary guidelines on breast cancer and lymphedema have been 
developed.9,10 In relation to health problems during and after cancer treatment, a 
guideline on oncologic rehabilitation has been published.54 Moreover, a ‘Standard 
Exercise Intervention in Oncology’ is available to advise on general exercises for non-
complex patients with cancer.55 
To support the physical therapist in clinical reasoning, the Evidence Statement 
on Breast cancer was developed.13 Goals of this statement were: 1) to describe 
physical problems in arm and shoulder function after breast cancer treatment ; 2) to 
indicate diagnostic and evaluative measurement instruments in relation to the 
identified physical problems; and 3) to provide guidance for evidence based physical 
therapy treatment. 
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Aim and research questions of this thesis 
This thesis aims to identify risk factors for decreased arm and shoulder function 
associated with each modality of the medical treatment of breast cancer patients and 
to establish the most appropriate method to measure lymphedema in these patients 
before, during and after treatment. Specific research questions per chapter of this 
thesis are:  
1) Which adverse effects are related to each specific modality of medical breast
cancer treatment and predict persistent impairments in function and
structures of the upper extremities/thorax?
2) Which concepts are mentioned within the lymphedema-specific
questionnaires? Is it possible to link these concepts to the different categories
of the ICF?
3) Which measurement instruments, described in peer-reviewed literature, are
most appropriate to recommend in physical therapy practice to measure and
monitor lymphedema?
4) Is it possible to detect lymphedema by circumference measurement at a
single measurement location in both arms?
5) Which changes in arm volume and physical functioning are observed during
adjuvant treatment with docetaxel, doxorubicin and cyclophosphamide (TAC)
in patients with breast cancer?
Outline of the thesis 
Chapter two analyses the adverse effects related to breast cancer treatment and 
predicting factors for persistent impairments in function and structures of the upper 
extremities/thorax. Most important outcome variables are reduced range of motion, 
reduced muscle strength, pain, lymphedema, and limitations in activities in daily life. 
In this study, we especially focus on the relation between each specific medical 
treatment modality  (e.g. surgery, radiotherapy or systemic therapy) and the 
outcome variables. Aim of this systematic review is to indicate patients at high risk 
for developing problems in arm and shoulder function and to provide 
recommendations for the follow-up phase.  
Chapter three explores which concepts, described in the International 
Classification of Functioning (ICF) as 1) body functions and structures, 2) activities, 3) 
participation, 4) environmental factors and 5) personal factors, are addressed within 
lymphedema-specific questionnaires. Concepts within these questionnaires are 
linked to categories of the ICF. Aim of this chapter is to get insight in health problems 
associated with lymphedema and is part of the process to develop the ICF Core Sets 
for Lymphedema. 
Chapter four describes which measurement instruments are most appropriate 
in measuring and monitoring lymphedema. Aim of the systematic review and meta-
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analysis is to indicate the most reliable measurement instrument for measuring (the 
onset of) lymphedema.  
Chapter five examines detection of lymphedema in the arm by circumference 
measurement of both arms at a single measurement location by tape measurement. 
Aim of this investigation is to determine if a single measurement point is a valid 
method to detect onset of lymphedema in the arm in patients at risk.  
Chapter six evaluates changes in arm volume and physical functioning during 
adjuvant treatment with docetaxel, doxorubicin and cyclophosphamide (TAC). Health 
problems, including onset of lymphedema, in patients before, during and one month 
after treatment with TAC are described. Aim of this prospective cohort study in 51 
patients with breast cancer is to investigate when and in which patients lymphedema 
develops, and which health problems are related to lymphedema and treatment with 
TAC. 
Chapter seven summarizes and discusses the main findings of the thesis and 
provides recommendations for future research and ends with implications for clinical 
practice in physical therapy. 
1514
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Abstract 
Background 
Breast cancer is the most common type of cancer in women in the developed world. 
As a result of breast cancer treatment, many patients suffer from serious complaints 
in their arm and shoulder, leading to limitations in activities of daily living and 
participation in work, sports and leisure activities. In this systematic literature review 
we present an overview of the adverse effects of the integrated breast cancer 
treatment related to impairment in functions and structures in the upper extremity 
and upper body and limitations in daily activities. Patients at highest risk were 
defined and protocols for monitoring can be established. 
 
Methods and findings 
We conducted a systematic literature search using the databases of PubMed, 
Embase, CINAHL and Cochrane from 2000 to October 2012, according to the PRISMA 
guidelines. Included were studies with patients with stage I-III breast cancer, treated 
with surgery and additional treatments (radiotherapy, chemotherapy and hormonal 
therapy). The following health outcomes were extracted: reduced joint mobility, 
reduced muscle strength, pain, lymphedema, and limitations in daily activities of the 
upper extremity. Outcomes were divided in within the first 12 months and >12 
months post-operatively. Patients treated with ALND are at the highest risk of 
developing impairments of the arm and shoulder. Reduced ROM and muscle 
strength, pain, lymphedema and decreased degree of activities in daily living were 
reported most frequently in relation to ALND. Lumpectomy was related to a decline 
in the level of activities of daily living. Radiotherapy and hormonal therapy were the 
main risk factors for pain. Unfortunately, due to the large variety in medical 
treatments and outcome measures, we could not perform a meta-analysis of our 
data. Conclusions: Patients treated with ALND require special attention to detect and 
consequently address impairments in the arm and shoulder. Patients with pain 
should be monitored carefully, because pain limits the degree of daily activities. 
Future research has to describe a complete overview of the medical treatment and 
analyze outcome in relation to the treatment. Utilization of uniform validated 
measurement instruments has to be encouraged. 
 
Introduction 
 
Breast cancer is the most common type of cancer in women in the developed world. 
Due to new treatment modalities, breast cancer survival has improved over time. 
However, as a result of breast cancer treatment, many patients suffer from adverse 
effects and have serious complaints in their arm and shoulder e.g. decreased joint 
mobility, muscle strength, pain and lymphedema, leading to limitations in activities of 
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daily living and participation in work, sports and leisure activities.1-3 In a prospective 
Australian study, 62% of the population still suffered from at least one impairment as 
a complication of breast cancer treatment and 27% suffered from two to four 
impairments after six years.4 Reported variability in onset and severity of upper limb 
symptoms of patients with breast cancer reported in studies is large5 and a 
systematic overview of risk factors related to medical treatment is lacking. This 
information is of direct clinical relevance, as early physical therapy intervention for 
these complaints as well as surveillance of patients at risk for developing 
impairments in daily activities reduces the need for intensive rehabilitation and the 
associated costs.6 Based on the misconception that disabilities such as decreased 
range of motion, pain and lymphedema will resolve over time without intervention, 
combined with denial of the possible benefits of physical therapy interventions, this 
has led to the inadequate monitoring of disabilities.7 To the best of our knowledge, 
this is the first systematic review with an evidence synthesis on the physical adverse 
effects of all components of breast cancer treatment, analyzed for each treatment 
modality, on impairments in the arm and shoulder, leading to limitations in activities 
that potentially warrant treatment. If the clinician is aware of the risk of adverse 
effects of the treatment, clinical reasoning regarding surveillance and the early 
detection of impairments in patients at risk can be applied in a systematic way. 
In this article, we present a systematic literature review of the adverse effects 
of breast cancer treatment in terms of development of constraints in the arm and 
shoulder in patients with stage I-III breast cancer who underwent curative treatment. 
We describe the adverse effects for treatment-induced disorders of the 
musculoskeletal system - classified by International Classification of Functioning, 
Disability and Health (ICF) domains8 - and assess the influence of pre-existing 
comorbidity. More specifically, the following key question is answered in this 
systematic review: which adverse effects related to breast cancer treatment predict 
persistent impairments in function and structures of the upper extremities/thorax, 
e.g. reduced joint mobility, reduced muscle strength, pain, lymphedema and 
limitations in daily activities?  
 
Methods 
 
Study selection criteria 
Search strategy 
We conducted a systematic literature search using the databases of PubMed, 
Embase, CINAHL and Cochrane. Published studies in English, French and German 
language were eligible for inclusion. We started with the inclusion of eligible meta-
analyses and systematic reviews, and then considered the inclusion of prognostic 
cohort studies, case-control studies and cross-sectional studies that were not 
included in published systematic reviews. To minimize bias, only studies with at least 
2120
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100 patients were included. Studies which had already been included in systematic 
reviews or meta-analyses were not analyzed separately. To allow for an adequate 
follow-up and description of late adverse effects, only studies with a follow-up period 
of at least 3 months were included. When more publications of the same study were 
published, data were extracted from the most recent publication. As we were merely 
interested in adverse effects in relation to current medical practice, studies published 
from January 2000 to October 2012 were included. The search strings are listed in 
table 1.  
 
Table 1. Search string adverse effects. 
Pubmed (((((("Breast Neoplasms"[Mesh] OR "Breast Neoplasms" OR "breast cancer")) AND 
(surgery))) AND (((((radiotherapy)) OR (((("Breast Neoplasms/drug therapy"[mesh])) OR 
("Antineoplastic Agents"[Mesh])) OR ("chemotherapy"[All Fields]))) OR ("Antineoplastic 
Agents"[Pharmacological Action])) OR (hormonal therapy)))) AND (((((((((activities)) OR 
("Activities of Daily Living"[Mesh]))) OR (range of motion)) OR (("Muscle Strength"[Mesh]) 
OR "Range of Motion, Articular"[Mesh])) OR (muscle strength)) OR (Lymphedema)) OR 
(pain)) AND (Dutch[la] OR English[la] OR German[la] OR French[la]) AND 
("2000/01/01"[PDAT] : "3000/12/31"[PDAT]) 
Cinahl TI breast cancer AND ((AB "Range of Motion" ) OR (AB "Muscle Strength”) OR (AB 
Lymph*) OR (AB “Activities of Daily Living” ) OR (AB pain)) Limiters: Published Date from: 
20000101-20121231 Language English 
Embase breast cancer.ti. AND ((activities of daily living.ab.) OR (range of motion.ab.) OR (muscle 
strength.ab.) OR (muscle strength.ab.) OR (lymphedema.ab.) OR (pain.ab.)) Limit to 
(English language and yr=“2000- 2012”) 
Cochrane Topic ‘breast cancer’  AND  ‘adverse effects’ 
 
Patients 
Studies on patients with curatively treated breast cancer (Stage I – III) were included.  
Intervention 
Included medical interventions were: surgery (mastectomy, lumpectomy, axillary 
lymph node dissection [ALND], sentinel node biopsy [SNB], and breast 
reconstruction) and additional treatments (radiotherapy, chemotherapy and 
hormonal therapy).  
Outcomes 
The following health outcomes were extracted: impairment in functions and 
structures in the upper extremity and upper body (reduced joint mobility, reduced 
muscle strength, pain, and lymphedema), and limitations in daily activities of the 
upper extremity. Outcomes had to be measured with instruments for which 
validation studies were published, or for which the authors described validation 
before initiation of the study. 
Description of adverse effects of the medical treatment was divided into 
effects within the first 12 months and late effects (> 12 months). When outcome 
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measures of severe cases were presented as well, these were presented between 
brackets in table 3. 
Quality assessment 
We evaluated the methodological quality of the included studies to test 
generalizability and possible bias. Studies were rated using the Oxford Centre for 
Evidence-Based Medicine, 2011 appraisal sheets and levels of evidence (see table 4).9 
Two authors (JH + CB) independently scored each item of the appropriate scoring 
sheet. Disagreements were discussed together or if appropriate in the research 
group. If the item was well described and its quality was good, a plus (+) was 
assigned, plus-minus (±) was assigned if the item was incompletely described, and 
minus (-) was used if the item was not clearly described or not described at all. Five 
items were used to score systematic reviews leading to a maximum score of 100% 
(see table 2). Only systematic reviews including meta-analysis could achieve a full 
score of 100%. For cohort studies, six items were scored. Since the type of surgical 
treatment may influence health outcomes, articles describing radiotherapy treatment 
not taking into account the type of surgical treatment were given no score to the 
item “Subgroups with different prognosis identified”. A full score was assigned to 
studies assessing the outcome “lymphedema” with measurements of the full arm, 
using tape measurements to calculate volume, water volumetry, perometry or bio-
impedance spectroscopy (BIS). When other methods of multiple tape measurement 
were used, plus-minus was assigned to “validated outcome” criterion. If the Common 
Terminology Criteria for Adverse Events (CTCAE) was used as a measurement 
instrument for lymphedema no score was given, because only one location was 
measured. Questionnaires on lymphedema were given plus-minus, as these 
questionnaires led to a higher incidence percentage in relation to volumetric 
measurements.10 In selecting studies with a quality score of >50% we aimed at 
reducing the risk of bias of the included studies resulting in more robust conclusions 
of our review. 
Synthesis 
First, we described detailed characteristics and the main findings of the included 
systematic reviews, RCTs, and cohort studies, as reported by the authors of the 
included studies. Second, we assessed adverse effects per impairment and activity 
limitations for each medical intervention and combination of medical interventions. 
Adverse effects were assessed for short-term impact (≤12 months follow-up) and 
long-term impact (>12 months follow-up). If a study did not identify which part of the 
treatment caused the adverse effects, the study was excluded from the analysis of 
outcome measures. Third, we assigned a level of evidence for each of the adverse 
effects related to the common harms of the medical intervention.9 We anticipated on 
using a quantitative assessment in a meta-analysis, but due to the heterogeneity of 
outcome measures, adverse effects, and (combinations of) medical treatment we 
were unable to pool data from separate studies.  
2322
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Figure 1. Flow diagram literature search adverse effects of breast cancer treatment. 
 
 
Results 
 
We identified 804 unique articles, of which 116 were eligible for full-text assessment 
(see figure 1 for a flow diagram). Of these, 54 studies were excluded because they did 
not meet the inclusion criteria. Another 23 studies were excluded because they had 
already been included in one or more systematic reviews(15) or had a quality rating 
≤50% (8). Finally, 39 articles were included. In the syntheses 13 articles could not be 
included because adverse effects were not analyzed separately for each treatment 
modality. 
Records identified through PubMed 
(n =773) 
Records identified through Embase, 
CINAHL and Cochrane 
(n = 170) 
Records after duplicates removed 
(n = 804) 
Abstracts screened 
(n = 564) 
Records excluded based 
on title 
(n = 240) 
Full-text articles assessed 
for eligibility 
(n = 141) 
Full-text articles excluded 
< 100 pts  (n = 18) 
Retrospective (n = 7) 
No match of outcome (n = 5) 
PT Intervention study (n = 2) 
Treatment before 2000 (n = 18) 
FU < 3 months (n = 1) 
Studies included in 
qualitative methodological 
assessment 
(n = 90) 
Studies included in 
qualitative and 
quantitative analysis  
(n = 39) 
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Legend table 3: 
Study design: CCT, clinical controlled trial; Cos, cohort study; CSS, cross sectional study; pts, patients; RCT, randomized controlled trial; SR, 
systematic review 
Intervention: ALND, axillary lymph node dissection; art, article; CE, cyclophosphamide, epirubicin;  CEF, cyclophosphamide, epirubicin and 
fluorouracil;  CT, chemotherapy; FU, follow up; Gy, Grey; HT, hormonal therapy; IMB, internal mammarial boost; IM-MS, internal mammary and 
medial supraclavicular lymph node chain; IORT, intra operative radiotherapy;  LRRT, locoregional radiotherapy corresponding to peri clavicular, 
axillary level 3, and for right-side breast cancers, the internal mammary nodes; LN, lymph node; M, metastasis; N, nodal status; PAB, posterior 
axillary boost; RT, radiotherapy; SC, supra scapular; SNB, sentinel node biopsy; T, docetaxel; T, tumor; TAM, tamoxifen; vs., versus; wks, weeks; 
ZOL, Zoledronic Acid 
Measurement instruments: BIS, bio impedance spectroscopy; BMI, body mass index; BSI, Brief Symptom Inventory; CPAQ, Chronic Pain 
Acceptance Questionnaire; CES-D, center for epidemiologic studies – depression scale; CTCAE, Common Terminology Criteria for Adverse Events ; 
DASH, disabilities of arm, shoulder and hand; EORTC-QLQ-C30-BR23, European organization for research and treatment of cancer – quality of life 
questionnaire- breast; FACT-G-B, functional assessment of cancer therapy – general – breast; FLIC, Functional living index – cancer; FQ, fatigue 
questionnaire; FPACQ, Flemish Physical Activity Computerized Questionnaire; GCQ, general coping questionnaire;  HADS, hospital anxiety and 
depression scale; ICD, international classification of diseases; IOC,  impact of cancer scale; KAPS, Kwan’s arm problem scale; LANSS, Leeds 
Assessment of Neuropathic Symptoms and Signs; LBCQ, lymphedema breast cancer questionnaire; LEFT-BC, Lymphedema Evaluation Following 
Treatment for Breast Cancer; LENT-SOMA, late effects normal tissue – subjective objective management analytic; Li-Sat, life satisfaction; MASS, 
measure of arm symptoms survey; MET, metabolic equivalent ; MOS, medical outcomes study; MPQ, McGill pain questionnaire; MRC-scale, 
medical research council scale; MSPQ, Modified Somatic Perception Questionnaire; NPRS, numeric pain rating scale; PAISSR, Psychological 
Adjustment to Illness Scale-Self-Report; PAQ, physical activity questionnaire; PSI-B, Problem solving inventory-brief; ROM, range of motion; SF-36, 
short form-36; SPADI, shoulder pain and disability index; ULDQ, upper limb disability questionnaire; v, version; VAS, visual analogue scale; WHR, 
Waist-Hip ratio 
Outcomes: ADL, activities in daily living; AWS, axillary web syndrome; CHF, cardiac heart failure; CTS, carpal tunnel syndrome; HR, Hazard Ratio; LE, 
lymphedema; LVEF, left ventricular ejection fraction; ns, non-significant; OR, odds ratio; MPS, myofascial pain syndrome; MSD, musculoskeletal 
disorders; PA, physical activity; PMPS, Post Mastectomy Pain Syndrome; RR, relative risk; sign, significant; *, data extracted from included studies 
 
Table 4. Oxford Centre for Evidence-Based Medicine, 2011 Levels of Evidence for common  
harms (Treatment harms). 
 
 
Methodological quality of the included studies 
The methodological quality of the included studies ranged from 60% to 90% for the 
systematic reviews, and from 58% to 100% for prognostic studies and RCTs (see table 
2). In four systematic reviews, the search strategy was limited to one database 
only.1,11,13 Results in four systematic reviews were not pooled due to the 
heterogeneity of the data.11,12,14,15 The majority of the cohort studies presented 
validated outcome measures, while seven of the 32 studies described outcome by a 
self-generated and self-validated questionnaire3,16,17 or performed incomplete 
measurements.18-21 In six studies, a description of the outcome was incomplete.22-27  
Adverse effects 
Table 3 presents a detailed overview of the results of the included studies. Six 
systematic reviews and 29 cohort studies presented analyses regarding the origin of 
Level 1 Systematic review of randomized trials, systematic review of nested case-control studies, n-of-1 
trial with the patient you are raising the question about, or observational study with dramatic 
effect   
Level 2 Individual randomized trial or (exceptionally) observational study with dramatic effect 
Level 3 Non-randomized controlled cohort/follow-up study provided there are sufficient numbers to rule 
out a common harm 
Level 4 Case-series, case-control studies or historically controlled studies 
Level 5 Mechanism-based reasoning 
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the adverse effects. Some studies analyzed the relationship of the adverse effects in 
relation to comorbidity, age or BMI.  
In most studies, different subgroups were identified based on surgical treatment. 
Four studies17,28-30 focused only on patients that underwent ALND. One systematic 
review1 and one cross-sectional study27 focused on the adverse effects of 
radiotherapy. The adverse effects of aromatase inhibitors focused on musculoskeletal 
pain.11,22,31 Zhou et al. described aromatase inhibitors in combination with zoledronic 
acids and pain.11 
Synthesis per outcome measure is summarized and presented in table 5, including 
levels of evidence. 
 
Reduction in range of motion (ROM) 
Reduced ROM was described in four systematic reviews1,12,13,15 and six cohort 
studies.19,28,32-35 General reduction in ROM was described12,15,1,28,35 or specified for 
the shoulder in different directions: abduction, or flexion/abduction and external 
rotation.32,33 
Regarding ALND as a medical intervention, one systematic review reported a 
reduction in ROM in abduction and flexion ranging from 132-175⁰, which was 
reported in 1-67% of the patients.15 Regarding SNB, a second systematic review 
described a reduction in ROM.[1] Percentages of patients with ROM reduction varied 
from 6%-31% after 12 months, and reduced to 0%-9% after 24 months. Regarding 
ALND (directly or after SNB) vs. SNB, change of ROM in the third systematic review 
was reported in 9%-56% vs. 3%-24% of the patients, or in a mean difference of 1⁰-20⁰ 
within 12 months and 8%-20% vs. 0%-4% over 12 months.13 Odds Ratios (ORs) in the 
included studies of this systematic review ranged from 1.02-9.0 for goniometric 
measurements.13 One cohort study described a reduced ROM of 21% vs. 56% at 6 
months and 6% vs. 9% at 12 months, with an OR of 1.56 at 12 months.32 Another 
cohort study reported reduced ROM at six months and > 12 months in a study 
population in which 71% underwent ALND. Reduction was present in 60% and 11% in 
flexion/abduction and 25% and 5% in external rotation.33 ROM reduction was related 
to ALND, a greater number of lymph nodes removed, cording, seroma, mastectomy, 
stage II, hand dominance, BMI ≥ 25 and older age (>65 years). 
Regarding mastectomy vs. lumpectomy, one systematic review presented an 
OR of 5.67 for mastectomy as a risk factor for reduced ROM.15 In one cohort study, 
ROM reduction was present in 33% of the study population.34 Mastectomy was 
indicated as risk factor. Regarding ALND and mastectomy vs. ALND, lumpectomy and 
radiotherapy reduced ROM was described at one, 12 and 24 months in overall 
percentages and percentages with severe reduction. Percentages reduced from 68% 
vs. 73% to 23% vs. 30%.28 
Regarding radiotherapy vs. no radiotherapy, one systematic review presented 
ORs of 2.07-12.30, a relative risk (RR) of 4.6 and reduced ROM in 34%-52% vs. 4%-
35 
 
20% of the study population in the included studies.13 One large cohort study 
presented an OR of 2.48 for radiotherapy as a risk factor for ROM reduction.32 
Regarding axillary radiotherapy vs. no axillary radiotherapy, the risk of decreased 
ROM was analyzed in two systematic reviews (RR 2.6; OR 1.67).1,15 A third systematic 
review reported changes in joint mobility in 14% vs. 2% of the patients in one 
included study; ORs in other included studies ranged from 1.70-6.83 for goniometric 
measurements. Regarding radiotherapy to the axilla and chest vs. radiotherapy to the 
chest, the same systematic review presented an RR of 1.7 in one included study and 
reduced ROM in 20%-49% vs. 4%-14% of the study population in other included 
studies.13 Regarding chemotherapy vs. no chemotherapy, one large cohort study 
reported an OR of 0.73 of chemotherapy as a risk factor for ROM reduction.32 
In synthesizing the results from the included studies, we found level 1 
evidence for mastectomy and radiotherapy to the axilla as risk factors for reduced 
ROM in abduction, flexion and external rotation, and level 2 evidence for ALND and 
radiotherapy to the chest wall.  
Reduction in muscle strength 
Reduced muscle strength was reported in four systematic reviews12,13,15,36 and five 
cohort studies.17,18,20,33,37 
Regarding ALND, one systematic review described reduced muscle strength 
(OR 3.03)15. One cohort study described reduced muscle strength in 28% of the study 
population.20 Regarding SNB, a second systematic review reported reduced muscle 
strength in 17%-19% of the patients after sentinel node biopsy and 11% in the long-
term.12 This systematic review identified patients with young age (<50 years) as a risk 
factor for muscle strength impairment based on results of one large study comparing 
ALND vs. SNB. Regarding ALND (directly or after SNB) vs. SNB, a third systematic 
review reported weakness in 48% vs. 16% of the patients, with loss of abduction 
strength of 12-15 Nm, loss of grip strength of 12-41 Nm in the included studies and 
ORs ranging from 5.14-8.82 reported in the included studies.13 
Regarding lumpectomy and ALND, one systematic review reported reduced 
muscle strength in9%-28% of the study population.15 Regarding ALND and 
mastectomy vs. ALND, lumpectomy and RT reduced muscle strength was described at 
one, 12 and 24 months.28 Percentages reduced from 67% vs. 72% to 39% vs. 56% 
reduced muscle strength. Reductions were larger in the first 12 months compared to 
later measurements (see table 5). 
Regarding chest radiotherapy vs. no radiotherapy, the risk of reduced muscle 
strength was analyzed in one systematic review.13 Extracted data from the included 
studies showed ORs from 1.70-6.83 for radiotherapy as a risk factor for reduced 
muscle strength and one included study reported reduced muscle strength in 14% vs. 
2% of the patients. Regarding axillary radiotherapy vs. radiotherapy to the chest wall, 
the risk of reduced muscle strength was analyzed in the same systematic review.13 
One included study reported an RR of 1.7; another study showed 59% vs. 40% of the 
3736
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patients with reduced muscle strength. Regarding concurrent radiotherapy and 
chemotherapy vs. sequential radiotherapy and chemotherapy, a fourth systematic 
review described the risk of reduced muscle strength by concurrent treatment with 
an OR of 2.09.36 
In synthesizing the results of the included studies, we found level 1 evidence 
for ALND, and concurrent radiotherapy and chemotherapy as risk factors for reduced 
muscle strength. We found level 2 evidence for SNB, radiotherapy to the chest wall 
and radiotherapy to the axilla and chest as risk factors for reduced muscle strength. 
Pain 
Pain was described in four systematic reviews11,12,15,36 and 10 cohort 
studies.17,22,28,31,33,35,37-40 
Regarding ALND, one systematic review15 and one cohort study38 described 
pain 12 months post-operative. This systematic review described an OR of 4.61 and 
percentages of shoulder pain (9%-68%) and breast pain (15%-72%) in the individual 
studies.35 The cohort study described pain in 53% of the population.38 Regarding SNB, 
a second systematic review reported pain in 8%-36% of the patients within 12 
months and 8%-21% at 24 months, analyzing young age (<50 years) as a predictive 
factor, described in one included study.12 Regarding ALND (directly or after SNB) vs. 
SNB, a third systematic review reported pain during motion in one included study in 
12% vs. 4% at 12 months and 9% vs. 3% at 19 months and an OR of 3.54 mentioned in 
another study.13 
Regarding ALND and mastectomy vs. ALND, lumpectomy and radiotherapy 
pain was described at 1 month post-operatively, and at 12 and at 24 months.28 Pain 
reduced from 75% vs. 82% to 42% vs. 56%. Regarding chest radiotherapy vs. no 
radiotherapy, one individual study in a systematic review reported at least weekly 
pain in 26% vs. 4% of patients (OR = 7.10), 6 to 13 years post-operatively.13 Regarding 
concurrent radiotherapy and chemotherapy vs. sequential radiotherapy and 
chemotherapy a fourth systematic review reported the risk of brachial neuropathy 
(OR 3.14).[2] Regarding chemotherapy vs. no chemotherapy, two cohort studies 
found chemotherapy to be a risk factor for pain,38 with a reported OR of 3.00.40  
Regarding the administration of zoledronic acids vs. no zoledronic acids, one 
systematic review reported the relative risk (RR) of arthralgia (RR 1.16) and bone pain 
(RR 1.26).11 Regarding the upfront administration of zoledronic acids compared to 
delayed administration, the same systematic review described an increased risk of 
pain (RR 1.28). Regarding exemestane vs. tamoxifen, one cohort study described an 
increased risk of carpal tunnel syndrome (OR 9.90).24 In this study, 43% of the 
patients had a musculoskeletal disorder and 2% carpal tunnel syndrome. Another 
cohort study described increased pain incidence by using tamoxifen at baseline and 
at younger age (< 55 years).22 
In general, pre-operative pain was a risk factor for post-operative pain (OR 
5.17) and prolonged pain.24,40 Pain was correlated with decreased muscle strength 
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and range of motion, decreased job participation, reduced use of the affected arm in 
leisure activities and with lifting a gallon of milk or during heavy household chores.33 
At 6 months, pain during daily activities was less than at rest.31,41 In contrast, one 
study reported an exacerbation of pain by exercise.40 Another study reported less 
pain during activities compared to rest at six months post-operative and more pain at 
60 months.39 Arm-shoulder pain led to sleep disturbances (OR 3.17).35 
In conclusion, we found level 1 evidence for ALND, radiotherapy before 
chemotherapy, and the administration of zoledronic acids (more in case of delayed 
administration) as risk factors for pain. We found level 2 evidence for SNB and 
radiotherapy as risk factors for pain. 
Lymphedema 
Lymphedema was described in three systematic reviews1,12,15 and 20 cohort 
studies.4,16-21,23,36-30,32,34,39,42-45 Eight studies reported subjective data based on a 
lymphedema questionnaire,16,23,26,28 CTCAE,[3, 4] telephone interview,23,26 or 
measured only 2 or 3 points of the arm.18,19 
Regarding ALND, two systematic reviews and five cohort studies described an 
increased risk of lymphedema. One systematic review described an RR of 3.47.1 A 
second systematic review described percentages of pain in the included studies 
ranging from 0%-34%.15 Percentages in the cohort studies varied from 13%-
30%.20,29,39 BMI ≥ 30 as a risk factor for lymphedema was described in one cohort 
study with an OR of 4.1244 and in another cohort study as an increase of 4.1% or HR 
of 2.61 for each lymph node removed.26 Regarding SNB, a third systematic review 
described percentages ranging from 3%-14% in the first 12 months to 7% in the 
follow-up of 60 months.12 Regarding ALND (directly or after SNB) vs. SNB, two 
systematic reviews and three cohort studies described lymphedema. One systematic 
review reported an RR of 3.07 (when compared to no axillary dissection 3.47),1 while 
another systematic review reported an OR of 11.67.15 In the cohort studies, 
percentages of patients with lymphedema varied from 3%-13% vs. 0%-9% in the first 
12 months to 14%-35% vs. 5%-8% in longer follow up.19,32,43 
Regarding mastectomy, lymphedema was described in one systematic review 
and one cohort study. The systematic review reported an RR of 3.28,1 while the 
cohort study reported an OR of 7.48.20 Regarding ALND and mastectomy vs. ALND, 
lumpectomy and radiotherapy lymphedema was described at one month post-
operatively, and at 12 and at 24 months.28 Percentages of patients with lymphedema 
increased from 27%-41% at one month to 33%-52% at 24 months post-operatively. 
Regarding breast reconstruction vs. no reconstruction, one cohort study 
described lymphedema in 5% vs. 18% of the study population.42 
Regarding radiotherapy to the chest and axilla vs. radiotherapy to the chest, two 
systematic reviews and one cohort study described lymphedema. One systematic 
review described an RR of 2.97,1 the second an OR of 2.4.12 The cohort study 
reported an OR of 3.57.17 Regarding concurrent radiotherapy and chemotherapy vs. 
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sequential radiotherapy and chemotherapy, one systematic review reported an OR of 
2.02.36 Regarding radiotherapy before chemotherapy vs. radiotherapy after 
chemotherapy, the same systematic review reported an OR of 2.11.  
Regarding chemotherapy vs. no chemotherapy, one cohort study reported a 
Hazard Ratio (HR) of 1.46.26 The risk of lymphedema in relation to chemotherapy was 
investigated in this cohort study in patients with ALND, comparing multi-agent 
chemotherapy with chemotherapy with anthracyclines. Regarding chemotherapy 
with radiotherapy vs. chemotherapy without radiotherapy, HRs in this study varied 
from 0.30-4.09 vs. 3.78-5.46. 
The overall incidence of lymphedema increased over time, except in one 
study where lymphedema decreased because of decongestive lymphatic therapy.18 
One case control study described the risk of lymphedema due to infection in patients 
with ALND (OR 3.80).30 BMI ≥ 30 as risk factor for lymphedema was described in one 
systematic review in patients with SNB as weak evidence, not providing data12 and in 
two cohort studies (OR 3.59; adjusted for ALND OR= 4.1),44 while an OR of 2.01 was 
found for BMI > 25.20 One study followed patients five years after ALND and provided 
nomograms that indicated a BMI >30 as a risk factor as well.29 The influence of age on 
the development of lymphedema was described in one systematic review and four 
cohort studies, indicating young age (<50 years)12,16,32 and age >65 years30 as risk 
factors and increasing by age in another cohort study.29 
One study reported that comorbidity led to a higher incidence of 
lymphedema.17 
We found level 1 evidence for ALND, radical mastectomy, radiotherapy to the axilla, 
concurrent radiotherapy and chemotherapy, and radiotherapy before chemotherapy 
as risk factors for lymphedema. 
Reduction in activities in daily living 
Limitations in activities in daily living were described in two SRs12,13 and eight cohort 
studies.3,17,28,33,38,41,45,46 
Regarding ALND, one cohort study reported decreased degree of daily 
activities.17 Regarding ALND vs. SNB one systematic review and one cohort study 
described an increased risk of problems in performing daily activities.3,13 ORs were 
calculated in two included studies in the systematic review (resp. 3.18 and 9.23).13 
Reported ORs for performing different tasks in one of the included studies in the 
systematic review varied from 2.13-2.34 when stratified by age, with age between 65 
and 74 years at most risk and between 40 and 54 years at least risk compared to a 
non-breast cancer population. Decline in one or more tasks was described in another 
included study (34% vs. 50%, OR 0.8). One cohort study described the avoidance of 
normal arm use in cases of ALND compared to SNB (p <0.001).3 Regarding ALND 
(directly or after SNB) vs. SNB vs. lumpectomy, one cohort study described a decline 
of activities in the first year post-operatively in 39%-44% of the patients after ALND, 
18%-19% in case of SNB and 12%-19% in case of lumpectomy.45 Regarding ALND and 
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mastectomy vs. ALND and lumpectomy, one cohort study reported more problems in 
arm and shoulder function, conducting social activities and work in the lumpectomy 
group (p < 0.001).3  
Regarding ALND and mastectomy vs. ALND, lumpectomy and radiotherapy, 
daily activities were described at 1 month post-operatively, at 12 and at 24 months in 
overall percentages and percentages with severe decline in daily activities.28 
Percentages reduced over time, with more problems in the lumpectomy group.  
Regarding chest wall radiotherapy vs. no radiotherapy, one systematic review 
reported a decline in daily activities with ORs in three individual studies (resp. 1.32, 
8.0 and 10.67) and percentages of 29% vs. 4% in another included study.13  
Regarding radiotherapy to the axilla and chest wall vs. radiotherapy to the chest 
alone, the same systematic review reported an OR of 2.64 in one included study. 
Regarding chemotherapy with cyclophosphamide, epirubicin and docetaxel vs. 
chemotherapy with cyclophosphamide, epirubicin and fluoracil, one cohort study 
described a higher risk in giving up daily activities (OR 1.59).38  Overall, 34% of the 
population in this study showed a decline in the level of daily activities. 
One cross-sectional study described a decline in activities in 31% of the 
population.34  
One cohort study related radiotherapy to later starting remunerable work.41 
Activity level did not return to the pre-operative level within one year,46 and at 10 
months, 83% of the patients returned to work.41 Young age as a predictive factor for 
a reduced number of metabolic equivalents was described in one cohort study.46  
Another cohort study described reduced use of the affected arm in leisure 
activities and with lifting a gallon of milk or during heavy household chores in relation 
to pain and feeling weak.33 Comorbidity was related to a decreased level of activities 
in daily living.17 
We found level 2 evidence for ALND and radiotherapy, especially when the 
axilla was involved, as risk factors for decreasing the degree of daily activities. 
 
Table 5. Adverse treatment effects in relation to impairments in upper extremities and 
thorax. 
Medical 
intervention 
≤12 months post-
surgery 
>12 months post-surgery  Level of 
evidence 
 %/p value/OR OR/RR/HR %/p-value 
Range of motion 
 1% – 67%15  p=0.000119 level 2 
 At 12 months: 
6%-31%%12 
 At 24 months:0%-9%12 level 3 
ΪǤ 
 
At 12 months:  
24% vs. 24% 
9% vs. 3%13*  
At 6 months: 
56% vs. 21% 
At 12 months: 
 9% vs. 6%                         
OR=1.5632 
OR=1.02/2.65/9.013* At 18 months: 8% vs.  4% 
At > 20 months: 20% vs. 
0%  
At median 30 months 
11% vs. 4%13* 
level 2 
ǦΪ
Ǥ
ǦΪ
Ϊ 
At 1 month:68% vs. 
73% 
At 12 months:32% vs. 
40%28 
 
 At 24 months:23% vs. 
30%28 
 
level 3 
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Table 5 continued. 
Medical 
intervention
≤12 months post-
surgery 
>12 months post-surgery  Level of 
evidence 
 %/p value/OR OR/RR/HR %/p-value  
Ǥ
 
 OR=2.07/6.60/12.3013* 
RR=4.613 
OR=2.4832 
34% vs. 20% 
38% vs. 4% 
52% vs. 15%13* 
level 2 
Ǥ  RR=2.6 (CI=1.42-4.03)1 
OR=1.67 (CI=0.98-2.86)15 
OR=2.4835 
 
 
 
level 1 
Ϊ
Ǥ
 
 OR=2.64/3.3713* 20% vs. 4% 
Flexion 39% vs. 4%; 24% 
vs. 5% 
Abduction 49% vs. 8%; 
35% vs. 7% 
External rotation 45% vs. 
14%; 41% vs. 13%13* 
level 2 
Ǥ  OR=0.73, p=0.00332  level 3 
Reduction in muscle strength 
     
  OR=3.03 (CI=1.25-7.32)15 28%20 level 1 
 17-19%12  At 24 months: 11%12 level 2 
ΪǤ 36%  vs. 8%13 OR=8.8213 48% vs. 16% 13 level 2 
Ϊ
 
9%-28%15  OR=4.61 level 1 
ǦΪ
Ǥ
ǦΪ
Ϊ 
At 1 month: 
67% vs. 72% 
At 12 months: 
48% vs. 51%28 
 At 24 months: 39% vs. 
56%28 
 
level 3 
Ǥ
 
 OR=1.70/3.37/ 6.8313* 14%  vs. 2%13 level 2 
ΪǤ
 
 RR=1.713 59%  vs. 40%13 level 2 
Ϊ
Ǥ 
 OR=2.09 (CI=0.92-4.75)36  level 1 
Pain 
  OR=4.61 (CI=2.01-10.59)15 Shoulder pain 9%-68%15 
Breast pain 15%-72%14 
53%37 
level 1 
 8 – 36%12  At 24 months:8-21% 
At 60 months: SNB 9%12 
level 2 
ΪǤ At 12 months:  
12% vs. 4%13 
OR=3.54 (1.88-6.66)13 At 18 months: 9% vs. 
3%13 
level 2 
ǦΪ
Ǥ
Ǧ
ΪΪ 
At 1 month:  
75% vs. 82% 
At 12 months:  
60% vs. 63%28 
 At 24 months: 42% vs. 
56%28 
 
level 3 
Ǥ  OR=7.1013 At 6-13 years: weekly 
pain 26% vs. 4%13 
level 2 
Ǥ
 
 Brachial neuropathy: 
OR=3.14 (CI=0.12-79.39)36 
 level 1 
Ǥ  OR=3.00 (CI=1.22-7.40)40  level 3 
Ǥ 
 
 
 Arthralgia: 
RR=1.16 (CI=1.096-1.232) 
Bone pain: 
RR=1.26 (CI=1.149-1.376)11 
 level 1 
Ǥ
 
 Bone pain: 
RR=1.28 (CI=1.135-1.453)11 
 level 1 
Ǥ
 
 OR=9.90  (CI = 3.52-27.82) for CTS24  level 3 

Ǣ
ȋȀ
Ȍ 
  Age <55 vs. 55-65 vs. >65 
yrs:  
Arthralgia 46% vs. 37% 
vs. 28%23 
CTS 2% 
MSD 43%24 
level 3 
Lymphedema 
  RR=3.471 
BMI > 30: OR=4.12 (CI=1.58-10.72)43 
0% - 34%15 
25%20 
each LN removed 4.1% 
↑26 
HR=2.61(CI=1.77-3.84)26 
At 60 months: 30%33 
13%39 
 
 
level 1 
41 
 
Table 5 continued. 
Medical 
intervention
≤12 months post-
surgery 
>12 months post-surgery  Level of 
evidence 
 %/p value/OR OR/RR/HR %/p-value  
 At 6 months: 3-10% 
At 12 months: 6-
14%12 
 7%12 level 2 
 %/p value/OR OR/RR/HR %/p-value  
ΪǤ 13% vs. 9%35 
3% vs. 0%44 
RR=3.07 (no ALND 3.47)1 
OR=11.67 (CI=1.45-93.65)15 
OR=6.61(CI=1.64-26.57)18 
35% vs. 5%19 
14% vs. 8%32 
 
level 1 
  Radical mastectomy vs. other 
mastectomy RR=3.281 
Modified radical mastectomy OR=7.48 
(CI=2.38-23.85)20 
 level 1  
 
level 3  
ǦΪ
Ǥ
ǦΪ
Ϊ 
At 1 month:27% vs. 
41% 
At 12 months:26% vs. 
48%28 
 At 24 months: 33% vs. 
52%28 
 
level 3 
Ǥ
 
  5% vs. 18%42 level 4 
Ǥ
 
 RR=2.971 
OR=2.412 
OR=3.5717 
 level 1 
Ǥ

 
 OR= 2.02 (CI=0.18- 22.61)36  level 1 
Ǥ
 
 OR=2.11 (CI=0.67-7.21)35  level 1 
Ǥ  HR=1.46 (CI= 1.04-2.04)26  level 3 
Reduction in level of activities in daily living 
Ǥ ↓arm use: p<0.0013 OR=3.18/9.2313*  level 2 
Ϊ
ǤΪ
 
shoulder/arm 
function, social and 
work activities: 
p=0.0013 
  level 3 
ΪǤ
Ǥ 
At 3 months:39% vs. 
18% vs. 12% 
At 6 months:40%  vs. 
12% vs. not described  
At 12 months: 44% 
vs. 19% vs. 18%46 
 Pain during activities vs. 
at rest: 36% vs. 30%40 
Daily activities↓, lifting 
objects↓ 25-35%; 
problems with transport-
tation 14%; gave up 
hobbies or sports 37%17 
level 2 
 
ǦΪ
Ǥ
Ǧ
ΪΪ 
At 1 month: 
Lifting↓ 83% vs. 88% 
Household chores 
61% vs. 64% 
Self-care↓ 56% vs. 
63% 
Physical activities↓ 
73% vs. 76% 
At 12 months: 
Lifting↓ 34% vs. 39% 
Household chores↓ 
28 vs. 33% 
Self-care↓ 16% vs. 
12% 
Physical activities↓ 
41% vs. 39%28 
 At 24 months: 
Lifting↓ 20% vs. 39% 
Household chores↓ 18% 
vs. 21% 
Self-care↓ 10% vs. 14% 
Physical activities: 34% 
vs. 31%28 
 
level 3 
Ǥ
 
 OR=1.3213 29 vs. 4%13 level 2 
Ϊ
Ǥ
 
 OR=2.64/4.6713*  level 2 
Ϊ	 34%39   level 3 
 
Intervention: ALND, axillary lymph node dissection; CEF, cyclophosphamide, epirubicin and fluorouracil; CE+T, cyclophosphamide, 
epirubicin + docetaxel; CT, chemotherapy; HT, hormonal therapy; LN, lymph node; MRM, modified radical mastectomy; RM, radical 
mastectomy; RT, radiotherapy; SC, supraclavicular; SNB, sentinel node biopsy; vs., versus 
Outcomes: CTS, carpal tunnel syndrome; HR, hazard ratio; MSD, musculoskeletal disorder OR, odds ratio; RR, relative risk; ZOL, 
zoledronic acids; *, data extracted from included studies 
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Discussion 
 
In this systematic review, we showed that breast cancer treatment results in multiple 
impairments in the arm and shoulder. We analyzed adverse effects for different 
components of breast cancer treatment and related these to the integrated 
treatment of breast cancer. Previous systematic reviews, as well as a part of the 
cohort studies included in this study, merely focused on only a part of the medical 
treatment and/or outcome measurements, while others only looked at a general 
level, without distinction between components. By distinguishing between each 
treatment modality and outcome measurement, we are the first to analyze the risk of 
each component of breast cancer treatment. We showed that patients treated with 
ALND are at the highest risk of developing impairments of the arm and shoulder. 
Reduced ROM and muscle strength, pain, lymphedema and decreased degree of 
activities in daily living were reported most frequently in relation to ALND. 
Lumpectomy was related to a decline in the level of activities of daily living. 
Radiotherapy and hormonal therapy were the main risk factors for pain. 
An integrated approach in assessing the adverse effects of distinct breast cancer 
treatment modalities on impairments in arm and shoulder function is of clinical 
importance. Recovery from adverse effects can be addressed in multidisciplinary 
treatment of patients; for example, physical therapy may be suitable for the recovery 
of ROM, muscle strength, lymphedema and daily activities. In general, we expect that 
awareness and timely referral are very relevant for patients with impairments 
interfering with daily activities in early recovery.47 More attention should be paid to 
scapular coordination and muscle strength in the early post-operative phase, as these 
impairments were reported even up to six years post-operatively.12,13,15,37 We noticed 
that the included studies focused more on impairments in function than on activities 
of daily living or participation in remunerable work, hobbies and social activities. In 
future research, more awareness of these issues is warranted, as performing 
activities is an important outcome for quality of life. This will further build the body of 
knowledge for regaining full recovery of activities of patients with breast cancer in a 
multidisciplinary approach. 
Unfortunately, due to the large variety in medical treatments and outcome 
measures, we could not perform a meta-analysis of our data. This emphasizes the 
importance of uniform description of treatment, analysis of outcomes, and use of 
uniform measurement instruments. Validated measurement instruments are 
important in assessing outcomes of treatments. We found a large variability of 
instruments, which made it difficult to compare studies and conduct a meta-analysis. 
This conclusion was also stated by authors of several included systematic reviews in 
our study.12,13,15 International consensus regarding measurement instruments and 
the way of using them should be encouraged. 
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From our review it became clear that reduced ROM, pain and lymphedema 
are the most commonly described impairments. ROM decreased, especially in the 
first month post-operatively. As most systematic reviews presented data only for 
long-term follow-up after treatment, reductions in the first month were less noticed, 
but when described in cohort studies significance existed. After 12 months, 
percentages of patients with reduction in ROM and differences in ROM between the 
affected and unaffected shoulder were reduced but still existed. Wide variation of 
percentages shows the variability in defining ROM impairment and the way of 
measurement. 
The incidence of lymphedema increased over time. One study reported a very 
high incidence of lymphedema after one month.28 This may be due to real 
lymphedema or rather seroma or radiotherapy-induced breast infection.48 
The study of Ozcinar et al.18 showed that treatment of lymphedema 
decreased its severity. In general, the reported percentages of patients with 
lymphedema were higher when lymphedema was measured by a questionnaire. The 
Norman questionnaire appeared to be sensitive for detection, but not specific,10 and 
may be used as an initial tool in detecting lymphedema. Volume is the most 
important outcome for lymphedema diagnosis and treatment evaluation; therefore, 
the questionnaire should be followed by tape measurement (calculated to volume) or 
water volumetry or perometry. Arm volume is also associated with Body Mass Index 
and body composition. Therefore, we advocate to use percentage difference 
between arms  (where A is the affected arm and U is the unaffected arm)  
 
 
or to use the formula for relative volume change (RVC) to determine outcome over 
time. 
 
Activities in daily living and participation are important parameters for quality of life. 
Limitation in body functions and structures may be restrictive in performing activities 
and participating in social events. Only one systematic review13 and six cohort 
studies3,17,28,38,41,46 described limitations in activities and only three cohort studies 
described problems in participation. As half of the patients with breast cancer were 
of working age, more attention should be paid to daily activities, work capacity, 
hobbies and sports. 
Several limitations to our study should be noted. Our cut-off point with a 
quality score >50% is to some extent arbitrary and may have resulted in the exclusion 
of valuable data in our analysis. Main reasons for the low-quality scores of excluded 
studies were issues with subgroup analysis, lack of outcome measures, poor 
presentation of results and lack of sufficient follow-up. Firstly, we analyzed which 
articles in our search were included in the systematic reviews. Four systematic 
reviews were excluded: based on treatment before 2000 or with low quality score. 
RVC = (A2/U2)/(A1/U1) - 1 
 
((A-U)/U) x 100 
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The review with low quality score was narrative and based on retrospective data. We 
therefore think the exclusion of these studies has avoided bias and contribute to the 
robustness of our conclusions. Based on the homogeneity of the results our choice 
seems to be justified. Another point is that, instead of relying on the review 
synthesis, it would have been a possibility to use existing reviews as sources to 
identify primary data, which would increase the value of the paper. We choose to 
follow the recommendations according the Oxford Centre of Evidence-Based 
Medicine. In this system systematic reviews are one of the factors in evidence 
classification. If it would have been possible to perform a meta-analysis the original 
data would have been extracted from the reviews. However, as described, this was 
not possible. We deemed additional analysis not to be of added value for the purpose 
of our paper. Therefore, we used quality scores to test the credibility of the 
conclusions of the original authors and used these in the synthesis. Adverse effects of 
radiotherapy that may influence limitations in arm and shoulder function, such as 
fibrosis of the skin and sub cutis, were not included in our study. In addition, adverse 
effects of chemotherapy and target therapy on general cardiopulmonary capacity 
were not included. Other reported symptoms such as sleep disturbances, weight 
gain, cardiac function and sensory disturbances have not been reported, as have 
anxiety and depression, while these problems may influence the capacity of 
performing daily activities.  
 
Conclusion 
 
Patients with breast cancer suffer from constraints in arm and shoulder in the first 
year post-operative and at long-term follow-up. Patients treated with ALND are most 
at risk for developing impairments of the arm and shoulder. Reduced ROM and 
muscle strength, pain, lymphedema and decreased degree of activities in daily living 
were reported most frequently in relation to ALND. Lumpectomy was related to a 
decline in the level of activities of daily living. Radiotherapy and hormonal therapy 
were the main risk factors for pain. 
An integrated approach in addressing the adverse effects of distinct breast 
cancer treatment modalities on impairments in arm and shoulder function is of 
clinical relevance. Patients treated with ALND require special attention to detect and 
consequently address impairments in the arm and shoulder. Patients with pain 
should be monitored carefully, because pain limits the degree of daily activities. 
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Abbreviations 
ALND = Axillary Lymph Node Dissection 
HR = Hazard Ratio 
OR = Odds Ratio 
SNB = Sentinel Node Biopsy 
RR = Relative Risk 
CB = Carien Beurskens 
JH = Janine Hidding 
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Abstract 
 
Purpose 
To identify and quantify the meaningful concepts within questionnaires focusing on 
lymphedema using the International Classification of Functioning, Disability and 
Health (ICF). 
Methods 
Electronic searches of Medline, EMBASE, CINAHL, CENtral and Pedro (2005–2010) 
were conducted. The concepts in the questionnaires were retrieved from the 
included studies and linked to the ICF. 
Results 
Of the 2381 abstracts retrieved, 136 studies were included. The study population 
suffered from lymphedema in the upper limb (65%), in the lower limb (25%), in the 
midline (3%) and in combinations of these areas (7%). In total, 12 lymphedema-
specific questionnaires were found (nine  for the upper limb,  two for the  lower limb 
and one  for lymphedema in general). A total of 301 concepts were extracted from 
the questionnaires, of which 271 (90%) could be linked to the ICF. There were 45 
two-level ICF categories linked to concepts in ≥ 2 questionnaires; 13 in Body 
Functions, 6 in Body Structures, 16 in Activities and Participation and 10 in 
Environmental Factors. The most frequently measured categories were ‘‘Structure of 
upper extremity’’, ‘‘Immunological system functions’’, ‘‘Looking after one’s health’’, 
‘‘Sensation of pain’’, ‘‘Touch functions’’, ‘‘Dressing’’ and ‘‘Health services, systems 
and policies’’. 
Conclusion 
The ICF provides a valuable reference to identify concepts in questionnaires focusing 
on individuals with lymphedema 
 
 
Introduction 
 
Lymphedema is a chronic condition resulting in an abnormal accumulation of 
extracellular fluids as a result of disturbed lymphatic flow, primarily in the 
subcutaneous tissues and subfascial compartments. In lymphedema, the transport 
capacity of the lymphatic system is compromised because of less activity or less 
capacity of the lymphatic vessels or obstruction of the lymphatic system.1 
Lymphedema can occur in both upper and lower limbs and in the midline (head, 
neck, abdomen and thorax). 
The precise epidemiology of lymphedema is unknown because it is not a 
regularly registered disease. The number of lymphedema patients worldwide  is 
estimated  to be approximately  140–250 million.2 
Lymphedema is divided into primary lymphedema and secondary 
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lymphedema. Primary lymphedema is inherited as it is caused by gene mutations and 
starts at adolescence, or sometimes earlier, and affects mainly the foot and calf. 
Some congenital types are already visible at birth (Milroy’s disease). Secondary 
lymphedema is acquired as a result of an injury or infection of the lymph system. In 
the Western world, 80% of lymphedema cases are acquired after cancer treatment as 
a result of the removal of lymph nodes (mostly in the axilla or groin) and/ or 
radiotherapy.3 In the developing world, parasites (filariasis) are responsible for 
millions of patients with lymphedema.4 
Lymphedema after cancer treatment 
Williams et al.3 stated that the incidence of lymphedema is 30% after axillary lymph 
node dissection. Norman et al.5 reported a cumulative incidence of subject-reported 
lymphedema 5 years after axillary lymph node dissection in 50% of patients younger 
than 50 years, in 40% of patients between 50 and 70 years and in 26% of patients 
older than 80 years. Eighty percent of lymphedema patients developed the condition 
in the first 2 years after the operation. Lee et al.6 described factors, such as higher 
age, post-operative wound infections (or later infections on the operated side) and 
obesity as cumulative risk factors  for lymphedema after axillary node dissection. 
Obesity as a risk factor for developing lymphedema was described by several 
authors.7-14 
Cormier et al.15 described an overall incidence of lymphedema of 15.5% after 
cancer treatment beyond breast cancer,  16%  after  cancer  treatment  for  
melanoma,  20%  after cancer treatment for gynaecological cancer, 10% after cancer 
treatment for genitourinary cancer, 4% after cancer treatment for head/neck cancer 
and 30% after cancer treatment for sarcoma. Increased lymphedema risk was 
described for pelvic dissections (22%) and radiation therapy (31%). Incidence 
reporting has increased using objective measurement  methods and longer follow-up. 
Lymphatic filariasis 
According to a WHO report, ~120 million people in 72 countries were infected with 
lymphatic  filariasis  in  2010,  of  which 15 million people suffered from the 
stigmatizing and disabling manifestations of lymphedema (elephantiasis).4 
Symptoms of lymphedema 
Initially lymphedema is non-pitting and the affected skin feels soft. In later stages, the 
skin may feel hard and thickened as a result of fat deposits and fibrosis in the swollen 
area. In severe, long-lasting lymphedema, skin changes are visible as keratosis. 
Lymphedema results in many symptoms such as decreased mobility of the limb,5 
slower wound healing, increased risk for infection, feelings of heaviness and 
tightness, discomfort and tight fitting of jewelry or clothes on the affected body 
parts.6-8 It leads to impairments such as limited walking distance in leg lymphedema 
and to limitations in personal care, domestic life, occupation and socialization. 
Lymphedema is a chronic condition and its limitation on physical functioning can 
result in distress9 and loss of quality of life. Generally, the activity level of 
5352
52 
 
lymphedema patients is lower compared with healthy persons of the same age.  
Altered body shape and the necessity of daily use of special garments  or  
bandaging  as  a  standard  treatment  for  stabilized lymphedema make acceptance 
of lymphedema difficult for the patient and for his family. 
Treatment and health classifications 
Lymphedema requires lifelong skin care and precautions to minimize (recurrent) 
swelling. Patients are advised to practice certain regimens, such as daily bandaging or 
the use of special garments, skin care and caution with open wounds. 
Today medical treatment of patients with lymphedema is primarily aimed at 
reducing volume, but treatment should most likely be aimed at other problems as 
well. An important basis for the optimal treatment and management of lymphedema 
is an in-depth understanding, systematic consideration and sound measurement of 
its consequences at different levels of a person’s functioning.  To achieve this  goal, it 
is necessary to develop a comprehensive framework and classification which can 
serve as a universal language, understood by health professionals, researchers, policy 
makers, patients and patient organizations. The International Classification of 
Functioning, Disability and Health (ICF)10 is a widely used classification system in 
which terms and classes are designed to describe functioning, disability and health in 
people with health disorders. The terms and classes in the ICF consist of both 
descriptions and codes. Descriptions are culturally tuned and provided in many 
languages. The pertinent codes (letters and numbers) are identical world- wide. The 
ICF terms can be understood by health professionals, researchers, policy makers, 
patients and patient organizations. The International Society for Lymphology  (ISL)  
mentioned the importance of the use of the ICF in their latest revision of 
lymphedema consensus document (2009).11 
The ICF contains two parts. Part 1 describes Functioning and Disability and 
includes three components: Body Functions, Body Structures and Activities and 
Participation. Part 2 addresses Contextual Factors and includes two components: 
Environmental Factors and Personal Factors. However, ‘‘Personal Factors’’ is not 
elaborated as a classification in the ICF because of the large social and cultural variety 
associated with these factors.10 
With the ICF codes, linkage among data across conditions or interventions is 
possible as a necessary step in the development of efficient, transparent and cost-
effective health care.12 Although the ICF classification system with more than 1400 
categories can serve as a reference, the ICF is not easily applicable in clinical practice. 
Therefore, tools such as ICF Core Sets (health-specific selections of ICF categories)13 
are helpful to make the ICF more appealing for the implementation in medical/allied 
health care.14 Health-specific Core Sets choose the appropriate terms and classes to 
describe the functioning of the patient and make the formulation of treatment goals 
easier, faster and more transparent. Therefore, these data are also appropriate for 
use in electronic health records. Core Sets are available to all types of health care 
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providers, researchers,  health insurance  companies and  policy makers. Once a Core 
Set is developed, one can select measurement instruments for each code (or 
combination of codes), thereby creating a basic set of measurement instruments as 
well. To date, ICF Core Sets have been developed for various burdensome chronic 
conditions,12,15,16 such as stroke, multiple sclerosis and breast cancer. Core Sets have 
also been developed for an acute hospital and early post-acute rehabilitation 
facilities.7,8,10-20 ICF Core Sets for lymphedema are not yet developed. 
Stucki et al.13 have composed a standard method to develop ICF Core Sets. 
The development of ICF Core Sets for lymphedema will follow this method. The 
method consists of the following component studies: (a) a literature review: a search 
for meaningful concepts (i.e. a unit of text that conveys a single theme21) in the 
literature regarding the outcomes used in clinical trials, qualitative research and 
selected observational studies, representing the researchers’ perspective; (b) focus 
groups of patients with lymphedema (patients’ perspective); (c) an expert survey on 
the outcomes gathered in studies (a) and (b) using the Delphi technique (perspectives 
of various relevant groups); and (d) an empirical, cross-sectional study to gather 
concepts that are named in clinical situations (health care providers’ perspectives). 
The final composition of the ICF Core Sets for lymphedema will take place at an ICF 
Core Set Consensus Conference (study e), which will integrate evidence from the 
previous studies (a–d). The development of ICF Core Sets on lymphedema (a–e) will 
be carried out in ~ 3 years.  
This article represents the researchers’ view (study a). The literature will be 
systematically searched for meaningful concepts, especially   meaningful   concepts   
within   lymphedema-specific questionnaires. An analysis of meaningful concepts 
within the text of published studies (also part of study a) will be published separately. 
Objectives 
The objectives of the literature review are as follows: (1) to identify questionnaires in 
studies focusing on patients with lymphedema and (2) to link meaningful concepts 
within these questionnaires to the ICF. 
 
Methods 
 
Search strategy 
Electronic searches were carried out in CINAHL, EMBASE, Medline, CENtral and 
Pedro databases from 2005 to 2010 using the search terms lymphedema, 
elephantiasis, lymphatic edema, lymphostatic edema and Milroy’s disease (the 
detailed search strategy is available upon request). The target population in the 
included studies was patients who were 18 years or older and had a clinical diagnosis 
of lymphedema. Studies with one of the following designs were included: (1) 
randomized clinical trials, (2) controlled clinical trials, (3) observational studies, i.e. 
cohort studies  and  cross-sectional  studies,  (4)  guidelines,  and  (5) qualitative 
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studies. The publication language was English. If a study was described in a 
number of publications, only the publication in the journal with the highest impact 
factor was included. The exclusion criteria for the studies were as follows: (1) 
studies with exclusively laboratory parameters, (2) genetic studies, (3) animal 
experiments, (4) letters, (5) comments, (6) editorials, (7) systematic reviews, (8) 
case reports, and (9) meta- analyses. 
Data collection procedure 
In the first step, the abstracts of the retrieved studies were checked for the inclusion 
criteria. For the selected abstracts, the whole publication was studied, and a 
decision was made as to which of the publications should be included in the study. 
In the second step, measurement methods, including questionnaires, were 
identified. In the third step, meaningful concepts were extracted from the selected 
questionnaires. The identification of meaningful concepts was performed separately 
by two researchers (PV and JH) who are trained in this type of identification before 
the research, using the first specific rule for health-status measures of Cieza et 
al.13 (‘‘Before starting the process of linking health-status measures to the ICF 
categories, identify all meaningful concepts within each item of the health status 
measure under consideration.’’). The concepts should be focused only on patients 
themselves and their surroundings. Examples of therapies mentioned were not 
included. In the fourth step, the meaningful concepts were linked to ICF categories 
using rule 2 (‘‘Each meaningful concept is linked to the most precise ICF category’’) 
of Cieza et al.22,23 
Coding principles 
Coding was performed until the fourth level of the ICF. Each defined 
class/category/code was used only once for each questionnaire (e.g. pain has been 
marked as a meaningful concept; when pain in the foot and pain in the leg were 
described in the same questionnaire, only one single ICF code (b28015: pain in lower 
limb) was registered).  
If a meaningful concept pertained to a personal factor, such as ‘‘age’’, ‘‘sex’’ 
and ‘‘education’’, the concept was coded as ‘‘pf’’ because various personal factors 
are only named as examples but are not yet properly classified within the ICF. If a 
concept described an aspect of functioning and health that is not covered by the 
ICF, such as ‘‘taking up time’’ and ‘‘suffered’’, the code ‘‘nc’’ (not covered) was 
attributed. If a concept pertained to health conditions, such as ‘‘lymphedema’’ and 
‘‘breast cancer’’, which are not included in the ICF, the code ‘‘hc’’ (health condition) 
was attributed. When the concept was related to ‘‘quality of life’’, the code ‘‘nd-
qol’’ (not definable – quality of life) was given. 
Inter-coder agreement 
The following steps of the study were performed by two researchers (PV and JH) 
independently: (1) eligibility check of the abstracts, (2) extraction of the 
meaningful concepts of all selected  questionnaires, (3) specification of the concepts 
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and (4) linking of the concepts to the ICF. After steps 1 and 2, both researchers 
compared their results. Initial  disagreement was resolved after the discussion. If 
any disagreement remained, a third person (YH or DVR) was consulted. After steps 
2, 3 and 4 (taken together), the inter-coder agreement was quantified by calculating 
the kappa with its 95% confidence interval (CI). Calculations were performed with 
the statistical software package SPSS, version 19.0 (IBM SPSS, Armonk, NY). This 
was performed for all the questionnaires. After the kappa calculations, 
disagreement (first on extraction/specification of concepts, second on proper ICF 
code) was also resolved together or by a third person. These steps together 
provided the final codes of the meaningful concepts that are presented in this study. 
Data analysis 
Frequencies of the linked ICF categories are reported when measured in more than 
two questionnaires. If a concept was linked to a third or fourth level ICF category, the 
corresponding second- level category is reported in this article to avoid long lists of 
ICF categories. This is appropriate because the lower level categories share the 
attributes of the higher level categories.10 
 
Results 
 
From the 2381 abstracts retrieved, 149 studies were selected based on the 
inclusion and exclusion criteria. Reading of the publications occurred in 
alphabetical order based on the name of the first author. After the full-text articles 
were read, an additional 13 studies were excluded because they did not fit into the 
inclusion criteria (e.g. being  comments, case reports or not primarily focusing on 
lymphedema), which was not evident from the abstracts. In the remaining 136 
studies, 88 (65%) of the study population consisted of patients with lymphedema in 
the upper limb, 34 (25%) of the study population consisted of patients with 
lymphedema in the lower limb, 5 (3%) of the study population consisted of 
patients with midline lymphedema and 9 (7%) of the study population consisted of 
patients who had lymphedema in combinations of locations. The included studies 
consisted of 46 intervention studies (n = 40 for upper limb; n = 4 for lower limb; n = 1 
for midline; n = 1 for combinations), 67 observational studies (n = 43 for upper limb; 
n = 16 for lower limb; n = 4 for midline; n = 4 for combinations), 19 qualitative studies 
(n = 4 for upper limb; n = 12 for lower limb; n = 3 for combinations) and there were 4 
clinimetric studies (n = 1 for upper limb; n = 2 for lower limb; n = 1 for combinations). 
The measurement methods described and used in the 136 studies are listed in 
Table 1. The next step was to filter out the questionnaires that were  used (Table 2). 
Finally, only the lymphedema-specific questionnaires were selected (Table 3).6,7,9,24-32 
 In total, 12 lymphedema-specific questionnaires were found (10 for the 
upper limb, 1 for the lower limb and 1 for lymphedema in general). From these 
questionnaires, all meaningful concepts were determined and linked to the ICF. 
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Table 1. Measurement methods used in the 136 studies. 
Questionnaire 114 
Circumferential measurement 49 
BMI 28 
Water displacement device 23 
VAS 17 
Bio impedance 12 
Perometer 9 
Goniometry 9 
Lymphoscintigraphy 7 
Palpation 4 
Sonography 4 
Tonometry 3 
Blood samples 3 
Grip strength 3 
Diary 2 
Water composition 2 
Duplex Ultrasound 2 
3D Measuring 1 
MRC 1 
Optoelectronic system 1 
Lymphangiography 1 
Plethysmography 1 
Functional Tests 1 
Electrical Impedance 
Spectrography 
1 
Magnetic Resonance Imaging 1 
Computer Tomography 1 
1 RM test 1 
 
 
Table 2. Questionnaires used in the 136 studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inter-coder reliability 
The inter-coder agreement for the determination of meaningful concepts was 80% 
(kappa 0.55; 95% CI 0.48–0.63).  
For  the  linking  with  the  ICF,  the  inter-coder  agreement was 63% (kappa 
0.28; 95% CI 0.18–0.37).  
Name of questionnaire Number 
of studies 
Short Form-36 14 
Functional Assessment of Cancer Therapy Breast plus 4 subscales 7 
Lymphedema and Breast Cancer Questionnaire 7 
European Organization for Research and Treatment of Cancer –Quality of 
Life Questionnaire –Cancer 30 
5 
Dermatology Life Quality Index 4 
Disabilities of Arm Shoulder and Hand 3 
European Organization for Research and Treatment of Cancer –Quality of 
Life Questionnaire –Breast 23 
3 
Nottingham Health Profile 3 
Upper Limb Lymphedema 27 3 
Borg Rate of Perceived Exertion Scale 2 
Center for Epidemiologic Studies of Depression Scale 2 
General Health Questionnaire -30 2 
McGill Pain Questionnaire 2 
Short Form -12 2 
World Health Organization Disability Assessment Schedule 2 2 
Selfreport (Norman) 2 
Various 51 
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Table 3. Lymphedema-specific questionnaires used in the 136 studies.6,7,9,24-32  
 
Name Author Location (A = arm, B = leg, 
C = combinations) 
Number of 
studies 
Lymphedema and Breast 
Cancer Questionnaire 
Armer et al.31 A 7 
Upper Limb Lymphedema 27 Viehoff et al.28 A 3 
Arm Symptom Distress Scale Mak et al.27 A 1 
Edema Scale Belcaro et al.30 C 1 
Gynaecologic Cancer 
Lymphedema Questionnaire 
Carter et al.2.4 A 1 
Lymphedema and Pain 
Questionnaire 
Oliveri et al.26 A 1 
Lymphedema Risk-Reduction 
Behaviors 
Fu et al.7 A 1 
Lymphedema Signs and 
Symptoms Questionnaire 
Dawes et al.25 A 1 
Measure of Arm Symptom 
Survey-Lymphedema 
Swenson et al.9 A 1 
Memorial Symptom 
Assessment Scale (adapted) 
Norman et al.6 A 1 
Questionnaire for 
Lymphedema-Related 
Subjective Symptoms 
Szolnoky et al.29 A 1 
Supportive Care Needs 
Survey Short Form 
(Lymphedema supplement) 
Beesley et al32 B 1 
 
Disagreement originated most often in the same direction by the same differences in 
coding (e.g. when both researchers consistently coded the same meaningful concept 
in different ways. For instance, ‘‘Do you have limited movement of your foot’’ was 
coded ‘‘b7100 Mobility of a single joint’’ by one researcher and ‘‘b7101 Mobility of 
several joints’’ by the other continuously). In only three cases, no consensus was 
reached by the two researchers about linking a meaningful concept to the ICF. These 
could be resolved by the third researcher. 
Identified concepts and ICF codes 
A total of 301 concepts were extracted from the 12 questionnaires. Out of these, 4 
concepts in a total of 3 questionnaires were considered as ‘‘not covered’’ (‘‘nc’’) by 
the ICF, 13 concepts in a total of 11 questionnaires as ‘‘health condition’’ (‘‘hc’’), 1 as 
‘‘quality of life’’ (‘‘nd-qol’’) and 12 concepts in a total of 4 questionnaires as 
‘‘personal factor’’ (‘‘pf’’). Examples of Personal Factors found were ‘‘Date of birth’’, 
‘‘Age’’, ‘‘Lifestyle’’ and ‘‘Race’’.  
The other 271 concepts (representing 90%) could be linked to a total of 117 
different ICF categories. In all, 1 concept was linked at the level of an ICF chapter 
only, 6 concepts were linked to the first level of the ICF categories, 116 concepts 
were linked to the second level and 148 concepts to the third level. Not a single 
concept was linked to a fourth-level category. Later, the third- level categories were 
merged into the corresponding second-level categories for purposes of this article.  
Tables 4–7 list the 45 second-level ICF categories representing the concepts 
contained in two or more questionnaires. Of these 45 categories, 13 categories 
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belong  to  the component ‘‘Body Functions’’, 6 to the component ‘‘Body Structures’’, 
16 to the component ‘‘Activities and Participation’’ and 10 to the component 
‘‘Environmental Factors’’. 
The second-level categories of the ‘‘Body Functions’’ component that were 
found most frequently were ‘‘b435, Immunological system functions’’ (10 
questionnaires), ‘‘b280, Sensation of pain’’ (9   questionnaires) and ‘‘b265, Touch 
Functions’’ (8 questionnaires) (Table 4). 
 
Table 4. Frequency of second level categories of the ICF linked to concepts contained in the 
12 questionnaires: component Body Functions ( A = code found in upper limb questionnaire, 
B = code found in lower limb questionnaire, C = code found in lymphedema general 
questionnaire).  
 
ICF code Description Number of 
questionnaires 
Chapter 1: mental functions   
b126 (A) Temperament and personality 
functions 
3 
b134 (A,B) Sleep functions 5 
b152 (A,B) Emotional functions 3 
b180 (A,C) Experience of self and time functions 4 
Chapter 2: sensory functions and pain   
b265 (A,B) Touch functions 8 
b280 (A,B) Sensation of pain 9 
Chapter 4: functions of the 
cardiovascular, haematological, 
immunological and respiratory 
systems 
  
b435 (A,B,C) Immunological system functions 10 
Chapter 5: Functions of the digestive, 
metabolic and endocrine systems 
  
b550 (A,B) Thermoregulatory functions 2 
Chapter 7: neuromusculoskeletal and 
movement-related functions 
  
b710 (A,B) Mobility of joint functions 4 
b730 ((A,B) Muscle power functions 2 
Chapter 8: functions of the skin and 
related structures 
  
b810 (A,B,C) Protective functions of the skin 5 
b820 (A,B) Repair functions of the skin 2 
b840 (A) Sensation related to the skin 3 
 
 
Of the ‘‘Body Structures’’ component, the most frequently found categories were 
‘‘s730, Structure of upper extremity’’ (10 questionnaires) and ‘‘s630, Structure of 
reproductive system’’ (6 questionnaires) (Table 5).  
The most frequently found categories in ‘‘Activities and Participation’’ were 
‘‘d570,  Looking after one’s health’’ (9 questionnaires), ‘‘d540, Dressing’’ (7  
questionnaires), ‘‘d445, Hand and arm use’’ (6 questionnaires) and ‘‘d850, 
Remunerative employment’’ (6 questionnaires as well) (Table 6).  
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Table 5. Frequency of second-level categories of the ICF linked to concepts contained in the 
12 questionnaires: component Body Structures ( A = code found in upper limb questionnaire, 
B = code found in lower limb questionnaire, C = code found in lymphedema general 
questionnaire). 
 
 
 
Table 6. Frequency of second-level categories of the ICF linked to concepts contained in the 
12 questionnaires: component Activities and Participation ( A = code found in upper limb 
questionnaire, B = code found in lower limb questionnaire, C = code found in lymphedema 
general questionnaire). 
 
ICF code Description Number of 
questionnaires 
Chapter 2: General tasks and demands   
d230 (A,B) Carrying out daily routine 4 
Chapter 3: Communication   
d325 (A,B) Communicating with –receiving- written messages 2 
d330 (A) Speaking 2 
Chapter 4:  Mobility   
d415 (A) Maintaining a body position 3 
d430 (A) Lifting and carrying objects 2 
d440 (A,B) Fine hand use 3 
d445 (A) Hand and arm use 6 
d450 (A) Walking 2 
d470 (A) Using transportation 4 
Chapter 5: Self-care   
d520 (A) Caring for body parts 2 
d540 (A) Dressing 7 
d570 (A,B,C) Looking after one’s health 9 
Chapter 6: Domestic life   
d640 (A,B) Doing housework 4 
d650 (A) Caring for household objects 2 
Chapter 8: Major life areas   
d850 (A,B) Remunerative employment 6 
Chapter 9: Community, social and civic life   
d920 (A) Recreation and leisure 5 
 
The most frequently found ‘‘Environmental Factors’’ were ‘‘e580, Health services, 
systems and policies’’ (7 questionnaires) and ‘‘e115, Products and technology for 
personal use in daily living’’ (6 questionnaires) (Table 7). 
 
 
 
 
ICF code Description Number of 
questionnaires 
Chapter 6: Structures related to the 
genitourinary and reproductive 
systems 
  
s630 (A,B) Structure of reproductive system 6 
Chapter 7: Structures related to 
movement 
  
s720 (A) Structure of shoulder region 2 
s730 (A,C) Structure of upper extremity 10 
s750 (B,C) Structure of lower extremity 3 
s760 (A) Structure of trunk 3 
Chapter 8: skin and related structures   
s810 (A) Structure of areas of skin 3 
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Table 7. Frequency of second-level categories of the ICF linked to concepts contained in the 
12 questionnaires: component Environmental Factors( A = code found in upper limb. 
questionnaire, B = code found in lower limb questionnaire, C = code found in lymphedema 
general questionnaire). 
 
Discussion 
 
Using the ICF as a reference, it was possible to identify meaningful concepts in 
questionnaires focusing on patients with lymphedema. Many of these concepts 
could be linked to the ICF. The identification of the ICF categories contributed, 
from the researcher’s point of view, to the development of ICF Core Sets for 
lymphedema.  
This research covered a period of 5 years. Most literature reviews concern 
the evidence for certain treatments or diagnostic methods,  often  using  a  period  of  
more  than  5  years.  In  this case, the review aims at classifying meaningful 
concepts used in  scientific  literature concerning  lymphedema. A 5-year-period is 
considered to be sufficient for this particular goal.33,34 Coincidentally, between 2005 
and 2010 literature about lymphedema focused more on other items than only 
swelling and there was paid more attention to lymphedema other than caused by 
breast cancer than in the years before. This enlarged the variety of meaningful 
concepts in this research.  
Compared to previously published systematic reviews  for ICF Core Set 
development,35 this study not only included RCTs but also studies with other designs, 
such as observational studies and qualitative studies. The reason for including 
observational and qualitative studies was that these types of studies might be more 
appropriate to disclose the everyday problems related to lymphedema. Expanding 
the scope of studies included offering a chance to reveal more meaningful concepts. 
 
ICF code Description  Number of 
questionnaires 
Chapter 1:products and technology   
e110 (A) Products and substances for personal 
consumption 
4 
e115 (A) Products and technology for personal use 
in daily living 
6 
e125 (A,B) Products and technology for 
communication 
2 
e135 (A,B) Products and technology for employment 4 
Chapter 2: Natural environment and 
human-made changes to environment 
  
e225 (A) Climate 2 
e245 (A,C) Time-related changes 3 
Chapter 3: Support and relationships   
e310 (A,B) Immediate family 2 
e325 (A,B) Acquaintances, peers, colleagues, 
neighbours and community members 
3 
e355 (A) Health professionals 5 
Chapter 5: services, systems and policies   
e580 (A,B) Health services, systems and policies 7 
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The ICF codes were summarized into two-level codes to ensure readability and 
practical use. This way of presenting was performed previously in ICF Core Set 
development,33 although this procedure seems to be contrary to Coding Rule 2, as 
described by Cieza et al.,13 which states that the most precise ICF category should be 
identified. More detailed data will be used for the next studies on developing the 
Core Sets (studies b–e). 
The somewhat low kappa of 63% of the inter-coder reliability in comparison 
to other studies (e.g. Geyh et al.;36 82% can be partly explained by the fact that in our 
study kappa values were calculated after a fully independent formulation of 
meaningful concepts by two persons and the linking of the concepts to ICF codes. 
Inter-individual differences can result from differences in the identification of 
meaningful concepts as well as in differences in the selection of ICF codes. In the 
study of Geyh et al.36 the kappa values were calculated after consensus was reached 
for the meaningful concepts. Furthermore, it was not simple or straight- forward to 
link meaningful concepts derived from the questionnaires to the appropriate ICF 
category because concept wordings are often not very precise as to their exact 
meaning and are not equal to the ICF terms. Thus, the coding frequently requires 
discussion. Recent linkage exercises, however, have demonstrated that it is possible 
to examine and compare the content of measures based on the ICF framework and 
predefined linking rules.22,23,37  A  third  explanation  might  be  that  both  reviewers 
had good theoretical knowledge of the ICF, but less experience in the linking process. 
In the lymphedema-specific questionnaires, the most frequently measured 
categories were ‘‘s730, Structure of upper extremity’’ (10 questionnaires), ‘‘b435, 
Immunological system functions’’ (10), ‘‘d570, Looking after one’s health’’ (9), 
‘‘b280, Sensation of pain’’ (9), ‘‘b265, Touch functions’’ (8), ‘‘d540, Dressing’’ (7) 
and ‘‘e580, Health services, systems and policies’’ (7). Because most of the 
measurement instruments concerned about upper extremity lymphedema, it is 
clear that ‘‘s730, Structure of upper extremity’’ was found most frequently. 
Lymphedema is a chronic health condition that presents with swollen extremities. 
This explains the high frequency of ‘‘b435, Immunological system functions’’, 
implying the swelling of arms and legs. Self-management of lymphedema seems to 
be important, considering the high frequencies of ‘‘d570, Looking after one’s 
health’’ and ‘‘d540, Dressing’’. Many questionnaires contain items related to 
therapy and caregivers, which can be deduced from the high frequency of the 
category ‘‘e580, Health services, systems and policies’’, indicating their importance 
for patients with lymphedema. 
Concerning the Body Functions category, much lymphedema research still 
focuses on the symptoms, pain and swelling, and little attention is paid to other 
problems, such as skin problems (Chapter 8 – Functions of the skin and related  
structures). More research from the patient’s, clinician’s and expert’s point of view 
will show whether skin problems really are of less importance. 
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 Although lymphatic filariasis (a mosquito-transmitted chronic, incurable disease 
often found in Third World  countries) damages  mostly  the  lymphatic  system  of  
the  lower  extremity,38-43 most of the questionnaires were found to be concerned 
about lymphedema of the upper extremity. This is the reason why, for example, 
‘‘d450, Walking’’ has a relative low frequency. There is a need in this field of 
research to provide more insight into these limitations. 
The other measurement methods (not the questionnaires) that were 
identified in the studies were almost always related to the classification ‘‘Body 
Functions’’ of the  ICF.  These  methods are concentrated on clinical symptoms, such 
as swelling  and pain. H owever, from a more holistic point of view (e.g. using the 
perspective of the ICF), there are other fields important to describe the patient’s 
functioning as well. 
Considering the questionnaires, it is striking that there are 51 different 
questionnaires in the included studies, so it seems that every researcher used his/her 
own questionnaire. To achieve more uniformity in this perspective, the ICF, and more 
specifically the Core Sets for lymphedema, can work as a framework in the future. 
Most of the included meaningful concepts could be linked to the ICF 
(90%), but a small proportion could not. Of these, ‘‘Health Conditions’’ can be 
classified with the ICD-10. Unfortunately, the ‘‘Personal Factors’’ component,  as  
part  of the ICF, is still under development. 
The selection of studies might have been biased by including only studies 
and questionnaires published in English. The search concerned publication years 
2005–2010, so it is possible that more recent studies would have revealed 
different results. 
Because  the  large  majority  of  meaningful  concepts  found in the 
questionnaires concerning lymphedema could be linked to the ICF,  this  type  of  
classification  appears  workable. Recent publications44,45 stress the importance of 
implementing the ICF. 
The ICF provides a valuable reference to identify and quantify the meaningful 
concepts focusing on individuals with lymphedema. The findings of this literature 
review indicate a need to define and to agree on ‘‘what should be measured’’ in 
lymphedema care. This is one of the goals of the ICF Core Set development for 
lymphedema. ICF Core Sets should allow for a comparable and comprehensive 
description of patient populations, their functioning and health across studies and 
interventions. 
 
Abbreviations 
 
DVR = Dorien van Ravensberg 
ICF = international classification of functioning and health 
JH = Janine Hidding 
PV = Peter Viehoff 
YH = Yvonne Heerkens 
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Abstract 
 
Background 
Lymphedema is a common complication of cancer treatment, resulting in swelling 
and subjective symptoms. Reliable and valid measurement of this side effect of 
medical treatment is important. 
Purpose 
The purpose of this study was to provide best evidence regarding which 
measurement instruments are most appropriate in measuring lymphedema in its 
different stages. 
Data sources: The PubMed and Web of Science databases were used, and the 
Preferred Reporting items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines were followed. 
Study selection 
Clinical studies on measurement instruments assessing lymphedema were reviewed 
using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2).  
Data extraction: Data on reliability, concurrent validity, convergent validity, 
sensitivity, specificity applicability and costs were extracted. 
Data synthesis 
Pooled data showed good intrarater interclass correlation coefficients (ICCs) (0.89) 
for Bio Impedance Spectroscopy (BIS) in lower extremities, and high intra- and 
interrater ICCs for water volumetry, tape measurement and perometry (0.98 -0.99) in 
the upper extremities. In the upper extremities, the standard error of measurement 
was 0.7% (σ=0.8%) for water volumetry, 2.1% (σ=2.6%) for perometry and 2.8% 
(σ=3.2) for tape measurement. Sensitivity of tape measurement in upper extremities, 
using different cut-off points, in upper extremities varied from 0.73 to 0.90 and 
specificity from 0.72 to 0.78.  
Limitations 
No uniform definition of lymphedema was available and a gold standard as reference 
test was lacking. Items concerning risk of bias were study design, patient selection, 
description of lymphedema, blinding of test outcomes and number of included 
patients. 
Conclusions: Measurements instruments with evidence for good reliability and 
validity were BIS, water volumetry, tape measurement, and perometry, where BIS 
can detect alterations in extracellular fluid in stage 1 lymphedema and the other 
measurement instruments can detect alterations in volume starting from stage 2. In 
research, water volumetry is indicated as reference test for measuring lymphedema 
in upper extremities.  
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Introduction 
 
Lymphedema is a complex problem that can occur in any body part. Primary 
lymphedema develops as a result of dysfunction or malformation of the lymphatic 
system. It is assumed to occur in 1.15/100.000 persons aged over 20 years.1 Patients 
with lymphedema experience swelling and impairments, limitations, and restrictions 
in functioning and encounter environmental factors, as described in the International 
Classification of functioning, Disability and Health (ICF) Core Set Lymphedema.2 
Secondary lymphedema is caused by disruption of the lymphatic system, mostly as a 
result of cancer treatment and especially after lymph node dissection or radiotherapy 
to the lymph nodes and in patients with  
advanced cancer.3 The incidence differs per tumor type, area and stage: from 5% 
after sentinel node biopsy in breast cancer to 42% in cervical cancer.4  
In patients suspected with lymphedema, a thorough examination on the 
origin of the swelling is required, to exclude other reasons of swelling. Stages of 
lymphedema have been described by the International Society of Lymphedema, 
ranging from subclinical (Stage 0) to hard (fibrotic) edema with fat deposition and 
skin alterations (Stage 3).5 Generally, patients complain about subjective symptoms 
such as feelings of heaviness, numbness, or tingling.6 To get insight in these 
symptoms, lymphedema specific questionnaires or symptom lists can be used.3 In 
stage 1 of lymphedema, the amount of extracellular water or subcutaneous water 
can be measured to quantify lymphedema.  The ratio between the amount of total 
body water and extracellular fluid can be measured by Bio Impedance Spectroscopy 
(BIS).7 Bio impedance is a measure of the resistance to the flow of an electric current 
through the body or a body part. It is a non-invasive method to measure body 
composition and usually frequencies from 4 kHz to 1 MHz are used. The 
MoistureMeter (Delfin LTD, Kuopio, Finland) measures the percentage of water 
under the skin (tissue dielectric constant), using a probe with a 300 MHz signal.8 
Swelling occurs from stage 2 lymphedema. Swelling of limbs can be measured by 
water displacement (volumetry or inversed volumetry), perometry or circumferential 
measurements by tape measurements.9 A special device for circumferential 
measurements is a perimeter: a metal or hard plastic bar with tape at every four 
centimeters on the bar with a 20 gram weight at the end of each tape.10 In later 
stages accumulation of adipose tissue and fibrotic alterations change the consistency 
of the lymphedema, and especially in stage 3, the resistance in the skin can be 
measured by tonometry.11 
Prevention and early detection of lymphedema is important, because early 
treatment results in less burden for the patient and is cost-effective.12 The most 
common treatment for lymphedema consists of manual lymphatic drainage, 
compression therapy, exercises and skin care.5 
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To the best of our knowledge, no systematic literature review has been published 
assessing the measurement properties of clinical instruments for measurement of 
lymphedema. A complicating factor is that a clear gold standard for lymphedema 
measurement is lacking. In research as well as in clinical settings different 
measurement instruments are used, without consensus on the best measuring 
method. Moreover, in the midline (head and neck, breast, trunk or genitalia) 
lymphedema volume or circumference measurements are difficult to perform. In this 
systematic review we focus on instruments for measuring and monitoring 
lymphedema. Ideally, the measurement instrument must be easily applicable, short 
in measurement time, cheap, and acceptable by the clinician as well as the patient.  
The primary question in this review was: Which instruments are most 
appropriate in measuring and monitoring lymphedema? Specific questions to be 
answered were: (1) Which measurement instruments are described in peer reviewed 
literature and which  edema aspect is measured? (2) Which measurement instrument 
is most reliable and can be indicated as most appropriate for measuring 
lymphedema, based on test-retest reliability, lowest standard error of measurement 
(SEM) and smallest detectable change (SDC)? (3) Which measurement instrument(s) 
are reliable and feasible for application in clinical practice, considering different 
stages of lymphedema and different locations of the body?  
 
Methods 
 
Data sources and searches 
We conducted a systematic literature search conform the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for identifying 
measurement instruments for diagnosing and quantifying lymphedema, using the 
databases of PubMed and Web of Science up till November 11, 2015 (see appendix 
1). Published studies in English, Dutch, French and German language were eligible for 
inclusion. No limit on date of publication was applied. The search string was 
developed according to recommendations for sensitive search of measurement 
properties of the COnsensus-based Standards for the selection of health 
Measurement INstruments (COSMIN) group.13 See appendix 1 for the full search 
string. 
Target population 
Studies in patients with lymphedema or at risk for developing lymphedema, 
regardless of whether compared to healthy controls were included.  
Inclusion criteria 
Prognostic, cross sectional and case-control studies assessing measurement 
properties of clinical measurement instruments for lymphedema with at least two 
repeated measurements with one instrument, and studies describing comparisons 
between two or more measurement instruments were included.  
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Exclusion criteria  
Intervention studies not evaluating properties of measurement instruments related 
to lymphedema and studies in a healthy population were excluded. Measurement 
instruments such as computed tomography, magnetic resonance imaging,  dual-
energy x-ray absorptiometry scan, caliper, goniometer or weighting scale/body mass 
index were excluded. We also excluded studies, where healthy controls were 
involved with a difference in mean age of more than 10 years between study groups. 
Studies that used only patient-reported questionnaires, retrospective studies and 
conference papers were also excluded. 
Study selection 
Initial study selection was performed by the first author (J.T.H.). Two independent 
authors (J.T.H. and P.B.V.) reviewed the list of papers based on title and abstract. Full 
text papers were then retrieved and examined independently to obtain a final list of 
eligible studies. If consensus could not be achieved, the review team adjudicated.  
Quality assessment 
We defined lymphedema as a difference between (left and right) extremities or 
between measurements in case of two-sided or midline involvement. The Quality 
Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) scoring instrument was 
used to evaluate the quality of the initially selected studies.14 The QUADAS-2 scoring 
instrument includes four domains in assessing the quality of diagnostic instruments: 
patient selection, index instrument, comparator instrument, time and flow. Two 
researchers (J.T.H. and P.B.V.) independently scored each item of the QUADAS-2 
scoring list. Disagreements were discussed together to reach consensus. Items with 
low risk of bias or no concern regarding applicability were assigned as “+”; those with 
unclear risk of bias as ”?”, and those with high risk of bias or serious concerns 
regarding applicability as “-“. The decision criteria were described in table 1. The total 
test score per domain was estimated as the median of all “risk of bias” criteria within 
that domain. For each domain, an overall score of more than “?”, was indicated low 
risk of bias or no major concerns and was marked as “+”, those with unclear risk of 
bias or concern regarding applicability were assigned a quality score of “?”, and those 
with high risk of bias or serious concerns regarding applicability were assigned a 
quality score of “-“. Eligible studies for inclusion in data synthesis needed to have an 
overall low risk of bias in the domain “method of patient selection”, and an overall 
medium or low risk of bias in the domains “index test” or “comparator test”. As 
advised by Whiting et al.,14 a total score was not generated and conclusions were 
based on domain scores. 
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Table 1. Items of Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2): Risk of 
Bias and Applicability Concerns Specified for Lymphedema Measurementsa. 
 Item to score + ? - 
Method of patient selection 
1 Included patients Diagnosis of  
lymphedema or at risk 
clearly described  
Lymphedema not clearly 
defined; other edema; 
age unclear; 
inappropriate exclusions 
No match on 
sexes/age (> 10 
years difference; 
not mentioned) 
2 Case-control avoided Yes Unclear No 
3 Patient selection Consecutieve/random 
sample ≥25 pts 
Consecutieve/random 
≥10 and <25 pts 
Flyers, 
advertisement 
4b Concerns about no match 
to review question 
Inclusion and exclusion 
criteria appropriate 
Inclusion and exclusion 
criteria unclear; no 
patients with 
lymphedema 
Inappropriate 
inclusion criteria 
Index test  
5 Measurement protocol Appropriate protocol 
described for research 
question, both sides 
measured  
Incomplete protocol 
described for research 
question, both sides 
measured, use of > 1 
landmarks 
Protocol not 
appropriate for 
research question, 
one side measured 
6 Blinding (e.g. masking) Results blinded; tester 
unaware of other 
outcome test 
Unclear or <30 minutes 
between measurements 
Results not blinded;  
7b Concerns about no match 
to review question 
Threshold predefined in 
healthy population and 
population with 
lymphedema; whole 
extremity measured  
Threshold predefined 
only in healthy 
population.  
For tape measurement, 
sum of circumferences; 
tonometry and 
MoistureMeter:  ≥5 
points measured 
Threshold not 
predefined.  
For tape 
measurement, 
tonometry and 
MoistureMeter, not 
whole extremity or 
<5 points measured 
Comparator instrument 
8 Measurement protocol Appropriate protocol 
described for research 
question, both sides 
measured  
Incomplete protocol 
described for research 
question, both sides 
measured  
Protocol not 
appropriate for 
research question, 
one side measured 
9 Blinding Results blinded; tester 
unaware of outcome 
other test 
Unclear or <30 minutes 
between measurements 
Results not blinded 
10b Concerns about no match 
to review question 
Threshold predefined in 
healthy population and 
population with 
lymphedema; whole 
extremity measured  
Threshold predefined 
only in healthy 
population.  
For tape measurement, 
sum of circumferences; 
tonometry and 
MoistureMeter:  ≥5 
points measured 
Threshold not 
predefined.  
For tape 
measurement, 
tonometry and 
MoistureMeter not 
whole extremity or 
<5 points measured 
Flow and timing 
11 Measurements 
performed 
All patients were 
measured with both/all 
measurement 
instruments 
≤25 patients were 
measured with both/all 
measurement 
instruments 
<10 patients were 
measured with 
both/all 
measurement 
instruments 
12 Interval between index 
test and reference test 
Same part of day 
 
Time point of multiple 
measurements unclear 
Tests performed 
over >1 d with 
unclear time points 
13 Intervention NA   
14 Withdrawal  NA   
15  Bias due to patient flow NA   
a + =low risk, ? =unclear risk, - =high risk, NA=not applicable 
b with focus on applicability  
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Data extraction 
The following measurement properties of identified instruments in the finally 
included studies were extracted by one reviewer (J.T.H.) and verified by a second 
reviewer (C.B.): intraclass correlation coefficients (ICCs) for estimating the 
measurement differences within and between raters; SEM to describe the 
measurement error; SDC for estimating which change in measurement outcome will 
be clinically relevant; concurrent validity and convergent validity to estimate whether 
the instruments measure the same construct; and sensitivity and specificity to 
estimate the difference in interpretation concerning the presence of lymphedema 
between the comparator test and other measurement instruments. Concurrent 
validity was defined as comparison of outcomes between tests or between groups, 
administered on the same time, based on their correlation. Convergent validity was 
assessed by comparing similarity of different procedures of a certain measurement 
instrument, based on their correlation. If available, results regarding applicability and 
costs were extracted as well.  
Data synthesis and analysis 
For quantitative analysis on reliability the following measurement properties for each 
measurement instrument were extracted: ICC, SEM, SDC, sensitivity and specificity. 
Where ICCs were reported for each level of tape measurement, mean ICC and 
standard deviation were calculated. Where possible, data were pooled to estimate 
ICC. For statistical pooling of data, Fisher’s estimated r to z transformation for ICC 
was used, in which the number of examiners and participants are included in the 
formula. SDC was calculated from the standard deviation of the difference (SDdifference) 
or, when not available, derived from the SEM.  The weighted mean SEM and 
SDdifference were calculated based on the number of included subjects in the studies. 
Variance (σ) of SEM and SDC was calculated based on the pooled data in relation to 
the data in the original studies. When data of different calculations for tape 
measurement were available, data from the frustum method were extracted (for 
formulas see appendix 2). When different distances between tape measurements 
were used, the measurement nearest to 4 centimeters was used. Based on the 
highest ICC with the lowest SEM, SDC and variance, the most appropriate 
measurement instrument for measuring lymphedema was indicated as the reference 
test. Concurrent validity, sensitivity and specificity were described in relation to the 
comparator test. Correlations between measurement instruments or measurement 
procedures were interpreted as follows: r > .75 is excellent; r .40 to .75 is fair to 
good.15 ICCs were interpreted as follows: r > .90 high; r > .80 good. 
 
 
 
 
 
7372
72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow diagram of literature search of measurement instruments for lymphedema.  
QUADAS-2=Quality Assessment of Diagnostic Accuracy Studies-2 
 
 
Records identified through PubMed 
(n=529) 
Records identified through Web of 
Science 
(n=479) 
Records after duplicates 
removed 
(n=631) 
Records excluded based on 
title 
(n=455) 
Full-text articles assessed for 
eligibility 
(n=103) Full-text articles excluded 
(n=51) 
Only healthy participants 
(n=13) 
Quality of life (n=5) 
No study question (n=9) 
Retrospective (n=1) 
Statistics unclear (n=3) 
<10 study participants (n=2) 
Healthy participants > 10 years 
younger (n=18) 
Articles included in QUADAS-
2 assessment (table 2) 
(n=54) 
Articles included in 
qualitative and quantitative 
analysis (table 3 - 5) 
(n=30) 
Records screened based on 
abstract  
(n=176) 
References from full 
text articles included 
(n=2) 
Excluded based on 
abstract 
(n=73) 
Excluded based on 
poor quality in 
QUADAS-2 assessment 
(n=24) 
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Table 2. Quality of the assessed studies, following Quadas-2 and the criteria specified in  
table 1. 
         
Study Body 
part 
Patient selection Q Measurement 
instrument 
Q Measurement 
instrument 
Q Flow and 
timing 
  1 2 3 4  5 6 7  8 9 10  11 12 
       BIS Tape 
measurement 
  
Blaney et al24 UE + + + + + + - + ? + - + ? + + 
Cornish and 
colleagues7,25 
 + - + + + + - + ? + - - ? ? - 
Fu et al26  - - + + - + - + ? - - + - + - 
Hayes et al27  + + + + + + - + ? + - ? ? + - 
Ridner et al28  + - ? + ? + - + ? + - + ? + - 
Smoot et al29  + + + + + + - + ? + - + ? + - 
Gordon et al11 LE + + + + + + - + ?     + - 
       BIS Perometry   
Bundred et al30 UE + + + ? + - - + - - - + - + + 
Czerniec and 
colleagues31,32 
 ? + + + + + ? + + + ? + + + + 
Jain et al33  + + - + + + - + ? + - + ? + - 
Ridner et al28  + - ? + ? ? - + - ? - + - + + 
Ward et al34  + - + + + ? - + - ? - + - + - 
Ridner et al37  ? - - + - ? ? + ?     NA NA 
Moseley et al23 LE + + + + + + - - ? + - - ? + - 
Gaw et al35 UE/ LE - - + ? - ? - - -     NA NA 
Ward et al36  - - - ? - + ? - +     NA NA 
Warren et al22  - - ? + - ? ? + ?     NA NA 
       MoistureMeter Tape 
measurement 
  
Mayrovitz et al38 UE - - ? + - + - - ? ? - - - + - 
Mayrovitz et al8  - - ? ? - + - - ? + - + ? + - 
Mayrovitz et al39  ? - + ? ? ? ? ? ?     NA NA 
Birkeballe et al40 LE + - + + + + + - +     NA NA 
       Tape measurement Volumetry   
Adriaenssens et 
al50 
UE - - + + - + - + ? + ? + + + - 
Armer and 
collegues6,51 
 - - - + - ? ? + ? - ? + - ? + 
Brorson and 
Hoijer41 
 + + ? + + + - + ? + - + ? + - 
Chen et al16  + + ? + + - - - - + - + ? - - 
Damstra et al42  + + + + + + - - ? + - + ? + + 
Deltombe et al9  + + + + + + - + ? + - + ? + - 
Devoogdt et al10  - + + ? + + - + ? + - + ? + + 
Gjorup et al43  + + - + + + - + ? + - + ? + - 
Godoy et al17  ? + + + + + - + ? + - + ? + - 
Karges et al44  + + ? + + + - + ? + - + ? - ? 
Megens et al45  + + + ? + + + + + + + + + + + 
Meijer et al46  + + + + + + - + ? + - + ? + - 
Mori et al49  + + ? + + + - + ? + - + ? ? + 
Sander et al47  + + + + + + - + ? + - + ? + + 
Taylor et al52  - - + + - + ? + + ? ? + ? + - 
Tewari et al48  ? + + + + + - + ? + - + ? + - 
Borhtwick et al53 Hand + + + + + + ? + + + + + + + ? 
Sander et al47  + + + + + + - + ? + - + ? + + 
Spillane et al21 LE - + + + + ? - ? - + + ? + + - 
Tierney et al54  ? - + ?* ? + - ? ? + - ? ? + - 
Sawan et al55  + + ? + +     + ? + + NA NA 
Pani et al18 Foot ? + + + + ? - ? - ? - + - + - 
Adriaenssens et 
al50 
UE - - + + - + ? + + + ? + + + - 
Armer and 
colleagues6,51 
 - - - + - - ? + - - ? + - ? + 
Deltombe et al9  + + - + + + - + ? + - + ? + - 
Lee et al68 Hand + - ? + ? + ? + + + ? + + + - 
Spillane et al21 LE - + + + + + ? + + + ? + + + - 
Tierney et al54  ? - + ?* ? + - ? - + - ? ? + - 
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LE=lower extremity, UE=upper extremity, BIS=bio impedance spectroscopy, NA=not applicable, 1=included patients,2=case 
control avoided, 3= patient selection, 4=concerns about no match to review question, 5=measurement protocol, 6=blinding, 
7=concerns about no match to review question, 8=measurement protocol, 9=blinding, 10=concerns about no match to review 
question. 11=measurements performed, 12=interval between index test and reference test, +=low risk of bias or no concern 
regarding applicability; ?=unclear; -=high risk of bias or serious concerns regarding applicability, Q: quality (+=mean score of the 
risk of bias section is good, = mean score of the risk of bias section is fair, -=mean score of the risk of bias section is poor. Open 
boxes: no comparison test applied. *Partly venous disease, no lymphedema. 
 
Results 
 
Included studies 
We identified 631 unique studies of which 103 were eligible for full-text assessment. 
Two references used in these studies were included as well (see figure 1). Of these 
studies, 51 studies were excluded because they did not meet the inclusion criteria. 
Exclusion of these studies resulted in the initial selection of 54 articles representing 
50 unique studies. Four studies were reported in more than one article, which were 
assessed together. Forty-one studies compared 2 or more measurement instruments. 
In general, testers were not blinded to the patient’s condition and outcome of the 
index and/or comparator test. In most studies tests were conducted directly after 
each other. Therefore, we cannot rule out that test procedures have not resulted in 
bias (See table 2). All studies were conducted in hospital settings. Four studies were 
not conducted in Western countries.16-19 Most studies were conducted in female 
Table 2 continued. 
Study Body 
part 
Patient selection  Q Measurement 
instrument 
Q Measurement 
instrument 
Q Flow and 
timing 
  1 2 3 4  5 6 7  8 9 10  11 12 
       Perometry Volumetry   
       Tape measurement Perometry   
Adriaenssens et 
al50 
UE - - + + - + - + ? + ? + + + - 
Armer and 
colleagues6,51 
 - - - + - ? ? + ? - ? + - ? + 
Czerniec and 
colleagues31,32 
 ? + + + + + ? ? + + ? + + + + 
Deltombe et al9  + + - + + + - + ? + - + ? + - 
Ridner et al28  + - ? + ? ? - + - ? - + - + - 
Stanton et al56  - - + + - + - + ? + ? + + + - 
Ancukiewitz and 
colleagues63,69 
 + + + + +     + ? + + NA NA 
Stout et al59  + - + + +     ? ? + ? NA NA 
Spillane et al21 LE - + + + + ? - ? - + ? + + + - 
Tierney et al54  - - + ?* - + - ? ? + - ? ? + - 
Engelberger et 
al70 
 - - + - -     + ? ? + NA NA 
       BIS Tonometry   
Moseley and 
Piller58 
Breast ? + ? ? + + - - ? + - - ? + - 
       MoistureMeter Tonometry   
Mayrovitz et al57 LE - - ? ? - + ? - + + ? - + + + 
       Volumetry Tonometry   
Bagheri et al60 UE + + ? + + + ? + + + - + ? - - 
       Tape measurement Tonometry   
Chen et al16 UE + + ? + + - - - - - - - - - - 
Gordon et al11 LE + + + + + ? - ? - + - ? ? + - 
Kar et al19  - - + + - - ? - - ? ? - ? + - 
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patients. In 5 studies both female and male participants were included.11,20-23 Fifteen 
studies reported reliability using ICC; SEM was reported in 9 studies and SDC was 
reported in 2 studies. Concurrent validity was reported in 16 studies and convergent 
validity was reported in 8 studies. The following measurement instruments were 
described for measuring and quantifying lymphedema: water volumeter, tape 
measure, perometer, bioimpedance spectroscope, MoistureMeter, and tonometer.  
Eight articles7,11,24-29 compared tape measurement with BIS. Seven 
articles23,28,30-34 compared perometry with BIS. Four studies22,35-37 investigated BIS. 
Two studies8,38 compared tape measurement with MoistureMeter. Two studies39,40 
investigated solely MoistureMeter. Twenty-two articles6,9,10,16-18,21,41-54 compared 
water volumetry with tape measurement. One study investigated tape 
measurement.55 Ten articles compared tape measurement with 
perometry.6,9,21,28,31,32,50,51,54,56 Four studies11,16,19,57 compared tape measurement 
with tonometry. One study58 compared tonometry with BIS in the breast. None of the 
studies described measurement properties in different stages of lymphedema. Study 
characteristics of the included studies are described in table 3 and are further 
analyzed and summarized in table 4. 
 
Table 3. Study characteristics of the studies on measurement instruments in lymphedema, 
selected after QUADAS-2 evaluation. 
Study/Year 
of 
publication/
Country 
Patients diagnosis /controls 
/sexes /age (mean and 
SD/range) 
(Comparison of) 
measurement method(s) 
Outcome measure(s) 
Bundred et 
al30 2015 
United 
Kingdom 
BC (n=612)/F/age 55 (24-90) Perometry ↔ BIS Perometry ↔ BIS: r = .40 at 3 months; r = .60 at 6 
months; Using perometry as gold standard: 
sensitivity .73 (95% CI .59 - .84); specificity .84 
(95% CI .80 - .87) 
Birkeballe et 
al40 
2014 
Denmark 
LE lower extremities (n=10); 
new LE patients (n=9), 
lipedema (n=10), healthy 
(n=10) /F/age 20-73 
MoistureMeter ICCinter foot: .63 (95% CI .43 - .79); ankle .94 (95% CI 
.89 – .97); lower extremity .94 (95% CI .88 – .97); 
Using cut-off point of .40: sensitivity .93; specificity 
.90. Positive predictive value .8; Negative 
predictive value .9 
Mori et al49 
2014 
Israel 
Unilateral BC + LE (n=17)/F/ 
age 60.4 (±9.5) 
Water volumetry ↔ tape 
measurement 
Water volumetry: ICCintra .94; tape measurement: 
ICCintra .99; water volumetry ↔ paper tape 
measurement by patient: .65; by therapist .72; 
water volumetry↔  plastic tape measurement: 
.80 
Borthwick et 
al53 
2013 
United 
Kingdom 
BC + hand swelling 
(n=25)/F/age 51.5 (38-68) 
Water volumetry ↔ tape 
measurement  
Water volumetry: ICC .99; SEM 8.4 ml; tape 
measurement: ICCinter .84; ICCintra .90; SEM 7 - 6 
mm; water volumetry ↔ tape measurement  r = 
.73 
Brorson et 
al41 2012 
Sweden 
Unilateral BC + LE 
(n=10)/F/age not mentioned 
Water volumetry ↔ tape 
measurement 11 points 
↔ 5 points 
Covariance 4 cm .6%; 10 cm .6%; 4 cm ↔ 10 cm r 
= .9; water  volumetry ↔ tape measurement 10/4 
cm r = .87 
Gordon and 
Hoijer11  
2011 
Australia 
LF positive (n=25), negative 
(n=28)/ F/M/age 16.5 (10-21) 
Tape measurement ↔ 
tonometry ↔ goniometry 
↔ BIS 
BIS: concordance correlation .88 (95% CI .82 - .92); 
Tonometry: mean/SD LF+ 5.3/.99; LF- 4.4/1.1; 
Using a cut-off point of 3.5: sensitivity 1.00 (95% CI 
.86-1.00); specificity .2 (95% CI .08-.41); positive 
predictive value .5  
Smoot et al29 
2011 
United States 
BC +/- LE (n=70, n=71)/F/age 
56.4 (±9.4) 
Tape measurement ↔ SF-
BIS ↔  NQ 
Water volumetry AUC (3SD) = .8 (95% CI .74 – .89); 
sensitivity .5 (95% CI .39–.64); specificity .9 (95% CI 0.90–
1.00); tape measurement AUC (3SD)= 0.7 (95% CI .64–
.75); sensitivity: .4 (.27–.51); specificity 1.0 (.95–1.00); BIS 
AUC (3 SD) = .7 (95% CI .62–.74); sensitivity .4 (95% CI .26–
.50) ; specificity  .9 (95% CI .92–1.00); BIS ratio ↔ volume 
ratio r=.8; BIS ratio ↔ volume difference r=.83 
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Table 3 continued 
Study/Year 
of 
publication/
Country 
Patients diagnosis /controls 
/sexes /age (mean and 
SD/range) 
(Comparison of) 
measurement method(s) 
Outcome measure(s) 
Stout et al59 
2011 
United States 
BC+LE (n=45); BC 
(n=45)/F/age 45.8 (±12.2) 
Perometry  Correlations between segments and total volume: 
10-20 cm: r2=.77; 20-30 cm: r2=.95 
Czerniec and 
collegues31,32 
2010, 2011 
Australia 
BC + LE (mild - severe) (n=29); 
without LE (n=11)/F/age 58.2 
(±8.3) 
Tape measurement ↔ 
perometry (all segments of 
10 cm) ↔ MFBIA ↔ self-
report 
Tape measurement: LE: ICC .95 (95% CI .90-.98); 
SEM 7%/100 ml; without LE: ICC .58 (95% CI .17-
.82); SEM 6%/53 ml; perometry LE/without: ICC 
1.0 (95% CI .99-1.00); SEM 4%/81 ml (LE 82 ml; 
without LE 60 ml); BIS with LE ICC .95 (95%CI .90-
.98); SEM 12.9Ω; without LE ICC .81 (95% CI .56-
.93); SEM 16.7Ω; tape measurement ↔ 
perometry r = .9; tape measurement ↔ BIS r = 
.99; BIS ↔ perometry r = .89; peak bias perometry 
in 10-20 cm segments (16.6%) 
Gjorup et al43 
2010 
Denmark 
BC + LE (n=24)/F/age 63 (46-
76) 
 
Water volumetry ↔ tape 
measurement ↔ DXA 
Water volumetry: ICC .99; tape measurement: 
ICCinter/intra .99; SEM LE upper extremity 81.4 ml; 
control upper extremity 78.4 ml; water volumetry 
↔ tape measurement .99 
Devoogdt et 
al10 2010 
Belgium 
 
BC (n=112)/F/age 54.5 
(±11.9) 
Water volumetry ↔ 
perimetry  
Water volumetry: ICCinter .99 (95% CI .98-.99); 
ICCintra .99 (95% CI .99); perimeter: ICCinter .94-.99 
(95% CI .83-.99); ICCintra .97-.99 (95% CI .96-.99); 
SEM 22-26 ml (1.3-1.5%); perimeter ↔ water 
volumetry r=.97 (95% CI -231-57 ml) 
Jain et al33 
2010 
USA 
BC (n=10)/F/age 59.6 (49-67) Perometry ↔ BIS BIS: ICCinter .99 (95% CI .97-.99); ICCintra .99 (95% CI 
.97-.99); perometry ↔ BIS r=.90 
Sawan et al55 
2009 
United 
Kingdom 
Vulva cancer(n=10); control 
(n=8)/F/ age 71.5 (41-87) 
Tape measurement ↔ 
symptoms ↔ general QoL 
Tape measurement: SDCintra 264.1 ml; SDCinter 
1014.5 ml; responsiveness  treatment vs. control 
10% increase 5/8 vs. 3/10; absolute volumes 6/8 
vs. 7/10 
Chen et al16 
2008 
Taiwan 
BC+ LE (n=14 for tape 
measurement n=17 for 
tonometry)/F/age 57.6 (±9.9) 
Water volumetry ↔ tape 
measurement (3 sites) ↔ 
tonometry (3 sites) 
Water volumetry: ICCinter .99 (95% CI .99-1.00); 
ICCintra .99 (95% CI .99-1.00); SEM 27.2-27.3 ml; 
SDC 75.4-75.5 ml; tape measurement: ICCinter .99 
(95% CI .99); ICCintra .99 (95% CI .99); SEM 13-37 
mm; SDC 3.7-7.1 mm; tonometry: ICCinter .69-.71 
(.32-.89); ICCintra .66-.88 (.27-.95); SEM .1-.4 mm; 
SDC .3–1.0 mm 
Spillane et 
al21 2008 
United States 
Melanoma + (ilio-)inguinal 
dissection (n=66)/M/F/age 
not mentioned 
Water volumetry ↔ tape 
measurement ↔  
perometry; difficulties in 
performing daily 
activities/swelling 
Water volumetry SEM 11.7-13%; perometry SEM 
15%; tape measurement (SOAC) sensitivity .5; 
specificity .83; perometry: sensitivity .56; 
specificity .95; misclassification rate -.2 
Tewari et al48 
2008 
Australia 
BC (n=87)/F/age 58.6 (17-81) Water volumetry ↔ tape 
measurement  
Tape measurement wide ↔ narrow rc .9; tape 
measurement ↔ water volumetry 8 mm tape: 
r=.9 (.89–.94); 15 mm tape: r=.92 (.84–.91) 
Deltombe et 
al9  2007 
Belgium 
BC + LE (n=30)/F/age 63 (46-
79) 
Water volumetry ↔ tape 
measurement (segments 
of 5 cm) ↔ perometry 
Water volumetry ICCinter/intra .99; tape 
measurement frustum ICCinter .94; ICCintra .96 (95% 
CI .94-.99); disk ICCinter/intra .99; perometry 
ICCinter/intra .99 
Godoy et al17 
2007 
Brazil 
BC (n=90)/F/age not 
mentioned 
Water volumetry ↔ tape 
measurement  
Difference between the affected and unaffected 
upper extremities water volumetry ≥ 200 ml and ≥ 
2 cm for any-one of the seven measurements: 
sensitivity 90%; specificity 71.7%; positive 
predictive value 61.4%; negative predictive value 
93.5; ≥ 100 ml and ≥ 2 cm; sensitivity 83.7%; 
specificity 69.4%; positive predictive value 57.8%; 
negative predictive value 91.5; water volumetry ≥ 
10% and calculated volume tape measurement ≥ 
10%: sensitivity 73.3%; specificity 78.3%; positive 
predictive value 62.9%; negative predictive value 
85.5% 
Damstra et 
al42 2006 
Netherlands 
 
 
BC+LE (n=25)/F/age 61.7 (47-
82) 
Inverse water volumetry 
↔ tape measurement  
Water volumetry ICCinter .98-.99 (SD 78-154 ml); 
ICCintra .95-.99 (SD 87-93 ml); SDdiference 2.5% 
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Table 3 continued 
Study/Year 
of 
publication/
Country 
Patients diagnosis /controls 
/sexes /age (mean and 
SD/range) 
(Comparison of) 
measurement method(s) 
Outcome measure(s) 
Bagheri et 
al60 2005 
Sweden 
BC+LE pre-/post liposuction; 
non-pitting (n=20)/F/age 50 
(34-77) 
Water volumetry ↔ 
tonometry horizontal ↔ 
vertical  
Tonometry: ICCinter .94 
Hayes et al27 
2005 
Australia 
BC (n=176)/F/ 54 (±10) Tape measurement ↔ 
MFBIA ↔ self-report of 
arm swelling 
SOAC >5 cm ↔ MFBIA: sensitivity .35; 
specificity .89; SOAC >10 cm sensitivity .05; 
specificity 1.00; self-report sensitivity .65; 
specificity .77 
Meijer et al46 
2004 
Netherlands 
BC+LE (n=30/F/ age 56.4 
(±11.6) 
Water volumetry ↔ tape 
measurement  
Water volumetry ICCinter .92; ICCintra .97; tape 
measurement: ICCinter 4 cm interval .87; 8 cm 
interval .73; ICCintra 4 cm .95; 8 cm .81; tape 
measurement 4 cm↔8 cm r=.86; r=.9;  tape 
measurement 8 cm ↔ water volumetry r=.79 
Karges et al44 
2003 
United States 
LE (n=14)F/age 44-71 Tape measurement ↔ 
water volumetry 
Water volumetry: ICC .99; SEM 11.5 ml; tape 
measurement: ICC .99; SEM 9.4 ml; water 
volumetry ↔ tape measurement r=.99; side-to-
side difference r=.96 
Moseley et 
al23 2002 
Australia 
LE lower extremities 
(n=33)/M/F/age 59 (±13) 
Perometry ↔ BIS CV=.2-.9; volume change r=.61 
Sander et al47 
2002 
United States 
LE upper extremity 
(n=50)/F/age 56 (25-85) 
Water volumetry ↔ tape 
measurement  
Water volumetry ICCinter upper extremity .99; hand 
.97 (95% CI .91-.98) ICCintra upper extremity .99 
(95% CI .96-.99); hand .97 (95% CI .94-.98); SEM 
upper extremity 117 ml; hand 22 ml; tape 
measurement: ICCinter arm .99 (95% CI .99); hand 
.91-.98 (95% CI .74-.99); ICCintra upper extremity .99 
(95% CI .97-.99); hand .92-.99 (95% CI .85-.99); 
SEM upper extremity cylindrical formula 120-130 
ml; conical formula 114-116 ml; hand 16-33 ml; 
tape measurement-cylinder upper extremity 3-6-9 
cm r=.97-.98; tape measurement-frustum upper 
extremity 3-6-9 cm r=.97-.98; tape measurement-
rectangle upper extremity 3-6-9 cm r=.97-.98; 
water volumetry ↔ tape measurement upper 
extremity rc=.99; hand rc=.81-.91 
Cornish and 
colleagues7,25 
2001, 2002 
Australia 
BC (n=102, LE in FU=20), 
healthy (n=60)/F/age 51.7 
(25-84) 
tape measurement 
(segments of 10 cm) ↔ 
MFBIA (segments of 10 
cm)  
MFBIA: SEM 4.6%; correlation between 
frequencies .8-.9; tape measurement ↔ BIS bias 
3.1% 
Megens et 
al45 2001 
United States 
BC (n=25)/F/age 35-67 Water volumetry ↔ tape 
measurement  
Water volumetry: ICC .99; tape measurement: ICC 
.99; water volumetry ↔ tape measurement r=.97 
 
BC: breast cancer; CEAP: clinical, etiological, anatomical, pathophysiological; CVI: chronic venous insufficiency; LE: lymphedema; 
FU: follow up; obj.: objective; subj.: subjective; BIS=Bio Impedance Spectroscopy; FU=follow up; GCLQ=gynecologic cancer and 
lymphedema questionnaire; KAPS=Kwan´s Arm Problem Scale; LBCQ=lymphedema and breast cancer questionnaire; 
LF=lymphatic filariasis; MFBIA=multi frequency bio impedance analysis; ml: milliliters; NQ=Norman questionnaire; QoL=Quality 
of life; SFBIA=single frequency bio impedance analysis; SF-BIS=single frequency bio-impedance spectroscopy; SOAC=sum of arm 
circumferences; min=minutes; sec=seconds; AUC=area under the curve; c=model of best fit; CI=confidence interval; 
CV=coefficient of variation; ICC=intraclass correlation; SD=standard deviation; SEM=standard error of measurements; 
SDC=smallest detectable change. DXA=dual-energy x-ray absorptiometry; F=female; M=male. 
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Table 4. Measurement properties of included studies.  
 
When more distances in tape measurement were reported, the distance nearest to 4 cm was used. When more formulas for 
calculation of volume were reported, the frustum method was used. When therapists and patients both measured, therapist 
outcomes were used. 
*Not reported in original article AUC, area under the curve; CV, covariance; ICC, intraclass coefficient; SDC, smallest detectable 
change, SEM, standard error of measurement; BIS, bio impedance spectroscopy; cm, centimeters; LE, lymphedema; LF, 
lymphatic filariasis, ml, milliliters; PM, perometry; TM, tape measurement; WV, water volumetry; μm, micrometers 
 
Study Reliability Validity 
 ICC 
intra 
ICC 
inter 
SEM SDC Concurrent 
validity 
(comparator 
instrument) 
Convergent 
validity 
 BIS      
Bundred et a;29     .40-.60 (PM)  
Cornish et al25   SEM 4.6%   .80-.98 
(comparison 
different 
frequencies) 
Czerniec et al 
total32 
.94  SEM 14.9Ω 29.2Ω* .99/.89 
(TM/PM) 
 
Czerniec et al LE32 .95      
Czerniec et al 
healthy32 
.81      
Gordon et al11 .88      
Jain et al33 .99 .99   .90 (PM)  
Moseley and 
Piller23 
    .61 (PM)  
Smoot et al29     .83 (WV)  
 MoistureMeter 
Birkeballe et al40  .63-
.94 
    
 Water volumetry   
Borthwicket al53 .99 .99 .8% 3.0%* .73(TM)  
Brorson and 
Hoijer41 
    .87 (TM)  
Chen et al16 .99 .99 .1% 2.2%*   
Damstra et al42 .95 .98 1.4% 4.9%   
Deltombe et al9 .99 .99 2% 8.8%*   
Tewari et al48     .92 (TM)  
 Tape measurement  
Borthwick et al53 .90 .84 .8% 3.0%* .73 (WV)  
Brorson an Hoijer41     .87 (WV) Comparison 4 to 
10 cm: .87 
Czerniec and 
collegues31,32 
.96  6.6% 7.7%* .99 (WV/PM)  
Deltombe et al9 .96 .94 5.6%;  9.4%*   
Devoogdt et al10 .99 .98 1.7%;  6.7% .97 (WV)  
Gjorup et al43 .99 .99 3.6% 7.1%* 1.00/.99 (WV)  
Karges et al44 .99  .1% 4.5%* .99(WV) Comparison side 
to side difference: 
.96 
Megens et al45 .99    .97(WV)  
Meijer et al 46 .90 .80 .9% 2.6%* .86 (WV) Comparison 4 to 8 
cm: .79 
Mori et al49 .98    .80 (WV) Comparison 
plastic with paper 
tape: .98 
Sander et al arm47 .99 .99 cylinder 120-130 ml; 
frustum 114-116 ml 
cylinder 590-
639 ml frustum 
560-570 ml  
.99 (WV) Comparison 3 to 6 
to 9 cm: .97-.98 
Sander et al hand47 .96 .95 SEM 16-33 ml 79-162 ml .81-.91 (WV)  
Sawan et a55    intra 264.1 ml; 
inter 1014.5 ml 
  
Tewari et al48     .92 (WV) Comparison 
narrow to wide 
tape: .95 
 Perometry   
Bundred et al30     .40-.60 (BIS)  
Czerniec et al32 .99  4% 7.8%* .89 (TM/BIS)  
Deltombe et al9 .99 .99 .3% 3.3%*   
Moseley et al23     .61 (BIS)  
Spillane et al21   15% 29.4%   
Stout et al59      Comparison total 
volume to 10 cm 
segments: .77-.95 
 Tonometry  
Gordon et al11    1.9-2.2 μm   
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Reliability 
Reliability for measuring lymphedema using BIS was described in three studies. 
Intrarater reliability values ranged from .88 - .99.11,32,33 In the upper extremities, the 
ICC was .95 for the subgroup with lymphedema and.81 for the subgroup without 
lymphedema.32 Pooled ICCintra for lower extremities showed an ICC of .89 (95%CI .88, 
.90).11,33 
Reliability for measuring lymphedema using the MoistureMeter was described in one 
study: the ICCinter was .63 (95% CI .43 - .79) for the foot, .94 (95% CI .89, .97) for the 
ankle and .94 (95% CI .88, .97) for the lower leg.40 
Reliability for measuring lymphedema in the upper extremities using water 
volumetry was reported in 10 studies.9,10,16,42-44,46,47,49,53 Pooled data of the studies  
showed ICCintra9,42-44,46,47,49 and ICCinter9,10,16,42-44,46 values of .99 (95% CI .99, .99). The 
weighted mean SEM was 0.7% (σ=0.8%) and weighted mean SDC was 3.6% 
(σ=2.7%).9,10,16,42-44,46 
Reliability for measuring lymphedema using tape measurement was reported 
in 12 studies, of which10 studies of the upper extremities reported ICC values.9,10,32,43-
47,49,53 Pooled data of ICC in studies of arms showed an ICCintra of .99 (95% CI .99, 
.99)9,10,32,43-47,49 and ICCinter of .98 (95% CI .98 - .98).9,10,43,46,47 The weighted mean SEM 
was 2.8% (σ=2.6%).9,10,32,43,44,46 The SDC for the lower extremities was reported in one 
study55 (intra-rater difference 264.1 ml; inter-rater difference 1014.5 ml) and was not 
recalculated to percentual change. 
Reliability for measuring lymphedema using perometry was reported in 3 
studies.9,21,32 Pooled data of studies in the upper extremities showed an ICCintra value 
of .99 (95% CI .97,1.00).9,32 Interrater reliability was .99.9 The weighted mean SEM 
was 2.1% (σ=2.6%).9,32 The SDC in lower extremities was 29.4%.21 
Pooled results for reliability are summarized in table 5. The Fisher estimated r to z is 
shown in the appendix. 
 
Table 5. Pooled data for intraclass coefficients (ICC), Standard Error of Measurement (SEM) 
and weighted mean SDC. 
 
 
ICC-inter, intraclass coefficient for inter-rater reliability; ICC-intra, intraclass coefficient for intra-rater reliability; CI, confidence 
interval; SEM, standard error of measurement; SDC, smallest detectable change 
 
Measuremen
t instrument 
Body 
part 
ICCintra  
(95% CI) 
Variance ICCinter  
(95% CI) 
Variance Weighted 
SEM 
(variance) 
Weighted 
mean SDC 
(variance) 
Number 
of 
studies 
Bio 
Impedance 
Spectroscopy 
Lower 
extremity 
0.89 (95%CI 
0.88 - 0.90) 
0.1     211,33 
Volumeter Upper 
extremity 
0.99 (95% CI 
0.99 - 0.99) 
0.02 0.99 (95% CI 
0.99 - 0.99) 
0.03 0.7% (0.8%) 3.6% (2.7%) 89,16,42-
47,49 
Tape 
measurement 
Upper 
extremity 
0.99 (95% CI 
0.99 - 0.99) 
0.04 0.98 (95% CI 
0.98 - 0.98) 
0.09 2.8% (3.2%) 6.6% (2.6%) 99,10,32,43-
47,49 
Perometer Upper 
extremity 
0.99 (95% CI 
0.97 - 1.00) 
0   2.1% (2.6%) 
 
5.6% (4.2%) 29,32 
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Based on highest ICC with smallest variance and smallest SEM and SDC, we indicated 
water volumetry as index test in this article and for future research for measuring 
lymphedema in upper extremities. Information about measurement of lymphedema 
in lower extremities is scarce; therefore, no conclusion could be stated. 
Concurrent validity 
In upper extremities, correlations between water volumetry and tape measurement 
varied from .80 to .99.10,41,43-49 The correlation between water volumetry and BIS was 
.83.29 
Convergent validity 
Convergent validity was reported in 7 studies of patients with lymphedema. The 
correlation between different widths of tape and tape measurement was .95;48 the 
correlations among different measurement intervals varied from .79 to .98;41,46,47 and 
the correlation between plastic tape and paper tape was .98.49 Convergent validity in 
studies with different patient groups showed a peak bias in 10 - 20 cm segments of 
16.6%31 and variance in volume occurred mainly in 10- to 20-cm segments and in 20- 
to 30-cm segments (r2 = .77-.95).59 
Sensitivity and specificity 
Sensitivity and specificity were reported in 6 studies.17,21,25,27,29,40 In agreement with 
our analysis of reliability, measurement instruments ideally had to be compared to 
water volumetry. One study compared tape measurement with water volumetry in 
upper extremities.17 Using a cut-off point of 10% volume difference, sensitivity was 
.73 and specificity .78; using a cut-off point of 200 ml and 2 cm difference at any of 7 
measurement points, sensitivity was .90 and specificity .72. 
Variability in measurement procedures 
In using BIS, the position of the electrodes differed across the studies. Used methods 
were: 3 electrodes placed on the wrists and hands an 1 electrode placed on the 
foot,29,33 electrodes placed on both wrists and ankles,11 2 or 3 electrodes placed at 10 
cm intervals in upper extremities.27,31,32 Based on the results, no conclusion about the 
best measurement method in BIS could be stated. 
Water volumetry was carried out with a device containing water, and water overflow 
was measured with a weighing scale9,10,41,43,47,60 or a cylindrical measure.16,21,44-
46,48,49,53 Damstra et al. (2006) described a new device in which water shortness was 
measured.42 Studies using a weighing scale reported ICCintra and ICCinter values of .99. 
In studies using a cylindrical measure ICCintra values varied between .94 and .99 and 
ICCinter  values varied between .92 and .99. 
Tape measurements were carried out and interpreted in different ways. The 
starting point was the styloid process of the ulnae. Anatomical points were used as 
measurement points in 4 studies.17,21,43,49 Measurement intervals differed from 3 cm 
to 12 cm. Limb volume was calculated with the truncated cone formula,10,29,32,41,43-49 
the disk formula,9,47,55 the rectangle formula,47 or the trapezoidal formula47 or with 
the sum of circumferences.21,27 Hand volume was calculated with the trapezoidal 
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formula47 or figure-of-eight method.53 A flexible, non-stretch tape measure was used 
in all studies; in some cases a spring-loaded tape measure was used, to ensure equal 
pressure on the surface of the skin in all measurements; Devoogdt et al. used a bar 
with tapes at 4 cm distance.10 The limb volume difference calculation was handled in 
different ways: distraction of absolute volumes of limbs, summation of 
circumferences, calculation of percentage difference, or calculation of relative 
volume change.  
Feasibility 
The time needed  for measurements of the upper extremities, as reported in the 
studies, was 8 minutes for tape measurement and 5 minutes for water volumetry;42 1 
minute for each lower extremity for perometry23 and 2 minutes for BIS, when 
electrodes and apparatus were connected.23 The MoistureMeter needed 60 seconds 
per measurement.8 
In BIS measurement, patients have to avoid heavy activity for 2 hours before 
measurement, remove all jewelry and empty their bladder. The skin must be cleaned 
with alcohol. Electric devices such as a pacemaker interfere with the measurement, 
so these patients were excluded from measurements. Only costs of the tonometer 
were reported, being Australian $500 in 2011.11 
 
Discussion 
 
Our study showed clear evidence for good reliability of BIS in lower extremities and 
for high reliability and excellent validity of water volumetry, tape measurement and 
perometry in measuring and monitoring lymphedema in upper extremities. Water 
volumetry has the lowest variance, SEM and SDC in measurement of upper 
extremities, but differences in ICC as well as in SEM and SDC among water volumetry, 
tape measurement and perometry in upper extremities were very small. The 
correlation between water volumetry as a comparator test and BIS and tape 
measurement as index tests in upper extremities was excellent. In addition, we found 
moderate evidence for good reliability of ICCintra values of BIS in the upper extremities 
and high reliability ICCinter values for the MoistureMeter and good reliability of the 
tonometer in the lower extremities.  
Based on our analysis, BIS, volumetry, tape measurement and perometry can be 
recommended in clinical practice. However, the clinician has to keep in mind that 
measurement instruments are not interchangeable.43,47 In addition to considering 
reliability and validity, the choice for a measurement instrument depends on 
feasibility and costs and is related to the stage of lymphedema. In early stages of 
lymphedema (stage 0 to early stage 2), BIS can detect alterations in the amount of 
extracellular fluid earlier than swelling can be detect by volumetric measurement 
instruments. The MoistureMeter measures subcutaneous water, which alters from 
stage 0 as well. It is unclear if subcutaneous water can be measured in later stages of 
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lymphedema, when fibrosis and fat deposit are apparent. Starting from stage 2, 
swelling of limbs can be measured by volumetry. In the later stages of lymphedema, 
especially stage 3, the resistance of the skin or fibrosis can be measured by 
tonometry.  The bioimpedance spectroscope, MoistureMeter and perometer are 
expensive measurement instruments compared with the water volumeter or tape 
measure and, therefore, are less feasible in primary care practice. Moreover, in BIS 
expensive electrodes are needed every measurement. Due to lack of space in primary 
care practice, it is more difficult to create a permanent location for measuring by 
water volumetry than in clinical settings, and tape measurement is more feasible. To 
promote self-management, the patient can be instructed to measure by himself or 
herself or have measurements taken by a family member.49,61,62  
Only one study described sensitivity and specificity using water volumetry as 
reference instrument in the upper extremities.17 Ideally, a measurement instrument 
should have high sensitivity to detect every patient with lymphedema and high 
specificity to exclude false positive results. The study on measurement of upper 
extremity lymphedema showed high sensitivity (.90) of 200 ml in water volumetry 
and differences circumferences of 2 cm in any measurement point in tape 
measurement.17 However, absolute volume difference depends highly on body 
composition63 and many patients with breast cancer gain weight during cancer 
treatment.64 Moreover, differences less than 2 cm over more measurement points 
may indicate lymphedema. Future research is needed to analyze of different 
methods of calculating tape measurement compared with water volumetry. 
The time needed for measurement and the burden of different measurement 
instruments were reported scarcely in the included studies. The time to prepare the 
patient and the measurement instrument were not reported, nor was time to clean 
the measurement instrument. In tape measurement, the time needed to measure 
depends highly on the amount of measurement points. Calculated volume showed 
small variance among different measurement intervals. Therefore, it is acceptable to 
choose larger measurement intervals (ie, up to 10 cm). As tape measurement has 
higher variance compared to water volumetry, with perhaps higher variance in daily 
practice than in research, special attention is needed for an exact measurement 
protocol.  
Measurement properties of bioimpedance spectroscope, MoistureMeter, 
water volumeter, tape measure, perometer, and tonometer were mostly described 
for measuring lymphedema in the upper extremities and warrants future 
investigation in the lower extremities and at midline. Volumetry cannot be applied in 
midline (head, neck, trunk and genital region). Tonometry was investigated in 
patients with filariasis, with good measurement properties, using a rather high cutoff 
point for sensitivity analysis. In these patients, consistency of the lymphatic tissue 
was probably harder, as occurs in advanced stage 2 or 3 lymphedema. In midline, the 
bioimpedance spectroscope, MoistureMeter, and tonometer are possibly useful 
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instruments, because they are more practicable in these body regions. In lower 
extremities tape measurement and perometry are feasible as well; water volumetry 
requires good range of motion of the hip joint of the patient. The reliability and 
validity of measurement instruments in these body regions warrants further 
investigation. For reports of measurement burden, qualitative research in patients at 
risk for lymphedema or with lymphedema is needed. 
Strength and weakness of the study 
To our knowledge, this is the first systematic review on measurement properties of 
measurement instruments for measuring and monitoring lymphedema. We 
succeeded in performing a meta-analysis for reliability of tape measurement, water 
volumetry, and perometry on measurements in the upper extremities and of BIS in 
the lower extremities. Based on our analysis, recommendation of the use of water 
volumetry and tape measurement for measuring lymphedema is strong, as many 
studies were included in the meta-analysis.  
This study has several limitations. As there was no gold standard as 
comparator test, we reviewed all measurement instruments independently. 
Lymphedema is predominantly described in women with breast cancer and less in 
gynecological cancer. Medical treatment of these patients results in more risk in 
developing lymphedema than other types of cancer, except melanoma.4 Therefore 
lymphedema is more common and therefore probably more investigated in women 
than in men. On the other hand, primary lymphedema and filariasis (in tropical 
countries) are present in both sexes. Diagnosis of filariasis is based on analysis of 
blood or lymphatics, and measurement of lymphedema is secondary. Measurements 
in patients with primary lymphedema are poorly described.  
Based on the quality of the articles, we included only half of the initially 
selected articles for further analysis. In the rejected studies, a description of the 
procedure was lacking, especially in patient selection and measurement protocol. 
Regarding the risk of bias of the included studies, we noted several concerns. First, 
patient selection was diverse and not always described; consecutive patients were 
included in some studies, and random selection or enrollment via advertisement was 
mentioned. Second, only few authors described the severity of the lymphedema. 
Third, measurement protocols of the comparator test were poorly described, 
especially in studies on perometry, BIS and MoistureMeter. Fourth, blinding of 
investigators was clearly described in only 3 studies. Finally, only 9 studies included 
more than 50 patients, and two studies analyzed only a part of the study sample. 
Therefore, we cannot exclude bias in our review. 
Some articles stated that early detection of lymphedema is important and, 
therefore, recommended expensive tools such as computed tomography or magnetic 
resonance imaging.65 These modalities are not appropriate for surveillance during 
treatment of lymphedema, due to costs, patient burden and accessibility. One study 
reported that early detection of lymphedema by perometry and early treatment of 
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lymphedema based on perometry measurement are cost-effective and implies less 
burden for the patient.12 As perometry is highly comparable to water volumetry and 
tape measurement, these measurement instruments are suitable for surveillance of 
lymphedema as well. A widely accepted reference point to start treatment for 
lymphedema in the upper extremities is defined as a volume difference of 5% to 10% 
between the extremities.66 Clear cutoff points for the lower extremities are not 
available. Extensive lymphedema treatment generally starts with volume changes 
over 10%. It is unclear whether earlier identification of lymphedema makes clinical 
reasoning different, since special recommendations for prevention of lymphedema 
will be the same as for all patients at risk for lymphedema. Although the SEM is the 
smallest amount of change that can reliably be measured, SEM in volumetric 
measurement instruments is smaller than normal differences between extremities.67 
Therefore we propose the SDC as clinical relevant referring point to start treatment 
of lymphedema. Our review showed weighted mean SDC values of 3.6% for water 
volumetry, 5.6% for perometry and 6.6% for tape measurement. Treatment before 
these cutoff points can lead to overtreatment and has to be avoided. 
Implications for daily practice and future research 
Measures with evidence for good reliability and validity are BIS, water volumetry, 
tape measurement, and perometry, where BIS can detect alterations in volume 
starting from stage 2. Based on measurement properties and feasibility, we suggest 
water volumetry and tape measurement as best practice in measuring lymphedema 
in the upper extremities. Weighted mean SDCs of the different measures are 
indicated as the starting level of treatment of pre-clinical lymphedema. Volume has 
to be calculated to percentage difference. The styloid process or lateral malleolus is 
the starting point for tape measurement.  
In future research, measurement protocols and results have to be reported 
clearly and in a uniform way to allow meta-analysis. We recommend water volumetry 
using a weighing scale as a reference test in the upper extremities for future 
research. Measurement of midline lymphedema and lymphedema in lower 
extremities warrant more research. More attention in research must be paid to 
sensitivity and specificity of the clinical measurement instruments in lymphedema. 
Future investigation of the role of tonometry in patients with advanced stages of 
lymphedema and in case of fibrosis of the tissue also is needed.  
 
Abbreviations  
BIS = bio impedance spectroscopy 
ICC =  intraclass correlation coefficient 
SEM = standard error of measurement 
SDC = smallest detectable change 
J.T.H. = Janine Hidding 
P.B.V. = Peter Viehoff 
C.B. = Carien Beurskens 
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Appendix 1. Search strings measurement instruments on lymphedema. 
(((lymphedema) AND ((volume*[tiab]) OR (measurement[tiab]) OR (circumference[tiab])) AND 
(Validation Studies[pt] OR Comparative Study[pt] OR “psychometrics”[MeSH] OR psychometr*[tiab] 
OR clinimetr*[tw] OR clinometr*[tw] OR “outcome assessment (health care)”[MeSH] OR outcome 
assessment[tiab] OR outcome measure*[tw] OR “observer variation”[MeSH] OR observer 
variation[tiab] OR “Health Status Indicators”[Mesh] OR “reproducibility of results”[MeSH] OR 
reproducib*[tiab] OR “discriminant analysis”[MeSH] OR reliab*[tiab] OR unreliab*[tiab] OR 
valid*[tiab] OR coefficient[tiab] OR homogeneity[tiab] OR homogeneous[tiab] OR “internal 
consistency”[tiab] OR (cronbach*[tiab] AND (alpha[tiab] OR alphas[tiab])) OR (item[tiab] AND 
(correlation*[tiab] OR selection*[tiab] OR reduction*[tiab])) OR agreement[tiab] OR precision[tiab] 
OR imprecision[tiab] OR “precise values”[tiab] OR test–retest[tiab] OR (test[tiab] AND retest[tiab]) 
OR (reliab*[tiab] AND (test[tiab] OR retest[tiab])) OR stability[tiab] OR interrater[tiab] OR inter-
rater[tiab] OR intrarater[tiab] OR intra-rater[tiab] OR intertester[tiab] OR inter-tester[tiab] OR 
intratester[tiab] OR intra-tester[tiab] OR interobserver[tiab] OR inter-observer[tiab] OR 
intraobserver[tiab] OR intra-observer[tiab] OR intertechnician[tiab] OR inter-technician[tiab] OR 
intratechnician[tiab] OR intra-technician[tiab] OR interexaminer[tiab] OR inter-examiner[tiab] OR 
intraexaminer[tiab] OR intra-examiner[tiab] OR interassay[tiab] OR inter-assay[tiab] OR 
intraassay[tiab] OR intra-assay[tiab] OR interindividual[tiab] OR inter-individual[tiab] OR 
intraindividual[tiab] OR intra-individual[tiab] OR interparticipant[tiab] OR inter-participant[tiab] OR 
intraparticipant[tiab] OR intra-participant[tiab] OR kappa[tiab] OR kappa’s[tiab] OR kappas[tiab] OR 
repeatab*[tiab] OR ((replicab*[tiab] OR repeated[tiab]) AND (measure[tiab] OR measures[tiab] OR 
findings[tiab] OR result[tiab] OR results[tiab] OR test[tiab] OR tests[tiab])) OR generaliza*[tiab] OR 
generalisa*[tiab] OR concordance[tiab] OR (intraclass[tiab] AND correlation*[tiab]) OR 
discriminative[tiab] OR “known group”[tiab] OR factor analysis[tiab] OR factor analyses[tiab] OR 
dimension*[tiab] OR subscale*[tiab] OR (multitrait[tiab] AND scaling[tiab] AND (analysis[tiab] OR 
analyses[tiab])) OR item discriminant[tiab] OR interscale correlation*[tiab] OR error[tiab] OR 
errors[tiab] OR “individual variability”[tiab] OR (variability[tiab] AND (analysis[tiab] OR values[tiab])) 
OR (uncertainty[tiab] AND (measurement[tiab] OR measuring[tiab])) OR “standard error of 
measurement”[tiab] OR sensitiv*[tiab] OR responsive*[tiab] OR ((minimal[tiab] OR minimally[tiab] 
OR clinical[tiab] OR clinically[tiab]) AND (important[tiab] OR significant[tiab] OR detectable[tiab]) 
AND (change[tiab] OR difference[tiab])) OR (small*[tiab] AND (real[tiab] OR detectable[tiab]) AND 
(change[tiab] OR difference[tiab])) OR meaningful change[tiab] OR “ceiling effect”[tiab] OR “floor 
effect”[tiab] OR “Item response model”[tiab] OR IRT[tiab] OR Rasch[tiab] OR “Differential item 
functioning”[tiab] OR DIF[tiab] OR “computer adaptive testing”[tiab] OR “item bank”[tiab] OR “cross-
cultural equivalence”[tiab]))) NOT ((“addresses”[Publication Type] OR “biography”[Publication Type] 
OR “case reports”[Publication Type] OR “comment”[Publication Type] OR “directory”[Publication 
Type] OR “editorial”[Publication Type] OR “festschrift”[Publication Type] OR “interview”[Publication 
Type] OR “lectures”[Publication Type] OR “legal cases”[Publication Type] OR “legislation”[Publication 
Type] OR “letter”[Publication Type] OR “news”[Publication Type] OR “newspaper article”[Publication 
Type] OR “patient education handout”[Publication Type] OR “popular works”[Publication Type] OR 
“congresses”[Publication Type] OR “consensus development conference”[Publication Type] OR 
“consensus development conference, nih”[Publication Type] OR “practice guideline”[Publication 
Type]) NOT (“animals”[MeSH Terms] NOT “humans”[MeSH Terms])) AND ("2015/11/11"[PDAT]) 
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Appendix 2. Formulas used in “Measurement properties of instruments for 
measurement of lymphedema, a systematic review”. 
                                                    
1. SDC calculation 
1.a. SDC = 1.96 * SDdifference 
1.b. SDC = 1.96 * √2 * SEM 
 
 
2. SEM =SD2 * √(1-r) 
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3. ICC estimated formula for Fisher’s r to z transformation: 
 and for variance: , where n is the number of 
participants, and k the number of measurements 
 
4. Volumetric formulas 
4.a. Truncated cone formula  
, 
4.b. Disk formula  
21
4
n
i
i l
V LC
 −
=  ,27,35,39 
4.c. Rectangle formula  
,35 
4.d. Trapezoidal formula  
, 
V, volume; n, number of segments; L, length of each segment; C, circumference at 
each end of a segment; D, depth of each segment 
1
1 1 ( 1)log
2 1
k rZ
r
+ −
=
−
2
2( 2)( 1)
k
n k
 =
− −
2 2
1 1
1 ( )
12
n
i i i i
i l
V L C C C C

− −
−
= + +
n
i i
i l
V LW D
−
=
1 ( )( )
4
n
i i l i i l
i l
V L W W D D

− −
−
= + +
91 
 
Appendix 3. Pooled results of measurements in upper extremities. 
Figure 1. Pooled ICCintra  for volumetry in upper extremities.
 
Figure 2. Pooled ICCinter of volumetry in upper extremities. 
Figure 3. Pooled results ICCintra of tape measurements in upper extremities. 
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Figure 4. Pooled results ICCinter of tape measurements in upper extremities.  
 
Figure 5. Pooled ICCintra for perometry in upper extremities. 
 
Figure 6. Pooled ICCintra for BIS in lower extremities. 
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Abstract 
 
Purpose 
Early detection of breast cancer-related lymphedema through simple self-monitoring 
techniques may lead to early treatment and improved outcomes.  
Methods 
Prospective study of circumference measurements at four time points before, during 
and after adjuvant chemotherapy with docetaxel, doxorubicin and 
cyclophosphamide. Volume was calculated using the 10-cm interval circumference 
measurement method (reference test) and percentage difference between arms, for 
volume and circumference, was determined. First, the most valid single 
measurement location was determined by calculating Pearson’s correlations 
coefficient relative to the reference test. Second, to evaluate responsiveness to 
change over four time points, outcomes of the selected single measurement and the 
reference test were analyzed by repeated-measures ANOVA. Third, area under the 
curve (AUC) was used to determine the optimal sensitivity and specificity of the 
selected single measurement site (index test).  Relationship between lymphedema 
(yes/no) and heaviness and swelling (yes/no) was analyzed using Phi-coefficient.  
Results 
The measurement point 30 cm proximal to the styloid process showed the highest 
correlation with percentage difference in total arm volume (r = 0.80) and detected 
increased percentage difference between arms after treatment. Analyses showed 
high accuracy (AUC = 0.94; 95% CI 0.90 - 0.99), and good sensitivity (0.85) and 
specificity (0.85) using a cut-off score of 4% circumference difference between arms 
at this location. A moderate correlation between feelings of heaviness and swelling to 
lymphedema was observed (rφ=0.64).  
Conclusions 
Circumference difference between arms of 4% measured at 30 cm proximal to the 
styloid process can be used as a surveillance site for further monitoring of patients at 
risk for lymphedema and may contribute to early diagnosis. Feelings of heaviness or 
swelling have moderate relationship with lymphedema, which needs to be confirmed 
in clinical practice.  
 
Introduction 
 
Lymphedema in the arm is a chronic disease with swelling and impairments in 
function, resulting in limitations in activities in daily life.1-3 Detecting possible 
development of lymphedema in patients with breast cancer at risk is important, as 
early detection of adverse effects of breast cancer treatment and consequently early 
intervention can improve health outcomes and cost-effectiveness of care.4,5 
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Internationally, a volume difference between arms of ≥ 10% is considered as a cut-off 
point to diagnose lymphedema.6 Furthermore, earlier research showed that 
heaviness and swelling as reported by the patient is highly correlated with the 
diagnosis of lymphedema based on volume measurements.7,8 Water volumetry via 
water displacement in a water tank, and tape measurement using multiple 
measurement points are both reliable and feasible instruments to monitor swelling,9 
but these measurements are burdensome for the patient and the health care 
provider in terms of the time spent on the measurements. In general, differences 
between affected and unaffected arms are described in absolute or in percentage 
difference in circumference (in centimeters)  or volume (in milliliters). As absolute 
values in centimeters or milliliters are less valid and depend on body composition,10 
percentage volume difference between arms is considered the gold standard.9 
However, centimeter difference is easier to interpret for the patient than percentage 
difference. 
To support patients and clinicians in monitoring development of lymphedema 
in patients at risk for arm lymphedema, ideally the patient her/himself would be 
instructed to measure swelling and monitor the development of lymphedema in a 
simple way. Therefore, measuring circumference with a tape measure at a single 
measurement site, would be preferred. We hypothesized that it should be possible to 
identify patients at risk of lymphedema who need to consult a health care provider 
for further diagnosis by detecting a clinically relevant difference in circumference 
between arms using tape measurements at an appointed location, combined with 
feelings of heaviness and swelling.  
It is unknown which measurement locations are most closely associated with 
percentage difference in total arm volume, and whether the psychometric 
properties, particularly those related to validity of a single measurement site, are 
sensitive and specific enough to be used as a monitoring instrument. Therefore, this 
study focuses on the following research question: Is it possible to detect lymphedema 
in the arm using bilateral arm circumference measurement at a single site on each 
arm? The following hypotheses are formulated: 1) A valid single measurement 
location can be identified when compared to the reference test. 2) Percentage 
difference in total arm volume (calculated from circumference measurements) as 
well as the difference in circumference at the most valid single measurement can 
detect changes over time. 3) For the most valid single measurement, a clear cut-off 
point can be identified for detecting lymphedema, with good sensitivity and 
specificity. 4) Lymphedema is related to feelings of heaviness and swelling. 
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Methods 
 
Participants  
Patients with tumor stage I - III, scheduled for six-cycle adjuvant cytotoxic treatment 
with docetaxel, doxorubicin and cyclophosphamide (TAC) at the Radboud University 
Medical center were invited by a specialized nurse (WB) to participate in this 
prospective study. Patients were included between August 2011 and January 2015. 
Surgery was completed, as well as radiotherapy if indicated, at the start of the TAC 
treatment. Exclusion criteria were recurrence or second cancer and insufficient 
understanding of Dutch language for filling out the questionnaire. 
Patients were measured at four time points: before the start of cycle 1 (T0), 
cycle 2 (T1) and cycle 4 (T2), and one month after completion of the 6th cycle (T3).  
All participants signed informed consent before the first measurement. Formal 
ethical approval was waived by the Medical Ethical Committee of the Radboud 
University Medical center and registered under number 2011/234.  
Measurements   
Circumference measurements were performed with a tape measure using the 10-cm 
interval circumference measurement method, starting at the ulnar styloid process. 
Both arms were measured. Total limb volume was calculated from circumference 
measurements, using the conical formula, and differences between arms were 
calculated as percentage difference.9 Total limb volume measurement was the 
reference test used for assessment of validity. An arm volume difference of ≥ 10% 
was considered as lymphedema. For all used measurement sites, differences 
between both arms were calculated in percentage 
 as well as in absolute difference in centimeters 
(affected limb - unaffected limb). Tape measurement is a reliable measurement 
instrument, with excellent intra- and inter-test-retest reliability (intraclass correlatie 
coëfficiënt (ICC) 0.99 and 0.98 respectively) and good convergent validity (0.80 – 
1.00) compared with water volumetry (the gold standard) when a standardized 
protocol is used and both measurements are calculated to percentage difference.9 
Measurements were performed by three physiotherapists (CB, RD, JH), experienced 
in measuring circumferences. Investigators were blinded for results of prior 
measurements. The measurement protocol was described in detail to reduce 
measurement error and, if possible, patients were measured by the same therapist 
throughout the whole study. During measurement, the patient was sitting, with the 
hand supported on a pillow. Position of the shoulder was in 90 degrees ante-flexion 
with the elbow extended. 
Scores of heaviness and swelling were derived from the Lymph-ICF 
questionnair.11 The Lymph-ICF is a quality of life questionnaire developed for patients 
limb limb 100
limb
affected unaffected x
unaffected
−
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with lymphedema, with 29 items over five domains: physical function, mental 
function, household activities, mobility activities and social activities. Measurement 
properties of the Lymph-ICF have been studied before and showed a fair to excellent 
reliability for all scales (r = 0.65 – 0.93).11 Each item can be scored between 0 and 100 
on a horizontal line of 100 mm. A higher score means more patient complaints on 
that item (i.e., heaviness and swelling): scores under 25 indicate minor complaints, 
scores from 25 reveal marked problems.11 
Statistical Analysis 
Descriptive analyses were used to describe patient characteristics and treatment 
characteristics. For statistical analysis SPSS version 23 was used. To determine the 
most valid single measurement site, correlation between the reference test (total 
arm volume) and the difference in circumference measurement (percentage and 
absolute difference) was determined using Pearson’s correlation coefficients. 
Correlations between measurements were interpreted as follows: r > 0.75 is 
excellent; r 0.40 to 0.75 is fair to good.(15) ICCs were interpreted as follows: r > 0.90 
high; r > 0.80 good [18]. We assumed r > 0.75 sufficient to indicate a single 
measurement site valid when compared to percentage difference of total volume.12 
To determine responsiveness to changes between time points T0-T3 in 
percentage difference in total volume and in outcome of the most valid single 
measurement, repeated-measures ANOVA was used. To determine the optimal cut-
off point of the most valid single measurement, sensitivity and specificity were 
estimated and a Receiver Operating Characteristic  (ROC) curve was constructed, 
comparing the most valid single measurement, heaviness and swelling with the 
reference test (percentage volume difference ≥ 10% yes or no). An area under the 
curve (AUC) over 0.80 was considered as representing high accuracy, over 0.90 as 
excellent accuracy. In a second step, the optimal cut-off point was compared to the 
smallest detectable change at all time-points. 
To determine the strength of the relationship between lymphedema and 
feelings of heaviness and swelling as a clinical decision tool for development of 
lymphedema, percentage difference in total arm volume, and feelings of heaviness 
and swelling were dichotomized. Lymphedema was defined as ≥ 10% volume 
difference between both arms using the 10-cm interval circumference measurement 
method; swelling and heaviness as a score ≥ 25 on the Lymph-ICF questionnaire. For 
analysis, a Phi-coefficient was calculated. A p-value of < 0.05 (two-sided) was 
considered statistically significant. Sensitivity and specificity > 0.80 were considered 
clinically relevant. 
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Results 
 
A total of 74 patients scheduled for adjuvant TAC were invited to participate in the 
study. Fifty-one patients consented to participate, of which 48 completed all 
measurements. Two patients switched treatment to FEC (5-Fluorouracil, Epirubicine 
and Cyclofosfamide) after the third and fourth cycles. One patient was treated 
without docetaxel in the fourth cycle of TAC and stopped after this cycle. Mean age 
of the included patients was 51.3 years (range 30-68; standard deviation 8.5). Patient 
and tumor characteristics of these patients are summarized in Table 1.  All data 
provided by the patients were analyzed. In total, 199 measurements were analyzed. 
  
Table 1. Patient, tumor and treatment characteristics at baseline.  
 Number of patients Frequency % 
Sexes female/male 50/1 98/2 
Surgery dominant arm 25 (3 left, 22 right) 49 
non-dominant arm 26 (3 left, 23 right) 51 
mastectomy/lumpectomy 27/24 52.9/47.1 
ALND/ SNB 16/44 31.4/68.3 
Tumor grade 
 
 
 
Radiotherapy 
T0  1  2.0 
T1  4  7.8 
 T2 27 49.0 
 T3 19 39.2 
boost tumor bed 18 35.3 
axillary/supraclavicular 
radiation  
11 21.6 
ALND, axillary lymph node dissection; SNB, sentinel node biopsy  
Associations between percentage difference in total arm volume and single 
measurement sites are summarized in Table 2 and visualized in Figure 1. When 
differences between both arms were calculated to percentage difference, r ranged 
between 0.28 for the 0-cm measurement location and 0.80 for the 30-cm 
measurement location. When differences were calculated as centimeter difference, r 
ranged between -0.04 for the 10-cm measurement location and 0.71 for both the 20-
cm and 40-cm measurement locations. The 30-cm measurement location, with 
differences between both arms calculated in percentage difference, was indicated as 
the most valid measurement point. 
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Figure 1. Scatterplot of percentage difference of total arm volume and percentage 
difference at the 30 cm measurement site. 
 
A significant increase in percentage difference in total arm volume was observed at 
T3 compared to T0, as well as in percentage difference at the 30 cm measurement 
location at T3 compared to T1 (p < 0.05). At T0-T2, mean percentage difference of the 
circumference measurements ranged from 1.3 to 1.7%, increasing to 3.0% at T3. 
Before a significant increase was observed, the smallest detectable change ranged 
between 0.73 and 0.78% (Table 3). 
Analysis showed high accuracy with an AUC of 0.94 (95% CI 0.90 - 0.99; p < 
0.001) for the single measurement at 30 cm (Table 4). The preferred cut-off point as 
indication for lymphedema appeared to be 4% difference, with a sensitivity and 
specificity of 0.85 (Figure 2). A statistically significant relationship was observed 
between lymphedema and heaviness and swelling (rφ = 0.64, p < 0.001).  
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Table 2. Associations between percentage difference and centimeter difference of all 
measurement points and total arm measurement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*p < 0.05; **p < 0.01 
 
Table 3. Circumference measurements with tape measured with 10-cm distance 
intervals and circumference measurements of the 30-cm location, calculated as 
percentage difference between affected and unaffected upper extremity, at baseline 
before chemotherapy (T0), during chemotherapy before the second (T1) and fourth 
cycles (T2), and one month after completion of chemotherapy (T3).  
 
 
 
 
 
 
 
 
SD, standard deviation; SDC, smallest detectable change; SEM, standard error of measurement. 
T0, at baseline before chemotherapy;  T1, during chemotherapy before the second cycle; T2, before 
the fourth cycle;  T3, one month after completion of chemotherapy. 
* p < 0.05 compared to T0; **p < 0.05 compared to T1. 
# calculated from circumference 
† SDC = 1.96 * √2 * SEM 
 
 
 Total 
volume 
0 cm 10 cm 20 cm 30 cm 40 cm 
Percentage difference 
total volume 
(ml) 
1      
0 cm  .28 1     
10 cm .74** .28** 1    
20 cm .72** .40** .52** 1   
30 cm .80** .20** .62** .49** 1  
40 cm .73** .12 .56** .40** .66** 1 
Centimeter difference 
total volume 
(ml) 
1      
0 cm .67** 1     
10 cm -.04 .01 1    
20 cm .71** .40** .02    
30 cm .45** .16* .03 .29** 1  
40 cm .71** .11 -.06 .38** .33** 1 
 total arm volume difference  percentage difference at 30-cm 
location 
 Mean SD SEM Mean SD SEM SDC† 
T0 2.28% 5.42 0.76 1.31% 3.27 0.29 0.78 
T1 2.18% 5.04 0.71 1.29% 3.36 0.27 0.73 
T2 2.67% 5.15 0.72 1.71% 3.13 0.27 0.75 
T3 5.75%* 9.78 1.37 2.99%** 6.05 0.52 1.41 
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Table 4. Area under the curve (AUC) for percentage difference at 30 cm proximal of 
the styloid process and feelings of heaviness and swelling compared to percentage 
difference of total volume, calculated from circumference at 10-cm intervals. 
 
 
 
 
Figure 2. ROC curves of percentage difference between both arms at the 30-cm 
measurement location, heaviness and swelling in relation to lymphedema, defined as 
≥ 10% volume difference between both arms, measured by tape with the 10-cm 
interval circumference measurement method. 
 
Discussion 
 
A good association was observed between measurements at 30 cm proximal to the 
styloid process and percentage difference of total volume, when differences in 
centimeters between arms were calculated in percentage difference, with high 
accuracy and good sensitivity and specificity. Measurements over time showed the 
Measurement  Tape measurement 10-cm interval 
 AUC (95% CI) p-value 
30 cm location 0.94 (0.90 - 0.99) < .001 
heaviness 0.78 (0.68 - 0.88) < .001 
swelling 0.82 (0.71 - 0.93) < .001 
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single measurement site being responsive to change. The relationship between 
swelling and heaviness with lymphedema was moderate.  
The first hypothesis, that a valid single measurement site can be indicated 
comparing single measurements with the reference test is accepted. A good 
association between the reference test and percentage difference between arms at 
the 30-cm measurement location was observed. In contrast, using absolute 
difference in centimeters, fair associations were observed with percentage difference 
in total arm volume. The second hypothesis, that percentage difference of total 
volume as well as percentage difference of the most valid single circumference 
measurement can detect changes over time changes was also accepted. It can be 
stated as well that percentage difference of total volume as of a single measurement 
is sensitive to change over time. The third hypothesis, that for the most valid single 
measurement a clear cut-off point can be identified for development of 
lymphedema, with good sensitivity and specificity was accepted as well. Using a cut-
off point of 4% at the  
30-cm site, sensitivity and specificity in relation to percentage difference of total arm 
volume is good. The fourth hypothesis, that lymphedema is related to feelings of 
heaviness and swelling is accepted. However, as only a moderate association was 
observed, and only a part of the patients with lymphedema reported heaviness and 
swelling, this finding has to be investigated. 
The single measurement point at 30 cm proximal to the styloid process, 
calculated in percentage difference, appears to be a good control point for 
surveillance of patients at risk for lymphedema. In this study-population, the cut-off 
score of the single measurement for further diagnosis of possible development of 
lymphedema was beyond the smallest detectable change. A cut-off score of 4.0% 
difference in circumference between affected an unaffected arm can be indicated as 
decision tool for the patient to consult a health care provider for further analysis in 
relation to development of lymphedema. This finding, a cut-off score of 4% 
difference between arms, has to be investigated, following patients at risk for 
developing lymphedema, measuring by themselves over a longer time period. Even 
more, in a population of patients with lymphedema, outcomes may be different. 
Although a single measurement saves time, attention has to be given to the following 
aspects. Measurements in this research were performed by experienced therapists. 
For a patient, measuring by her/himself, it is more difficult to find the same location 
at every measurement time and in both upper extremities. Measurements have to be 
performed at a fixed daytime point, preferably early in the morning, as arm volume 
can change during daytime and can change as a result of activities during the day. 
Even more, during warm weather, volume can increase as well. Therefore, the 
patient needs to be instructed carefully. To facilitate measurements by the patient 
her/himself and for accurate measurements, preferably a tape measure with a 
locking mechanism should be used.  
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Dominance may play a role in volume differences between arms. One study showed 
no effect on volume difference in relation to surgery on dominant or non-dominant 
side.13 In our study, surgery on the dominant side showed no effect on percentage 
volume differences as well (data not shown); therefore, control for dominance seems 
not necessary. As earlier studies reported volume differences between arms, with the 
dominant arm being 2.2 - 3.0% larger,13-16 too small cut-off points (less than 3%) may 
overestimate signs of development of lymphedema. These findings are in line with 
the smallest detectable change as described above. 
Both our study and the study by Smoot et al. confirmed the 30-cm location as 
the measurement site with the highest accuracy.13 In contrast to our study, a cut-off 
point of 200 ml was used for diagnosis of lymphedema and ≥ 2 cm circumference 
difference between both arms as cut-off point for a single measurement site.13 The 
AUC in our study is higher than in the study of Smoot et al., where patients with and 
without lymphedema were included and measured only once. In their study a high 
specificity was chosen (0.94; 95%CI 0.86–0.98), resulting in a far lower sensitivity 
(0.36; 95%CI 0.25–0.48) than our ROC curve showed.13 This can be explained by 
findings of our study, indicating that percentage difference between arms is more 
sensitive than centimeter difference. Furthermore, including patients with 
lymphedema as well as without lymphedema may play a role in difference in 
outcomes between the studies, which has to be confirmed in future studies. 
In relation to self-measurements by the patient, reliability of tape 
measurement was reported in earlier studies, both using 10-cm interval 
measurements.17,18 One study reported a high intrarater reliability of tape 
measurements by the patient (ICCintra > 0.97).17 Another study compared self-
measurement by the patient with tape measurement by a therapist, and reported 
inter-rater reliability of dominant and non-dominant arm, with good to high reliability 
at the 30-cm location (ICCinter 0.88 and 0.91, respectively).18 These findings indicate 
that self-measurement using a tape measure is quite probably a reliable method for 
self-monitoring of swelling by the patient.  
For the patient as well as the clinician, a tool that registers outcomes of 
measurements over time would be helpful. In a simple way, the outcomes can be 
registered using a spreadsheet. Nowadays most people use their mobile phone for 
many purposes. As the 30-cm location is associated with percentage difference of 
total volume at all measurement time-points, a mobile application can be developed 
for self-management. Ideally this app should contain the formula for calculating 
percentage difference between affected and non-affected arm, to indicate if the 
difference between both arms can be indicated as possible development of 
lymphedema. Especially in patients with chronic diseases, self-efficacy is important in 
relation to quality of life, as well as in time spent with healthcare providers and may 
save costs. Self-monitoring by the patient, together with careful explanation of risk 
profile and signs of lymphedema by health-care providers and easy access to a 
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health-care provider in case of uncertainties, make patients stakeholder of their own 
health problems. If applicable, this clinical decision tool will help patients to control 
possible onset of lymphedema. 
 
Conclusion 
 
In patients with breast cancer at risk for developing lymphedema in the arm, 
percentage difference of circumference measurement at a single measurement site 
at 30 cm proximal of the styloid process is associated with percentage difference of 
total arm volume. A difference of 4% between both arms has high accuracy and good 
sensitivity and specificity in relation to total arm volume. Future research has to 
confirm usefulness and validity in clinical practice.  
Abbreviations  
AUC = area under the curve 
ICC = intraclass correlation coefficient 
TAC = docetaxel, doxorubicin, cyclophosphamide 
SEM = standard error of measurement 
CB = Carien Beurskens 
JH = Janine Hidding 
RD = Riet Dobben 
WB = Wilmy Bos 
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Abstract 
 
Purposes 
The purposes of this study were to investigate the incidence of lymphedema in 
patients with breast cancer during and after adjuvant treatment with docetaxel, 
doxorubicin and cyclophosphamide (TAC), to identify predictors for development of 
lymphedema, and to describe consequences in daily life in relation to lymphedema. 
Methods 
This is a prospective study with measurements before chemotherapy (T0), during 
chemotherapy before cycle 2 (T1), cycle 4 (T2), and one month after completion of 
treatment (T3). Volume change was monitored using tape measurement. 
Lymphedema was defined as ≥10% volume difference. Linear Mixed-effect Models 
were estimated to analyze changes in arm volume and consequences in daily life 
(total score and domain scores of the Lymph-International Classification of 
Functioning (ICF) questionnaire) over time, and to identify treatment and patient 
characteristics as predictors for changes in volume. 
Results 
Forty-eight patients completed all measurements. Volume did not change during TAC 
treatment.  One month after treatment, volume was significantly increased 
compared to T0-T2, and 12 patients (25%) had developed lymphedema. Axillary 
lymph node dissection was associated with lymphedema (ES 2.9, 95%CI 0.02 - 5.7; 
p<0.05). In patients with lymphedema at T3, a significant association between 
volume and total score on the Lymph-ICF questionnaire, on physical function and 
mobility activities was observed.  
Conclusions 
One month after treatment in 12 patients (25%), volume difference increased over 
10%. Axillary lymph node dissection was predictive for development of lymphedema. 
All patients, but more patients with lymphedema, perceived difficulties in activities in 
daily life after treatment.  
 
Introduction  
 
Lymphedema is a common side effect of breast cancer treatment, usually starting 
within 2 years after treatment.1 Patients with lymphedema suffer not only from 
swelling, but also from other impairments in functions and limitations in activities in 
daily life, as described in the Core Set Lymphedema based on the International 
Classification of Functioning (ICF).2 Lymphedema is defined as a volume difference 
between upper extremities of ≥ 10%,3 resulting in limitations in arm use during daily 
activities, emotional distress, restrictions in social activities, and limited work 
abilities.2,4,5  
109 
 
The estimated incidence of lymphedema five years after breast cancer treatment is 
16.6% and increase in arm volume is related to axillary lymph node dissection, the 
number of lymph nodes dissected, mastectomy, radiotherapy to the axilla and a body 
mass index over 25 kg/m2.1,6 Recent studies have indicated that the use of adjuvant 
cytotoxic treatment may be associated with the development of lymphedema after 
completion of treatment, especially regimens containing anthracyclines and 
taxanes.6-14 Swelling may decline over time, as a result of lymphedema treatment or 
due to spontaneous recovery of transient swelling within three months.13,14 Adjuvant 
chemotherapy has been shown to improve survival in patients with early-stage breast 
cancer. Second and third generation schemes are more effective in survival 
compared to first generation schemes.15 A frequently used third generation regimen 
consists of docetaxel, doxorubicin and cyclophosphamide (TAC).16 
Although the prevalence of lymphedema in the arm after completion of TAC 
has been reported,11-14 development of lymphedema during treatment with TAC and 
limitations in daily activities in relation to lymphedema during and after TAC are 
unknown. Early detection of lymphedema and consequently early intervention can 
lessen treatment burden and increase the cost-effectiveness of care.17 Therefore, it is 
clinically relevant to obtain insight in changes in the amount of extracellular fluid or 
volume differences in an early stage.  
The purpose of this study is to answer the following specific questions: (1) 
what is the change in arm volume during adjuvant treatment with TAC, and do 
patients develop lymphedema as defined by a volume difference between upper 
extremities of ≥ 10%, (2) which predictors for development of lymphedema can be 
identified, and (3) which consequences in daily life are related to the presence of 
lymphedema? 
 
Methods 
 
Study design 
We conducted a prospective cohort study in which patients with unilateral breast 
cancer were scheduled for adjuvant cytotoxic treatment with six cycles of TAC. 
Patients were measured at four time points: at baseline before cycle 1 (T0), during 
chemotherapy before cycle 2 (T1) and cycle 4 (T2), and one month after the 6th cycle 
(T3). Three months after completion the Lymph-ICF questionnaire was sent to the 
patients (T4). 
Patient population 
Patients, both female and male, with tumor stage I - III, scheduled for adjuvant 
cytotoxic treatment with TAC at the Radboud university medical center were invited 
by a specialized nurse (WB) to participate in this study. Patients were included 
between August 2011 and January 2015. Surgery was completed, as well as 
radiotherapy if indicated, before the start of TAC. Exclusion criteria were recurrence 
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or second cancer and insufficient understanding of Dutch language for filling out the 
questionnaire. Formal ethical approval was waived by the Medical Ethical Committee 
of the Radboud university medical center and the study was registered under number 
2011/234. All participants signed informed consent before the first measurement. To 
avoid a type 1 error, we calculated the sample size on the basis of arm volume 
difference of ≥ 10% as primary endpoint. A priori, a drop-out of 10% was taken into 
account. To detect changes at a two-sided significance level of 5% and an estimated 
power of 80%, we planned to enroll 50 patients . 
Chemotherapy 
Docetaxel (75 mg/m2), doxorubcine (50 mg/m2) and cycoclophosphamide (500 
mg/m2) were administered intravenously on day one of a 3-weekly cycle for a total of 
six courses. Dexamethason was administered 8 mg orally twice daily during three 
days, starting the day before start of TAC during all cycles. 
Measurements 
Demographic and tumor characteristics, type of surgery, axillary lymph node 
dissection, tumor stage, nodal stage, tumor grade, adjuvant radiotherapy, 
radiotherapy to the axilla or supraclavicular region, weight, and height were derived 
from electronic health records of the included patients. Early termination of TAC or 
dose reduction was registered, as well as the reason for the early stop and change of 
cytotoxic agents. Weight was registered before the first and after the last cycle to 
determine body mass index (BMI) and weight changes.  
Volume of both arms was measured by tape measurement,18 and 
impairments in functions and limitations in activities in daily life were measured by 
the Lymph-ICF questionnaire.19 Measurements were performed by three 
physiotherapists (CB, RD, JH), experienced in measuring arm volume.  Investigators 
were blinded for results of prior measurements. The measurement protocol was 
described in detail to reduce measurement error and, if possible, patients were 
measured by the same therapist throughout the whole study. All patients with 
identified lymphedema at any timepoint, defined as a volume difference of >10%, 
were referred for treatment. Both upper limbs were measured by tape measurement 
with 10 cm intervals up to 40 cm, starting at the ulnar styloid process. Position of the 
arm during measurement was in 90 degrees flexion of the shoulder with the elbow 
extended. Hands were supported on a pillow. To calculate volume, the conical 
formula was used.[18] Volumes between both upper extremities were converted to 
percentage differences (relative volume, in short mentioned as volume in this 
article). Tape measurement is a reliable measurement instrument, with excellent 
intra- and inter-test-retest reliability (ICC 0.99 and 0.98 respectively) and good 
validity (0.80 – 1.00) compared to water volumetry when a standardized protocol is 
used.18  
Volume changes, based on the tape measurement, were computed at all four 
time points. A volume difference ≥ 10% between both upper extremities was 
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indicated as swelling or development of lymphedema.3 To get insight in outcomes 
between patients without lymphedema and with lymphedema 1 month after 
completion, and to get insight in the association between volume changes and 
impairments in functions and limitations in activities in daily life, the patient group 
was dichotomized in two categories: with lymphedema and without lymphedema 1 
month after completion of TAC (T3).  
The Lymph-ICF questionnaire for the upper extremity was used to get insight 
in impairments in functions and limitations in activities in daily life.19 The Lymph-ICF 
is a quality of life questionnaire developed for patients with lymphedema, with 29 
items over five domains: physical function, mental function, household activities, 
mobility activities and social activities. Each item can be scored between 0 and 100 
on a horizontal line of 100 mm. Domain scores and the total score can be calculated 
from the items, both resulting in a score between 0 and 100. A higher score means 
more impairment in functions or limitation in activities: scores under 25 indicate a 
small problem, scores between 25 and 50 a moderate problem and scores more than 
50 a severe problem. Measurement properties of the Lymph-ICF have been studied 
before and showed a fair to excellent reliability for all scales (r = 0.65 – 0.93) 
compared to volume measurements.19 Patients filled in the Lymph-ICF questionnaire 
at every measurement point. To get insight in recovery after TAC, 3 months after the 
last TAC the Lymph-ICF questionnaire was sent to the patient for a final 
measurement. 
Statistical analysis  
Descriptive analyses were used to describe patient characteristics, treatment 
characteristics, the number of patients with lymphedema, and the scores of the 
Lymph-ICF questionnaire in total and its domains. 
To analyze differences in volume and consequences in daily life over time, and 
to identify treatment and patient characteristics as predictors for changes in volume, 
Linear Mixed-effect Models were used. We estimated a random intercept model with 
volume difference 
as dependent variable, and we estimated separate models with total score and 
domain scores of the Lymph-ICF questionnaire as dependent variables. To indicate 
predictors for lymphedema, univariate analysis was used to analyze the association 
between volume difference and type of surgery, surgery on dominant side, axillary 
lymph node dissection, tumor stage, nodal stage (N0 versus N1, N2 and N3), tumor 
grade (T1 versus T2 or 3), adjuvant radiotherapy, radiotherapy to the axilla or 
supraclavicular region and change of BMI between T0 and T3. Variables with an 
association p < 0.20 in the univariate analysis were included into the model as 
independent variables.  
To analyze the association between volume differences and impairments in 
functions and limitations in activities after completion of TAC, Pearson’s correlation 
coefficients between volume and the outcomes of the Lymph-ICF questionnaire (total 
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score and domain scores) were calculated for the total population. To analyze the 
relation between scores of the Lymph-ICF questionnaire and lymphedema, patients 
were dichotomized in patients without lymphedema and patients with lymphedema 
at 1 month after completion of TAC (T3). In both groups the association between 
volume and the scores of the Lymph-ICF questionnaire, its five domains, and 
individual items of the physical function domain and mobility activities domain (T3 
and T4) were analyzed, using Spearman’s correlations.  
Correlations between measurement outcomes were interpreted as follows: r 
between 0.40 and 0.75 is fair to good; r > 0.75 is excellent.20 
For statistical analysis SPSS version 22 was used. 
 
Figure 1. Flowchart patient inclusion for measuring before, during and after adjuvant 
TAC. 
 
Results 
 
A total of 74 patients scheduled for adjuvant TAC were invited to participate in the 
study. Fifty-one patients consented to participate, one of these was male. Mean age 
of the included patients was 51.3 years (30-68; SD 8.5). Patient and tumor 
characteristics of these patients are summarized in Table 1. Two patients switched 
treatment to FEC (5-Fluorouracil, Epirubicine and Cyclofosfamide) after the third and 
fourth cycle. One patient was treated without docetaxel in the fourth cycle of TAC 
and stopped after this cycle. Finally, 48 patients completed all follow-up 
measurements, of which 41 patients completed the full six cycles of TAC.  Four 
patients were treated with reduced dose (75%) after the third (n=2 patients), fourth 
(n=1 patient) or fifth cycle (n=1 patient) (see Figure 1). 
 
Patients included in study 
n=51 
Patients denied to participate n=23 
Reason: 
Lymphedema n=2 
Too much effort n=8 
Rather not n=7 
Language problem n=1 
Comorbidity n=1 
Other reasons n=4 
 
Patients treated following protocol 
n=44 
 
Eligible patients 
n=74 
Patients with interrupted treatment n=7 
Early stop n=3  
Dose reduction n=4 
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Table 1. Baseline patient, tumor and treatment characteristics. 
 
 
Number of patients Frequency % 
Sexes female/male  50/1  98/2 
Age (mean - SD) 51.3 8.5 
BMI (mean - SD) 26.26 4.44 
Surgery dominant arm  25 (3 left, 22 right) 49 
non-dominant arm  26 (3 left, 23 right) 51 
mastectomy/lumpectomy 27/24 52.9/47.1 
ALND/ SNB 16/44 31.4/86.3 
Tumor size ≤ 2 cm  22   43.1 
 2 – 5 cm  26   50.9 
 > 5 cm  3   5.9 
Histology ductal carcinoma  46   90.2 
lobular carcinoma  4   7.8 
other  1   2 
Tumor stage Tis 1 2.0 
T1 3 5.9 
T1b 2 3.9 
T1c 18 35.3 
T1(m) 2 3.9 
T2 17 33.3 
T2(m) 7 13.7 
T3 1 2.0 
Nodal stage No 10 19.6 
N0(i+) isolated tumor cells 11 21.6 
N1 10 19.6 
N1(mi) micro metastasis 11 21.6 
N(1a) 7 13.7 
N(2a) 2 3.9 
Tumor grade T0 1 2.0 
T1 4 7.8 
 T2 27 49.0 
 T3 19 39.2 
Estrogen 
Receptor  
positive/negative 45/6   85.2/14.8 
Progesterone 
Receptor  
positive/negative 34/17   66.7/33.3 
Radiotherapy  33   64.7 
boost tumor bed 18   35.3 
Axillary/supraclavicular 
radiation  
11   21.6 
ALND, axillary lymph node dissection; BMI, body mass index; SNB, sentinel node biopsy; cm, 
centimeter; SD, standard deviation. 
 
Changes in arm volume and lymphedema measured by tape measurement 
Mean volume did not change during treatment, but increased significantly from 2.3% 
at T0 to 5.1% at one month after completion of TAC (T3) (p = 0.01) (Table 2). In total, 
15 patients showed increased volume of ≥ 10% difference in at least one 
measurement point. In three of the six patients swelling deemed transient: volume 
decreased under the cut-off point of 10% volume difference within the study period; 
one of them without treatment. Fulfilling our definition, lymphedema was observed 
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in six patients during TAC treatment. These patients were referred for lymphedema 
treatment: two patients at either baseline (T0), before the second and the fourth 
cycle during chemotherapy (T1 and T2).  
 
Table 2. Lymphedema measurements with tape at 10 cm distance, calculated as 
relative volume difference between affected and unaffected upper extremity. 
 
 Mean(%) Standard error 95% Confidence Interval Significance 
T0 2.282% .925 .458 - 4.107  
T1 2.180% .925 .356 - 4.005 .938 
T2 2.689% .944 .827 - 4.550 .759 
T3 5.708% .924 3.872 - 7.633 .010* 
T0: before TAC 1; T1: before TAC 2: T2: before TAC 4: T3: one month after TAC 6. 
*significance p < 0.05 
Predictors for of lymphedema 
Axillary lymph node dissection, nodal stage, axillary radiation and difference in BMI 
identified between one month after completion of TAC (T3) and baseline (T0) were 
variables with a correlation (p < 0.10) with volume at T3 in the univariate analysis. 
The Linear Mixed-effect Model showed that axillary lymph node dissection was the 
only factor significantly associated with increased volume (ES 2.9%; 95% CI 0.02 - 5.7; 
variance 9.5%, p < 0.05). (see appendix 1); Odds Ratio 12.4 (95% CI 2.6 – 58.3; p < 
0.01). 
Impairments in functions and limitations in activities in daily life 
Mean total score of the Lymph-ICF questionnaire showed an increase from 14.6 at 
baseline (T0) to 19.5 at 1 month after completion of TAC (T3) and subsequently 
decreased to 16.5 three months after completion of TAC (T4). Longitudinal analysis 
showed no significant changes over time except in the domain physical functioning. 
One month after TAC completion, physical functioning showed a significant increase 
(p = 0.01) compared to T0 – T2. Three months after TAC physical functioning 
improved, but scores remained higher compared to T0 (p < 0.05) (Table 3).  
The number of patients with moderate to severe problems (scores ≥ 25) on 
the Lymph-ICF questionnaire decreased between T3 and T4. Looking at the number 
of patients without lymphedema and with lymphedema, relatively more patients 
with lymphedema experienced problems, especially in total score, physical 
functioning, mobility activities and social activities, 1 and 3 months after treatment 
(T3, T4). Patients without lymphedema reported more problems with mental 
functions 1 month after treatment (see Table 4). One month after completion of TAC, 
in patients with lymphedema, a significant association was found between volume  
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and the Lymph-ICF total score (r = 0.66), the physical function domain (r = 0.77), as 
well as the item scores for heaviness (r = 0.83) and swelling (r = 0.71) and the mobility 
activities domain (r = 0.66), as well the items activities above the head (r = 0.71) and 
cycling (r = 0.72). Three months after completion of TAC, in patients with 
lymphedema, the significant correlation between relative volume at T3 and the total 
Lymph-ICF score (r = 0.70) and mobility activities (r = 0.62) remained (see Table 5). 
 
Table 3. Lymph-ICF questionnaire and its domains at baseline before chemotherapy 
(T0), during chemotherapy before TAC 2 (T1) and before TAC 4 (T2), one month after 
completion of TAC 6 (T3) and 3 months after completion of TAC 6 (T4). 
 
*significance p < 0.05 
 
Measurement 
point 
Number Mean Standard 
Error 
Significance 95% Confidence 
Interval 
Total score 
T0 51 14.63 2.20  10.29 - 18.97 
T1 51 11.31 2.20 0.29 6.97 - 15.66 
T2 49 12.98 2.25 0.60 8.55 - 17.41 
T3 48 19.46 2.27 0.13 14.98 - 23.93 
T4 48 16.52 2.27 0.55 12.05 - 21.00 
Physical function 
T0 51 9.80 2.19  5.49 - 14.12 
T1 51 6.90 2.19 0.35 2.58 - 11.22 
T2 49 9.96 2.24 0.96 5.55 - 14.37 
T3 48 17.79 2.26 0.01* 13.34 - 22.24 
T4 48 16.67 2.26 0.03* 12.22 - 21.12 
Mental function 
T0 51 11.75 2.23  7.36 - 16.13 
T1 50 7.74 2.25 0.21 3.31 - 12.17 
T2 49 8.18 2.27 0.26 3.71 - 12.66 
T3 48 11.90 2.94 0.96 7.38 - 16.42 
T4 48 9.46 2.94 0.48 4.94 - 13.98 
Household activities 
T0 51 14.98 2.87  9.79 - 20.63 
T1 51 13.71 2.87 0.75 8.06 - 19.35 
T2 49 12.02 2.93 0.47 6.26 - 17.78 
T3 48 21.38 2.96 0.12 15.55 - 27.20 
T4 48 16.81 2.96 0.66 10.99 - 22.63 
Mobility activities 
T0 51 18.14 2.74  12.73 - 23.54  
T1 51 13.73 2.74  8.32 - 19.13 
T2 49 14.00 2.80 0.26 8.49 - 19.52 
T3 48 20.58 2.83 0.29 15.01 - 26.12 
T4 48 19.31 2.83 0.54 13.74 - 24.89 
Social activities 
T0 51 19.20 3.19  12.92 - 25.47 
T1 51 16.45 3.19 0.54 10.18 - 22.73 
T2 49 19.35 3.25 0.97 12.94 - 25.75 
T3 48 23.79 3.28 0.32 17.32 - 30.26 
T4 48 18.21 3.28 0.83 11.74 - 25.68 
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Table 4. Patients* with moderate (≥25; <50) and severe (≥50) problems indicated by 
the Lymph-ICF questionnaire after treatment with TAC. 
 One month after completion(T3) Three months after completion (T4) 
Reported score  ≥25; <50 ≥50 total ≥25; <50 ≥50 total 
TOTAL SCORE 12 5 17 6 4 10 
Without lymphedema 9 3 12 4 3 7 
With lymphedema 3 2 5 2 1 3 
PHYSICAL FUNCTION 10 4 14 6 4 10 
Without lymphedema 5 3 8 4 3 7 
With lymphedema 5 1 6 2 1 3 
MENTAL FUNCTION 3 3 6 - 4 4 
Without lymphedema 2 3 5 - 3 3 
With lymphedema 1 - 1 - 1 1 
HOUSEHOLD ACTIVITIES 11 6 17 6 5 11 
Without lymphedema 9 4 13 5 3 8 
With lymphedema 2 2 4 1 2 3 
MOBILITY ACTIVITIES 9 7 16 11 6 17 
Without lymphedema 6 5 11 9 4 13 
With lymphedema 3 2 5 2 2 4 
SOCIAL ACTIVITIES 10 8 18 7 8 15 
Without lymphedema 7 5 12 7 5 12 
With lymphedema 3 3 6 - 3 3 
*Patients without lymphedema n = 36; patients with lymphedema n = 12. 
 
Discussion 
 
During cytotoxic treatment with TAC, we observed no significant changes in volume 
between upper extremities in the total study population. However, 1 month after 
completion of TAC volume was increased significantly, and 25% of the patients had 
developed a volume difference over 10%, defined as lymphedema. Also, in this 
population, axillary lymph node dissection was predictive for development of 
lymphedema, as was reported in earlier studies as well[6, 21]. The Lymph-ICF 
questionnaire showed significant impairments in the physical function domain at 1 
and 3 months after completion. One month after treatment, 17 patients showed at 
least moderate problems on the total score of the questionnaire and reported 
problems in physical function, household activities, mobility activities and social 
activities. We observed a small decline in the number of patients with health 
problems between 1 and 3 months after completion of TAC. 
Reported prevalence of lymphedema, measured at a comparable time point 
after surgery in recent studies on breast cancer, was comparable with our study at 
baseline.13,14,22,23 DiSipio et al. described in their systematic review an prevalence of 
lymphedema of 10.3% (95%CI: 6.2 – 16.7) at the same time point as T3 in our study, 
after completion of cytotoxic treatment.1 In relation to their study, the prevalence of
11
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lymphedema at the endpoint in our study is higher. This could be the effect of the 
adjuvant treatment with TAC as suggested in a recent study indicating docetaxel as 
important risk factor for onset of lymphedema, with a chance of developing 
lymphedema being 4.8 times higher when compared to other treatment regimens10 
and reported in earlier studies as well.7-9,11-14 Compared to our study, earlier studies 
on TAC as a risk factor for lymphedema reported a higher prevalence of lymphedema 
over two or more years after treatment with TAC with 33.5%,12 42.2%;14 and 32% 
after treatment, declining to 23% at six months.13 Although bio-impedance 
spectroscopy (BIS) measures extracellular fluid more adequately and good 
correlations between volume measurements and BIS were found in case of 
swelling,18,24-26 we decided to decrease patient load during the study. As results from 
different studies can be compared, we decided to decrease patient load during the 
study. The somewhat lower prevalence of lymphedema (25%) in our study may be 
the result of lymphedema treatment of patients with a volume difference over 10%, 
later onset of lymphedema, as well as recent developments in supportive care 
encouraging patients to stay active during treatment with at least 30 minutes of 
moderate daily physical activity.27 Referral to physical therapy or lymphedema 
treatment was reported in one other study.10 Our analysis of predictive factors for 
development of lymphedema early after treatment with TAC confirms the findings of 
Lee et al.: axillary lymph node dissection is an important risk factor for development 
of lymphedema.13 
Concerning the Lymph ICF questionnaire, problems were apparent over a 
longer time period, in patients with lymphedema and without lymphedema. Looking 
to the results in Table 4 it can be observed that the number of patients with 
problems on the Lymph-ICF questionnaire are different between groups, while Tables 
5 and 6 point out that volume increase is associated with more problems at the 
Lymph-ICF questionnaire. This means that all patients, with or without lymphedema, 
experienced problems, that were not always noticed by caregivers. However, 
lymphedema increased the scores. Compared to the literature, in a study with FEC 
one third of the patients still had problems as well28 and problems related to work 
were reported in a recent systematic review.4 Especially mobility activities are an 
indication for decreased social contacts and participation in community life and work, 
which are important factors for quality of life.29,30 Moderate to high-intensity exercise 
during chemotherapy could have limited the decrease in activities during adjuvant 
treatment, as was reported in an earlier study in a comparable population, reporting 
significant positive effects of exercise on physical function, fatigue, and 
chemotherapy completion rates.31  
The item scores of heaviness and swelling were significantly associated with 
volume in patients with lymphedema. These self-reported outcomes can indicate 
lymphedema of the affected upper extremity,26,32,33 can be used as a patient’s 
reported outcome for lymphedema, and are supportive in the clinical decision 
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making on volume measurement and referral for lymphedema treatment. When 
moderate to severe problems are reported on the Lymph-ICF questionnaire, referral 
to specialized health care should be considered to improve functions and activities as 
soon as possible.34,35 In agreement with  a previous systematic review of the 
literature (2014),6 many factors play a role in complaints of patients after medical 
treatment for breast cancer. For the patient as well as the health care provider, it is 
important to know the origin of the complaints. It is unclear why the item cycling 
within the domain mobility activities has high scores in the majority of the patients; 
probably this can be related to reduced cardiovascular function as an adverse effect 
of TAC,16 to fibroses of the breast in patients treated with lumpectomy and 
radiotherapy (OR = 7)36 or pain after radiotherapy of the chest wall, as was reported 
by Levangie et al. in 26% of the patients, leading to reduced daily activities.5 
Limitations in activities above the head can be related to declined shoulder mobility, 
which is often described as adverse effect of axillary node dissection and/or axillary 
radiotherapy; or declined muscle strength or shoulder coordination, described as 
adverse effects of axillary node dissection and chemotherapy.6,37  
This is the first study describing arm volume during TAC as an objective 
measurement of lymphedema in combination with patient reported outcome 
measures on physical and mental function, household activities, mobility activities 
and social activities. However, some limitations have to be considered.  
Preoperative measurements were not incorporated in our measurement 
protocol, although such measurements have been recommended in the literature.38-
42 However, the first measurement was started within three months post-operatively 
and lymphedema is rarely reported within the first months post-operatively. 
Moreover, this timepoint was found as significant predictor by  Sun et al. (2016) for 
over- and underdiagnoses.40 Lymphedema defined as relative volume change (RVC) 
compared to baseline as used by Sun et al. is a different definition compared to our 
definition, using relative volume difference (RVD) between extremities. We used RVD 
following the commonly used definition in the literature.1,6 Future studies need to 
point out which of the definitions is most adequate. Furthermore, patient and 
treatment characteristics should be analyzed in relation to volume change during a 
longer follow-up with more measurement occasions. A rather conservative cut-off 
point of 10% between both upper extremities was defined as lymphedema, based on 
the smallest detectable change in tape measurement (6.6%, with excellent interrater 
reliability (ICCinter 0.98).18 Probably, a cut-off point of 5% would have increased the 
number of patients with (subclinical) lymphedema and transient edema. 
Although the sample was large enough to distinguish changes in volume 
difference during the study period, a larger sample size and a longer follow-up might 
have indicated more risk factors for development of lymphedema, and a higher 
prevalence of lymphedema, as reported in earlier studies on TAC and docetaxel.8-
12,14,40 As no measurements were performed between cycle 4 and 6, the exact time-
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point of onset of lymphedema cannot be determined. A longer follow-up would have 
enabled the distinction between transient swelling from persistent lymphedema. 
Swelling can be transient as a result of spontaneous recovery or by intervention, as 
reported earlier.1,8,10,13,14 In future research and in clinical practice, volume 
measurements should be taken at baseline and at least in the first follow-up visit  
after completion of TAC. Follow-up should be extended to differentiate between 
transient swelling and lymphedema, reporting lymphedema treatment as well. 
Altogether monitoring swelling seems to have added value and seems to be 
clinical relevant. 
 
Conclusion 
 
In our population, arm volume increased significantly 1 month after treatment with 
TAC and in 12 out of 48 patients (25%) relative volume difference increased over 
10%. Axillary lymph node dissection was predictive for development of lymphedema. 
After treatment with TAC, all patients, but more patients with lymphedema, 
perceived difficulties in activities in daily life. 
 
Abbreviations 
TAC = docetaxel, doxorubicin, cyclophosphamide 
ICF = international classification of functioning and health 
BMI = body mass index 
ICC = intraclass correlation coefficient 
RVC = Relative volume change 
RVD = Relative volume difference 
CB = Carien Beurskens  
JH = Janine Hidding  
WB = Wilmy Bos 
RD  = Riet Dobben 
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Appendix 1. Fixed effects of the Linear Mixed-effect model in relation to 
predictive factors for increase of relative volume at T3. 
Parameter Estimate Standard 
Error 
p-value 95% Confidence 
Interval 
Intercept 1.68 .63 .01 .44 - 2.93 
ALND 2.86 1.17 .05* .02 - 5.69 
Nodal stage 1.44 1.09 .20 -.72 - 3.60 
Axillary radiation .65 2.75 .81 -4.78 - 6.08 
BMI T3-T0 -.00 .00 .45 -.01 - .00 
ALND * Nodal stage -.26 3.16 .94 -8.82 - 8.30 
ALND * axillary radiation 297.67 181.87 .10 -61.30 - 656.64 
ALND * BMI T3-T0 2.02 .74 .07 -.26 - 4.30 
Nodal stage * axillary radiation -4.14 3.28 .21 -10.62 - 2.34 
Nodal stage * BMI T3-T0 .00 .48 1.00 -.95 - .96 
Axillary radiation * BMI T3-T0 .00 .00 .89 -.01 - .01 
ALND * Nodal stage * axillary radiation -298.79 187.54 .11 -668.96 - 71.37 
ALND * Nodal stage * BMI T3-T0 -.80 1.87 .69 -6.04 - 4.45 
ALND * axillary radiation * BMI T3-T0 310.77 189.37 .10 -62.99 - 684.54 
Nodal stage * axillary radiation * BMI T3-T0 -.00 .48 1.00 -.954 - .95 
     
ALND, axillary lymph node dissection; BMI, body mass index 
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In this thesis we aimed to identify risk factors for decreased arm and shoulder 
function in patients with breast cancer associated with medical treatment modalities 
during and after medical treatment. Moreover, we focused in more detail on the 
most appropriate method to identify and measure lymphedema, which is frequently 
present in this patient group. In this final chapter we first summarize the main 
findings of the studies, followed by a reflection on these findings, especially in 
relation to physical therapy practice. Thereafter, strengths and limitations of the 
studies will be discussed. Finally, the role of physical therapy in the care process and 
recommendations for future research will be given. 
 
Findings in the studies of this thesis 
In chapter 2 and 6 we identified risk factors for physical impairments in shoulder and 
arm function. The review in chapter 2 identified level 1 evidence for risk factors after 
axillary lymph node dissection, mastectomy, radiotherapy to the axilla, radiotherapy 
before or concurrent to chemotherapy, and administration of zoledronic acid. Range 
of motion is more reduced after mastectomy compared to lumpectomy, and after 
radiotherapy to the axilla compared to no radiotherapy. Muscle strength is more 
reduced after axillary lymph node dissection compared to sentinel node biopsy, and 
after concurrent radiotherapy and chemotherapy compared to sequential 
radiotherapy and chemotherapy. Lymphedema is observed more after axillary lymph 
node dissection compared to sentinel node biopsy, after mastectomy compared to 
lumpectomy, after radiotherapy to the axilla compared to no radiotherapy, after 
concurrent radiotherapy and chemotherapy compared to sequential radiotherapy 
and chemotherapy, and when radiotherapy is administered before chemotherapy 
compared to when radiotherapy is administered after chemotherapy. Pain is 
observed more after axillary lymph node dissection compared to sentinel node 
biopsy, when radiotherapy is administered before chemotherapy compared to 
radiotherapy after chemotherapy, and after treatment with zoledronic acids 
compared to no treatment with zoledronic acids. Taken together, we concluded that 
axillary lymph node dissection, mastectomy and radiotherapy were high-risk 
treatment modalities for developing physical impairments in shoulder and arm. 
In chapter 6 we focused on a cytotoxic treatment with docetaxel, doxorubicin 
and cyclophosphamide (TAC) and found reduced physical functioning one month 
after treatment. All patients perceived difficulties in activities in daily life, and 
patients with lymphedema perceived more difficulties than patients without 
lymphedema. Lymphedema was observed in 25% of the study population. Axillary 
lymph node dissection was identified as a risk factor for onset of lymphedema in this 
population.  
 Functioning related to lymphedema is firstly discussed in chapter 3, where we 
identified concepts of the International Classification of Functioning and health (ICF) 
in lymphedema-specific questionnaires. Approximately two-third of the selected 
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studies on lymphedema focused on the upper limb. Ninety percent of the concepts 
could be linked to the ICF and addressed problems directly or indirectly related to 
swelling. Measurement domains in the questionnaires were mostly related to  
‘‘Structure of upper extremity’’, ‘‘Immunological system functions’’, ‘‘Looking after 
one’s health’’, ‘‘Sensation of pain’’, ‘‘Touch functions’’, ‘‘Dressing’’ and ‘‘Health 
services, systems and policies’’. Based on these findings a first Core Set for 
lymphedema, mentioning the most important factors related to lymphedema, was 
established. 
In chapter 4 studies on measurement properties of measurement instruments 
for lymphedema are analyzed. Several instruments diagnose lymphedema by 
measuring circumference, volume, interstitial fluid, subcutaneous fluid, and 
resistance of the skin. Most of the studies that we identified, focused on 
measurement of lymphedema in the arms. In these studies, volume was measured 
directly by water volumetry or indirectly by tape measurement or perometry. 
Extracellular fluid was measured by bio-impedance spectroscopy and subcutaneous 
water by tissue dielectric constant (MoistureMeter). Resistance of the skin was 
measured by tonometry. Volumetric measurements were most valid, when 
differences in volume between both arms were converted to percentage difference.  
To recalculate circumference measurement outcomes to volume outcomes, 
the rectangle and the conical formula are both valid and showed a high correlation 
when compared to water volumetry outcomes. We identified water volumetry using 
a weighing scale as the gold standard (chapter 4) although in primary care, 
protocolized measurements with a tape measure are valid and the most feasible way 
of measuring the presence of lymphedema. 
Early detection of development of lymphedema through simple self-
monitoring techniques might lead to early treatment and, thereby, improved 
treatment outcomes. As we found in chapter 5, the measurement at a point 30 cm 
proximal to the styloid process showed the highest correlation with the traditional 
circumference measurements (more locations at the total arm). Moreover, this one 
point measurement was responsive to changes in percentage difference between 
arms after treatment with TAC. Analyses of measurements at this location showed 
high accuracy, and good sensitivity and specificity, using a cut-off score of 4% 
circumference difference between arms. A moderate correlation between feelings of 
heaviness and swelling to lymphedema was observed. These findings are promising 
for development of a self-measurement tool using innovative techniques, but need to 
be confirmed in clinical practice and future studies. 
 
Reflection on the findings of this study 
The Evidence Statement Breast cancer - published in 2011 - identified axillary lymph 
node dissection and axillary radiotherapy as risk factors for physical problems after 
medical treatment.1 Furthermore, a core set of measurement instruments was 
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proposed and evidence based physical therapy treatments were described.1 
Nevertheless, the discussion on when to refer which patients with breast cancer to a 
physical therapist is ongoing. 
This thesis aimed to contribute to further substantiation of the role of physical 
therapy diagnosis and treatment of physical problems, especially lymphedema, in 
patients with breast cancer. In this section we will reflect on the main findings of this 
thesis related to the role of a physical therapist. Firstly, we will reflect on the risk 
factors for adverse effects of medical treatment modalities, as risk factors are 
important for timely identification of limitations in arm and shoulder functioning of 
patients who can benefit from a consultation by a physical therapist for advice or 
treatment. Secondly, we will reflect on the validity of measurement of lymphedema, 
and thirdly on patient reported outcomes in patients with breast cancer. 
 
Risk factors for adverse effects of medical treatment modalities 
Medical treatment of patients with breast cancer generally consists of multiple 
modalities, each with its own impact on adverse effects on physical functioning, 
including lymphedema. Medical treatment options and clinical practice guidelines 
change regularly, based on new evidence that emerges. Each stage of breast cancer, 
during and after primary medical treatment, shows adverse treatment effects related 
to physical functioning. Physical therapy treatment can play an important role in 
reducing physical problems due to the medical treatment. When problems in arm 
and shoulder functioning are recognized in an early stage, physical therapy advice 
and if necessary early treatment can be more effective than wait-and-see procedure.1  
 
Figure 1. Current level 1 of evidence for the association between medical treatment 
for breast cancer and impairments in arm, shoulder and thorax. 
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In providing advice, the patient can be educated to perform preventive exercises and 
to recognize limitations in functioning in an early stage. Therefore, physical therapists 
need to have up-to-date information on current and new medical treatment options 
for patients with breast cancer, and their adverse effects, as well as up-to-date 
scientific evidence on the effectiveness of physical therapy treatment. In Figure 1 a 
summary is presented of the highest level (level 1) evidence between each modality 
of the medical treatment for breast cancer adverse effects resulting in impairments 
in arm and shoulder. Problems in relation to physical therapy treatment are reduced 
range of motion and muscle strength, pain, lymphedema and decline in activities in 
daily living. Decline in activities in daily living was poorly described in literature, 
therefore no level 1 evidence was found on this item. 
Surgery 
After publication of chapter 2 of this thesis, new evidence on adverse effects of 
axillary lymph node dissection was reported in two studies.2,3 One of these studies 
followed patients with breast cancer seven years after surgery.2 Especially range of 
motion in the direction of abduction and muscle strength of the shoulder abductors 
showed clinically relevant impairments, in respectively 26% and 24% of the patients 
after axillary lymph node dissection.2 As a result of these publications the evidence 
level for adverse effects of axillary lymph node dissection compared to sentinel node 
biopsy on range of motion can be increased to the highest level (level 1). Other 
recent publications on coordination of muscles of the shoulder and muscle strength 
in general contribute to earlier findings on reduced muscle strength and coordination 
of the shoulder girdle.3-5 These findings implicate that patients after axillary lymph 
node dissection and mastectomy are at high risk to develop physical complaints and 
need surveillance and referral to physical therapy treatment early after surgery. 
Radiotherapy 
In the past years, axillary lymph node dissection is being performed less regularly 
and, instead, many patients receive axillary radiotherapy. Radiotherapy to the axilla 
increases the risk to development of lymphedema, although the risk seems lower 
than after axillary lymph node dissection.6,7 Moreover, axillary radiotherapy is a risk 
factor for reduced range of motion.7 It is assumed, that both reduced range of 
motion as well as development of lymphedema are not observed directly after 
radiotherapy, but probably as a late effect, starting 4 - 6 months after treatment.8,9 
These findings indicate that range of motion of the shoulder and development of 
lymphedema require monitoring, and if indicated physical therapy intervention, also 
after axillary radiotherapy, as was already described for patients after axillary lymph 
node dissection.1,10 
Systemic therapy 
While in chapter 2 identified evidence of anti-hormonal therapy on pain was scarce, 
recent studies, analyzed in a systematic review, show that especially aromatase 
inhibitors are related to arthralgia, mostly reported in wrists and hands.11 Pain 
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interferes with activities in daily life, especially carrying objects and reaching 
overhead.12 A recent systematic review on distress in patients with breast cancer, 
reported that 75% of the included studies reported pain as a risk factor for distress,13 
thereby influencing quality of life. Pain appears to be a large problem in patients with 
breast cancer, whatever treatment modalities are given. During follow-up, 
experience of pain has to be examined and the cause of pain has to be explained to 
prevent high levels of chronic experienced pain.14  
Cytotoxic treatment is a risk factor for reduced muscle strength and loss of 
shoulder girdle coordination.3,5,15 Furthermore, when taxanes are used, cytotoxic 
treatment is a risk factor for lymphedema,16-21 as we found in our study (chapter 6) as 
well. A relationship between muscle strength and development of lymphedema has 
been suggested.1,22 In conclusion, during systemic therapy patients need strong 
advise to stay active and need monitoring on normal use of the arm and shoulder. 
During and after systemic therapy physical therapy treatment can play a role in 
distraction of experienced pain and in maintaining - during cytotoxic treatment - or 
increasing the general activity level. 
 
Lymphedema measurement  
Volume measurements are important for surveillance in patients at risk for 
lymphedema, and for follow-up of patients with lymphedema (chapter 4). From the 
studies in this thesis it is obvious that volume measurements by water displacement 
and tape measure have high reliability and good validity, and are responsive to 
change. We advocate that physical therapists choose one method for repeated 
measurements to increase validity of longitudinal monitoring. Circumference 
measurements at a single location in arms (30 cm proximal of the styloid process) are 
promising to allow patients themselves to monitor the onset or course of 
lymphedema (chapter 5). However, this method should be further tested for 
feasibility. In clinical practice, diagnosis of lymphedema is not only based on 
measurement of volume, but also combined with palpation of the lymphedema site. 
Palpation provides information on the consistency of the swollen tissue: in early 
lymphedema the tissue is soft; in longer existing lymphedema, when fat deposit and 
fibrosis replace extracellular water, the consistency of the tissue is harder.23 
Therefore, clinical examination of the lymphedema consists of objective 
measurements and impression of the consistency of the tissue by palpation. 
Measurement of subclinical lymphedema is only possible with expensive 
instruments such as tissue dielectric constant, bio-impedance spectroscopy, magnetic 
resonance imaging (MRI), or computer tomography (CT). The importance of diagnosis 
of lymphedema at this stage is questionable, as advise and treatment strategies are 
similar as for patients at risk for developing lymphedema: through regular 
surveillance of signs of lymphedema, feelings of heaviness and swelling (chapter 5 
and 6), and volume measurements in follow-up visits.24 In this stage, we advise to 
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inform the patient about signs of onset of lymphedema and the importance of 
normal use of the arm and shoulder. Awareness results in earlier detection of 
lymphedema, reduced risk of development of lymphedema,25 and reduced health 
care costs.26,27  
Early lymphedema is generally described as a volume difference of 5 – 10% 
between arms. Based on variance in the standard error of tape measurements and 
perometry (chapter 4), a volume difference of 5% is the absolute minimum difference 
to consider early lymphedema treatment. Volume differences between arms over 
10% are generally considered as the cut-off point for definitive diagnosis and 
treatment of clinical lymphedema.24 In the literature, some authors suggest that also 
changes in volume difference could be used as diagnostic measurement 
instrument.28,29 It is reported, that swelling may decline over time, as a result of 
lymphedema treatment or due to spontaneous recovery of transient swelling within 
three months.21,30 At this moment no literature is available to give insight in 
treatment effects guided by changes in volume difference. Thus, most treatment 
strategies are based on absolute volume difference between arms. In our research, 
we opted to diagnose lymphedema and referral for physical therapy treatment when 
volume difference between arms increased over 10% (chapter 5 and 6), to avoid 
overtreatment based on some natural fluctuations. We observed fluctuations in 
volume difference over time in almost a third of our study population, of which 25% 
showed a volume difference of 10% or more after TAC treatment (chapter 5).  
Only one study, included in our systematic review in chapter 4, reported 
measurements of edema in the breast with bio-impedance spectroscopy and 
tonometry.31 Breast edema is nowadays more prevalent, because of breast 
conserving surgery (lumpectomy) followed by radiotherapy.32,33 In literature on 
adverse effects of breast cancer treatment and presence of breast edema are 
reported, but not common. Moreover, most edemas are graded as low.32,33 Clinical 
diagnostic management is mainly dependent on palpation of the tissue of the breast 
to judge the consistency. A large gap in the current literature is knowledge about the 
objective measurement of edema and fibrosis in the breast, although some studies 
report the use of MRI and ultrasound.34  
 
Patient reported outcomes 
As patients with lymphedema report problems on various health domains, insight in 
patient reported outcomes is important to establish the best treatment options and 
to evaluate treatment effects. In physical therapy, ICF terminology is widely used to 
indicate health problems related to illness or disease and to hypothesize 
relationships between the various problems in relation to the underlying disease. 
Brief Core sets are developed to give insight in the most mentioned problems in 
patients with chronic diseases, but are not validated in clinical practice. In Dutch 
guidelines and statement on breast cancer and lymphedema, three questionnaires 
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are recommended in patients with breast cancer: the Disabilities of Arm, Shoulder 
and Hand questionnaire (DASH) for patients with breast cancer in general and the 
Upper Limb Lymphedema questionnaire (ULL-27) and Lymph-ICF questionnaire for 
patients with lymphedema in the arm.1,24,35-37  
One of the problems in daily practice is the large number of items in 
questionnaires and the fact that patients with both diagnoses breast cancer and 
lymphedema need to answer two questionnaires with overlapping questions. 
Therefore, it is important to reach consensus on which questionnaire is most 
adequate in practice.  
The Disabilities in Arm, Shoulder and Hand questionnaire (DASH), focusing on 
problems in functioning as well as activities and social life in relation to the upper 
extremity, is frequently used in research on breast cancer. This questionnaire is not 
disease-specific and it misses items, that are related to adverse effects of breast 
cancer treatment. The ULL-27 and Lymph-ICF questionnaire are lymphedema-
specific, but also cover items focused on the consequences of breast cancer and its 
treatments. The items of the ULL-27 and Lymph-ICF questionnaire are comparable 
and cover the same categories of the ICF. Looking more specifically, it is obvious that  
the items in the Lymph-ICF are formulated shorter, and therefore probably better 
understandable for patients than the ULL-27. An important advantage of both 
questionnaires is that they cover domains of both Brief Core Sets lymphedema and 
breast cancer. Table 1 shows an overview of the common domains mentioned in at 
least both Brief Core Sets for Breast Cancer and Lymphedema, or one Brief Core Set 
and the Lymph-ICF questionnaire. 
In earlier research, reliability, convergent and divergent validity of the Lymph-
ICF questionnaire were examined in patients with and without lymphedema 
(objective or subjective) and the questionnaire distinguished between patients with 
and without lymphedema. Clinical relevant change was calculated: 13.4 points for the 
total score, on a Visual Analogue Score of 100, but responsiveness to change was not 
evaluated.37 In the studies described in chapter 5 and 6, the Lymph-ICF questionnaire 
appeared sensitive to changes in physical performance after completing cytotoxic 
treatment in both patients with and without lymphedema. Smallest detectable 
change in our study was smaller than published earlier, with a maximum of 6.29 
points in the measurements after completion of cytotoxic treatment. In our view, for 
the moment, the Lymph-ICF questionnaire can be advised as surveillance instrument 
in all patients with breast cancer. However, to guarantee a complete overview, some 
additions should be made taking the Brief Core Sets as reference points, namely the 
external factors ‘Products and technology for personal use in daily living’ and 
relationships with ‘Immediate family’, ‘Friends’ and ‘Health professionals’. It is 
advised to measure objectively ‘Structures of the shoulder’ (mobility of the shoulder 
girdle and muscle strength of the shoulder muscles) and ‘Structures of the immune 
system’ (volume difference between both arms). To be feasible for all patients with 
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breast cancer, the questionnaire should be adapted in future studies, and contain 
elements of table 1. 
 
Table 1. Common domains in the Brief Core Sets for Lymphedema and Breast Cancer 
and the Lymph-ICF questionnaire. 
ICF 
code 
Meaningful concept Brief Core Set 
Lymphedema 
Brief Core Set 
Breast Cancer 
Lymph-ICF 
questionnaire 
b1 Mental functions  x x x 
b280 Sensation of pain x x x 
b435 Immunological system 
functions 
 x   x 
b455 Exercise tolerance x  x 
b710 Mobility of joint functions x x x 
b730 Muscle power functions x  x 
d230 Carrying out daily routine x x  
d430 Lifting and carrying objects  x    x 
d445 Hand and arm use x x x 
d5 Self-Care x  x 
d640 Doing housework    x x x 
d770 Intimate relationships x x  
d850 Remunerative employment x x x 
d920 Recreation and leisure x  x 
e115 Products and technology for 
personal use in daily living 
x x  
e310 Immediate family x x  
e320 Friends x x  
e355 Health professionals x x  
s420 Structure of immune system x x  
s730 Structure of upper extremity x x  
 
Role of the physical therapist in patients with breast cancer 
Treatment modalities of the physical therapist are 1) information and advice, 2) 
diagnosis, 3) treatment and 4) monitoring and prevention. In breast cancer 
treatment, physical therapy is part of the multidisciplinary care plan.10 In this 
paragraph, the role of the physical therapist will be described in relation to patients 
with breast cancer. 
Information and advice 
Medical treatment in combination with physical complaints may result in reduced 
level of activities,12,13 thereby reducing quality of life. Ideally, the nurse practitioner 
should inform patients about risks of adverse effects of every modality of the medical 
breast cancer treatment and possible problems in daily life. The role of the nurse 
practitioner as well the physical therapist is to coach the patient in performing 
preventive strategies and detect health problems in an early stage.38 Life style 
interventions on physical activity, dietary behavior and weight are effective.39 
Encouraging a healthy life style, education of self-management strategies and 
stimulation of positive thinking on self-efficacy are part of the care plan.38  
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Diagnosis and monitoring 
For all patients with breast cancer, it is important to identify and monitor physical 
functions, pain and activities in daily living during and after medical treatment.38 High 
exercise levels before and during treatment may result in less decline in functioning 
during treatment.3 Specialized nurses can advise and probably recognize physical 
problems, but are not trained in doing this. In case of decline in physical functioning 
and decreased level of activities in daily living during and after medical treatment, 
consultation of a physical therapist with knowledge and competences in oncology 
should be considered.  
 
 
Figure 2. Physical therapy consultation of high risk patients with breast cancer after 
medical treatment, time of referral, physical impairment and measurement 
instruments, based on the Evidence Statement Breast cancer1 and this thesis. 
 
It depends on how care is organized and on education of the nurse practitioner, 
whether a physical therapist is consulted and at what time point after surgery, to 
diagnose physical problems. The scheme in figure 2 can be used as starting point, for 
both the nurse practitioner and the physical therapist, when referral to physical 
therapy treatment should be considered and which measurement instruments are 
advised to evaluate different outcomes. Objective measurements of range of motion, 
muscle strength, pain and lymphedema are important as surveillance instruments in 
 Medical treatment   Time of referral       Physical impairment and measurement instruments 
Radiotherapy to the axilla 
Radiotherapy on the chest wall before start of radiotherapy Range of motion Goniometer 
Control length of pectoral muscles 
Lymphedema  at 30 cm of both arms, % difference 
2 weeks after radiotherapy 
4 months after radiotherapy 
Range of motion Goniometer 
 Control length of pectoral muscles 
Muscle strength Microfet 
 Shoulder muscles 
Pain   VAS or NPRS 
Lymphedema  at 30 cm of both arms, % difference 
Physical functioning Brief Core Sets or Lymph-ICF 
Axillary lymph node dissection 
Mastectomy 
 
before start of radiotherapy 
5-7 days post-operative 
Range of motion Goniometer  
 Anteflexion, abduction, external rotation 
Muscle strength Microfet 
 Shoulder muscles, big muscle groups 
Pain   VAS or NPRS 
Lymphedema  at 30 cm of both arms, % difference 
BMI   length and weight 
Physical functioning Brief Core Sets or Lymph-ICF 
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diagnosis. Furthermore, it is advised to explore the patients’ believes on pain, as pain 
interferes with activities in daily living.12 Objective outcome measures together with 
patient reported outcome measures indicate which physical functions and activities 
are compromised and give direction to individualized treatment goals and treatment 
options.  
Treatment and coaching 
Physical therapy treatment may play a role in restoring normal arm function, and 
improving or maintaining a healthy life style. Strong evidence was found that early 
physical therapy treatment on range of motion of the shoulder and muscle strength 
training in patients after axillary lymph node dissection improves shoulder function 
and reduces the risk of development of lymphedema (Level of Evidence 1).1,24,40,41 
During and after breast cancer treatment, it is important to coach patients in relation 
to pain, as pain is associated with declined physical activity, distress and declined 
level of quality of life.11,12 It is advised to explain the origin of the pain as precise as 
possible and encourage patients to use their arm normally despite experienced pain. 
One study suggested that exercise may influence  the level of pain as experienced by 
the patient, measured with the Shoulder Pain and Disability Index.42 Exercises 
including mobilization improve range of motion and decrease the level of 
experienced pain.43 With better arm functioning and pain education the attention to 
pain will decrease . 
Lymphedema, once existing, needs life-long self-management and monitoring, 
as the lymph flow is compromised and will not restore naturally.23,24 The 
effectiveness of compression garments has to be evaluated regularly.24 
Specific lymphedema treatment 
One study described a lower incidence of lymphedema as a result of three months of 
supervised strength training of large muscle groups, compared to usual care (Level of 
Evidence 3).22 Although this finding needs to be confirmed in future studies, strength 
training of large muscle groups complementary to training of shoulder muscles seems 
to have added value.  
In early lymphedema, swelling may be reversible and can be treated in an 
easy way with a confection arm sleeve for three months (Level of Evidence 2).24,26 It is 
supposed, that when percentage difference between arms decreases under 5%, no 
further compression is needed,26 and in case of return of feelings of swelling or 
heaviness arm circumference needs to be analyzed again.44 However, it is important, 
that patients are aware of the benefits of a healthy life style, stay active and monitor 
their weight. 
Preventive manual lymphatic drainage is not advised in the Evidence 
Statement on Breast Cancer nor in the multidisciplinary guideline on lymphedema.1,24 
However, the Evidence Statement of Dutch Skin therapists does recommend post-
operative manual lymphatic drainage for patients at risk for development of 
lymphedema,45 based on one study with methodological flaws.46 It is recommended 
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to give uniform treatment advices, for patients as well as care givers, as discrepancies 
in treatment advice result in uncertainty about qualitative good treatment. Looking 
more in detail to the evidence on effectiveness of preventive manual lymphatic 
drainage, outcomes of studies on preventive manual drainage are inconsistent.46-48 
Based on the quality and methodology of the studies and interpretation of the 
outcomes, preventive treatment with manual lymphatic drainage seems not cost-
effective and makes patients with subclinical and early lymphedema dependent of 
their care-givers (Level of Evidence 2).  
For patients with lymphedema, with a volume difference over 10%, treatment 
consists of manual lymphatic drainage combined with bandaging, exercises and skin 
care (complex decongestive therapy) (Level of Evidence 1).24 A positive treatment 
effect of decongestive therapy, consisting of reduced volume difference between 
arms and softer consistency of the tissue, is described. The same effect is reported 
for bandaging in patients with grade 3 lymphedema (Level of Evidence 3).1  A home-
based program with respiratory exercises, regular hand-pumping and resistance 
exercises showed significant and clinical relevant decrease of arm volume difference 
(Level of Evidence 3).49 
When a maximum decrease of volume difference is established with 
treatment, a well fitted, tailored compression garment has to be provided.24 With 
garments and instructions on exercising, advice on lifestyle and skin care, treatment 
of lymphedema by a specialized therapist should be limited in time.24 According to 
the chronic care model, only very complex patients need special care over a longer 
time period, consisting of monitoring volume difference between arms, coaching on 
self-efficacy strategies and if necessary lymphedema-specific treatment.24 To prevent 
further worsening of lymphedema or lymphedema-side effects, it is strongly advised 
that all patients with lymphedema have the possibility of consultation of a specialized 
physical therapist if necessary. 
Skin care is important for all patients with (or at risk for) lymphedema, as 
infection can result in decompensation of the lymph flow and progressive 
lymphedema is associated with the development of several skin changes.24 When 
treated properly and in time, morbid lymphedema with a volume difference over 
40% between arms, will occur less. Weight of an edematous arm will decrease arm 
and shoulder function. In morbid lymphedema, bandaging will decrease volume 
difference between arms and soften the tissue (Level of Evidence 3).50 Patients with 
morbid lymphedema have to be informed, that intensive treatment including 
compression therapy over a longer time period is necessary to be effective. As 
treatment is complex, consultation of a multidisciplinary lymphedema team should 
be advised for these patients. 
Monitoring and prevention 
In all patients with breast cancer, with and without lymphedema, life style advice is 
important, stimulating 30 minutes of moderate physical activity daily and weight 
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maintenance.10,24 Patients have to be informed about preventive strategies 
concerning adverse effects, as well as awareness of warning signs related to 
decreased functioning. During cytotoxic treatment, prevention of further functional 
decline will support continuing of cytotoxic treatment.51 To make treatment 
effective, in case of a sedentary life style, patients will benefit from coaching for self-
management and preventive strategies in relation to a healthy life style.39,52  
According to the multidisciplinary guideline on lymphedema, adequate 
information on signs of onset or worsening of lymphedema is important for all 
patients at risk for lymphedema and with lymphedema.24 Swelling and heaviness are 
the most mentioned signs for onset of lymphedema. To make the patient responsible 
for her own health, self-measurement of circumference of arms at 30 cm from the 
ulnar styloid process should be encouraged. In the population at high risk for onset of 
lymphedema, the lymph flow is decreased compared to healthy subjects, and 
patients are at risk to develop cellulitis.23 Patients should be aware that weight gain 
will compromise the lymph flow even more.23 Furthermore, skin care improves the 
quality of the skin, thus making the skin a better barrier for germs and thereby 
decreases the risk of developing cellulitis.24  
Taken together, it is advised to inform patients with breast cancer on a 
healthy life style, monitor range of motion, muscle strength, pain, lymphedema and 
arm- and shoulder functioning. When patients report problems on these items, 
consultation of a physical therapist is advised. 
 
Limitations of this thesis 
Limitations of the studies and this thesis have to be acknowledged. In the systematic 
review on adverse effects of the medical treatment, we only reviewed studies with at 
least 100 participants. Conclusions were robust, but no qualitative studies were 
included, which could have added value regarding patients’ experiences after breast 
cancer treatment. The purpose of the study on ICF categories in lymphedema specific 
questionnaires was only to extract meaningful concepts, without quality assessment 
of the included questionnaires. The construction and validation of these 
questionnaires was not always described. Regarding the TAC-study, in which we 
evaluated onset of lymphedema and patient related outcomes before, during and 
directly after cytotoxic treatment, pre-operative measurements of arm volume were 
not available. Our study showed, that the timepoint directly after cytotoxic treatment 
was important measurement to detect development of lymphedema. For future 
studies, over a longer time-period or when comparing with another cytotoxic 
treatment in a randomized design, this finding can be used in the study protocol.  
Although both multidisciplinary guidelines on breast cancer and lymphedema 
advise pre-operative measurements, this advice is not commonly implemented in 
clinical practice. Therefore, percentage difference between extremities before start 
of cytotoxic treatment was chosen as starting point to evaluate volume differences. 
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We argued that this is a not a major problem, as development of lymphedema within 
three months after surgery is rare.1,53 Post-operative physical therapy treatment of 
patients with axillary lymph node dissection, mastectomy or axillary radiotherapy was 
not part of the standard care. We hypothesize that early exercise after axillary lymph 
node dissection may have decreased the number of patients with lymphedema . 
Furthermore, patients in our TAC study were not routinely encouraged to stay active 
during cytotoxic treatment. By analyzing data of our TAC study, we noticed that 
exercises as part of the treatment plan appeared to be not common practice in 
treatment of patients with lymphedema. Lymphedema treatment consisted mainly of 
manual lymphatic drainage. Compression with bandaging was performed, but also 
lymph-taping, of which evidence is still lacking. Therefore it can be concluded, that 
awareness of best practice and implementation of guidelines is needed. Finally, the 
final measurements in the TAC-study were performed one month after cytotoxic 
treatment, while longer follow-up would have been of added value, enabling the 
identification of persistent lymphedema. However, as we defined lymphedema as ≥ 
10% difference between arms, a real volume change occurred, warranting 
surveillance of the swelling and possibly other impairments, and treatment by a 
physical therapist specialized in lymphedema. In the analysis of a single measurement 
site we used data of the TAC study. Patients in this study had a rather normal BMI, 
which could have influenced our conclusions. Because circumference was converted 
to percentage difference, weight gain will have minor influence on outcomes. 
During the TAC-study, patients reported whether they underwent physical therapy 
treatment and/or lymphedema treatment. These treatment were not evaluated 
further. The inclusion of a study about prevention and treatment of lymphedema, or 
an implementation study based on figure 2, will have added value in the future.  
 
Implications for future research 
Current medical treatment modalities as radiotherapy to the axilla instead of axillary 
lymph node dissection, neo-adjuvant cytotoxic treatments and targeted therapies 
result in less adverse effects as earlier treatments. It is advised to update the 
literature on evidence of adverse effects of the medical treatment. The new evidence 
should be translated to importance for physical therapy practice. To get insight in 
activities in daily living and participation in work and social environment, implications 
of breast cancer treatment on these items need more attention in future research. 
Future research on adverse effects of the medical treatment of breast cancer ideally 
should include a large population using reliable and valid measurement instruments, 
and should stratify risk factors by treatment modality. In our systematic review on 
adverse effects, we identified only one study related to breast reconstruction. Since 
this is a common treatment modality nowadays, information on potential adverse 
effects of breast reconstruction is needed.  
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As a result of our research, the multidisciplinary guideline on lymphedema has been 
updated with recommendations for using measurement instruments. It is advised to 
update the multidisciplinary guideline on breast cancer and the physical therapy 
evidence statement on breast cancer as well. To be more uniform in advice and 
treatment in relation to lymphedema, it is strongly advised that both organizations 
for physical therapists and skin therapist cooperate in all roles (information and 
advice, diagnosis, treatment and prevention), which is especially important for the 
patient.  
To get more insight in treatment of patients with breast cancer and to explore 
treatment outcomes, it is advised to develop a database with outcomes of a standard 
set of measurement instruments in physical therapy practice and skin care practice. 
This database will support future research on effectiveness of treatment modalities. 
As preventive strategy for lymphedema, strength training of large muscle groups in 
combination with coordinative exercises and arm resistance exercises have to be 
explored.   
For the moment, the Lymph-ICF questionnaire can be used to get more insight 
in patients reported outcomes, but questions have to be extended to complaints in 
the breast, apart from the arm. The questionnaire has to be developed further, so it 
can be used in all patients with breast cancer as surveillance instrument and as 
evaluative tool of physical therapy treatment. In relation to diagnosis and treatment 
of breast edema, insight in the incidence of breast edema and factors influencing 
development of edema in the breast need more attention in research. Up till now, no 
simple measurement instrument has been developed for midline lymphedema. 
When a reliable, valid and feasible measurement instruments for midline 
lymphedema has been explored, it is advised to develop treatment strategies for 
midline lymphedema.   
 
Conclusions 
 
Breast cancer treatment has various adverse effects on physical functioning. Axillary 
lymph node dissection, mastectomy and radiotherapy are the most reported risk 
factors. Patients treated with these modalities need monitoring on range of motion, 
muscle strength, pain, lymphedema, and activities in daily living. Water volumetry 
and tape measurement are reliable and valid measurement instruments for 
measuring and monitoring of lymphedema. In patients at risk for onset of 
lymphedema, measurement at one location, 30 cm proximal from the ulnar styloid 
process, as a self-monitoring tool is promising. Cytotoxic treatment with TAC 
decreases physical functioning in all patients with breast cancer and is a risk factor for 
onset of lymphedema one month after cytotoxic treatment. During cytotoxic 
treatment, axillary lymph node dissection increases the risk of onset of lymphedema.  
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Chapter 8.  
 
Summary 
 
Chapter 1 presents the motivation and rationale for this thesis. Starting point of this 
thesis is the Dutch Evidence Statement on Breast cancer, specifically developed for 
physical therapy practice in 2011. An overview is given of the epidemiology of breast 
cancer, its medical treatment and accompanying adverse effects on arm- and 
shoulder function, and the role of the physical therapist. Lymphedema is a specific 
adverse effect of medical treatment of breast cancer with impact on arm- and 
shoulder functioning and quality of life. Lymphedema is a complex problem that can 
occur in any body part. In patients with breast cancer, lymphedema is observed in the 
thorax, breast and arm. It develops because of a dysfunction or interruption of the 
lymphatic system and results in swelling and other impairments in function, activity 
limitations, and participation restrictions . 
This thesis describes the state of the art of identifying and evaluating arm- and 
shoulder problems and  lymphedema,  related to breast cancer treatment. This 
insight will support clinical reasoning of the physical therapist during the treatment 
process, and will reinforce the role of physical therapy interventions in the 
multidisciplinary approach of patients with breast cancer. The main research 
questions for this thesis were: which risk factors for decreased arm- and shoulder 
function are associated with each part of the medical treatment and what is the most 
appropriate method to measure lymphedema in patients with breast cancer before, 
during and after the medical treatment? 
 
Chapter 2 gives an overview of the adverse effects on arm- and shoulder function of 
each medical treatment in patients with breast cancer, and identifies patients at high 
risk. We conducted a systematic literature search, according to the PRISMA 
guidelines. Only studies with a large sample size (n>100) of at least moderate quality 
on patients with stage I-III breast cancer, treated with surgery and additional 
treatments (radiotherapy, chemotherapy and/or hormonal therapy) were included. 
Data on reduced joint mobility, reduced muscle strength, pain, lymphedema and 
limitations in daily activities were extracted from the studies. Outcomes were divided 
in midterm effects within the first 12 months and long-term effects over 12 months 
post-operatively. Reduced range of motion and muscle strength, pain, lymphedema 
and decreased degree of activities in daily living were reported most frequently in 
relation to axillary lymph node dissection. Lumpectomy was related to a decline in 
the level of activities of daily living. Radiotherapy and hormonal therapy were the 
main risk factors for pain.  
Patients with pain have to be monitored carefully, because pain limits the  
daily activities and quality of life. In conclusion, patients treated with axillary lymph 
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node dissection are at the highest risk of developing decreased arm- and shoulder 
function, and require special attention to detect and consequently address decreased 
arm- and shoulder function.   
 
Chapter 3 is part of the development process of the ICF Core Sets for Lymphedema. 
This chapter explores which meaningful concepts, described in the International 
Classification of Functioning and Health (ICF) as 1)body functions and structures, 2) 
activities, 3) participation, 4) environmental factors and 5) personal factors, are 
addressed within lymphedema-specific questionnaires. We included 136 studies, in 
which 51 different questionnaires were used. Twelve of these questionnaires were 
lymphedema-specific: nine for the upper limb, two for the lower limb and one for 
lymphedema in general. In total, 301 meaningful concepts were extracted from the 
lymphedema-specific questionnaires, of which 90% could be linked to the ICF. The 
most frequently measured categories were ‘Structure of upper extremity’, 
‘Immunological system functions’, Looking after one’s health’, ‘Sensation of pain’, 
‘Touch functions’, ‘Dressing’, and ‘Health services, systems and policies’.  
The ICF appeared a valuable resource to classify items from questionnaires, 
which are important for patients with lymphedema. 
 
Chapter 4 describes which measurement instruments are most appropriate in 
measuring and monitoring lymphedema. We selected clinical studies on 
measurement instruments assessing lymphedema. For quality assessment the 
QUADAS-2 scoring instrument was used. Data on reliability, concurrent validity, 
convergent validity, sensitivity, specificity, applicability and costs were extracted from 
the studies and synthesized. Measurement properties were reported mainly in 
relation to lymphedema in the arm. Pooled data showed good intrarater reliability for 
Bio Impedance Spectroscopy in lower extremities, and high  intra- and interrater 
reliability for water volumetry, tape measurement and perometry in upper 
extremities. Interrater reliability of the MoistureMeter in lower extremities was high 
and of the tonometer good. In upper extremities, the smallest detectable change of 
water volumetry was 3.6% (σ = 0.7%), of perometry 5.6% (σ = 2.1%), and of tape 
measurement 6.6% (σ = 2.6%). Sensitivity of tape measurement in upper extremities, 
with water volumetry as index test, varied from 0.73 to 0.90 and specificity from 0.72 
to 0.78, using different cut-off points. Measurement instruments with evidence for 
good reliability and validity are Bio Impedance Spectroscopy, water volumetry, tape 
measurement and perometry. Bio Impedance Spectroscopy can detect alterations in 
extracellular fluid in the early stage of lymphedema. Measurement instruments 
measuring alterations in volume are recommended starting from stage 2.  
Based on costs and feasibility, we concluded that water volumetry and tape 
measurements are recommended as best practice in measuring lymphedema in 
primary practice. For research purposes, based on high reliability and variance, water 
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volumetry is recommended as index test for measuring lymphedema in upper 
extremities.  
 
Chapter 5 examines the detection of lymphedema in the arm by circumference 
measurement of both arms at a single measurement location by tape measurement. 
We examined arm circumferences in a prospective study with measurements at four 
time points before, during and after adjuvant chemotherapy with docetaxel, 
doxorubicin and cyclophosphamide. Volume differences between both arms were 
determined by the 10 cm interval circumference measurement method (index test). 
In a first step, the most valid single measurement location was determined by 
calculating Pearson’s correlations with the index test. In a second step, 
responsiveness for change was analyzed at four time points by repeated 
measurements ANOVA. In a third step, area under the curve was used to determine 
the optimal sensitivity and specificity. Relationship between lymphedema (yes/no) 
and heaviness and swelling (yes/no) was analyzed using Phi-coefficient.  
We concluded that the measurement point 30 cm proximal of the styloid 
process, with a cut-off score of 4%, can be used as point for surveillance for further 
diagnosis of patients at risk for lymphedema. Feelings of heaviness and swelling have 
moderate relationship with lymphedema. Findings of this study have to be confirmed 
in a larger scale study. 
 
Chapter 6 evaluates changes in arm volume and physical functioning during adjuvant 
treatment with docetaxel, doxorubicin and cyclophosphamide (TAC). We conducted a 
prospective study with measurements before chemotherapy (T0), during 
chemotherapy before cycle 2 (T1), cycle 4 (T2), and one month after completion of 
treatment (T3). Volume change was monitored using tape measurements, starting 
from the ulnar styloid process, with 10 cm interval. Lymphedema was defined as ≥ 
10% volume difference. Linear Mixed-effect Models were estimated to analyze 
differences in arm volume and consequences in daily life (total score and domain 
scores of the Lymph-ICF questionnaire) over time, and to identify treatment and 
patient characteristics as predictors for changes in volume.  
We concluded that volume did not change during TAC treatment. One month 
after treatment, volume was significantly increased compared to T0-T2, and 12 
patients (25%) had developed lymphedema. Axillary lymph node dissection was 
predictive for lymphedema. All patients perceived difficulties in activities in daily life 
after treatment, but patients with lymphedema perceived more problems. In patients 
with lymphedema at T3, a significant association between volume and total score on 
the Lymph-ICF questionnaire, on physical function and mobility activities was 
observed. 
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Chapter 7 summarizes the main findings of this thesis. A reflection on our findings is 
given in relation to the risk factors for adverse effects of medical treatment 
modalities, related to limitations in arm- and shoulder functioning, to identify which 
patients need referral to a physical therapist for advice or treatment and at which 
moment, on the validity of measurement of lymphedema, and on patient reported 
outcomes in patients with breast cancer. Thereafter, implications for physical therapy 
practice are described. Finally, strength and limitations of the studies are discussed 
and recommendations for future research are provided.  
Breast cancer treatment has various adverse effects on physical functioning. 
Axillary lymph node dissection, mastectomy and radiotherapy are the most reported 
risk factors. Patients treated with these modalities need monitoring on range of 
motion, muscle strength, pain, lymphedema, and activities in daily living. Cytotoxic 
treatment with TAC decreases physical functioning in all patients with breast cancer 
and is a risk factor for onset of lymphedema one month after cytotoxic treatment. 
During cytotoxic treatment, axillary lymph node dissection increases the risk of onset 
of lymphedema. Water volumetry and tape measurement are reliable and valid 
measurement instruments for measuring and monitoring of lymphedema. In patients 
at risk for onset of lymphedema, measurement at one location, 30 cm proximal from 
the ulnar styloid process, as a self-monitoring tool is promising. 
It is advised to develop a database with a standard set of measurement 
instruments in physical therapy practice and skin care practice. This database will 
support future research on effectiveness of the treatment modalities. As preventive 
strategy for lymphedema, strength training of large muscle groups in combination 
with coordinative exercises and arm resistance exercises have to be explored.   
For the moment, the Lymph-ICF questionnaire can be used to get more insight 
in patients reported outcomes, but questions have to be extended to complaints in 
the breast, apart from the arm. The questionnaire has to be developed further, so it 
can be used in all patients with breast cancer as surveillance instrument and as 
evaluative tool of physical therapy treatment. In relation to diagnosis and treatment 
of breast edema, insight in the incidence of breast edema and factors influencing 
development of edema in the breast need more attention in research. 
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Hoofdstuk 1 beschrijft de doelstelling van deze thesis. Er wordt een overzicht 
gegeven van de epidemiologie van borstkanker, de bijwerkingen van de medische 
behandelingen voor borstkanker op arm- en schouderfunctie en de rol van de 
fysiotherapeut. 
De aanleiding voor deze thesis was de Evidence Statement Borstkanker, 
ontwikkeld in 2011 voor de fysiotherapie. Een specifieke bijwerking van de medische 
behandeling voor borstkanker is lymfoedeem; dit heeft impact op de arm- en 
schouderfunctie en de kwaliteit van leven. Lymfoedeem ontstaat als gevolg van een 
disfunctie of onderbreking van het lymfatische systeem en uit zich in zwelling en 
functionele stoornissen, beperkingen in dagelijkse activiteiten, en 
participatieproblemen. Bij patiënten met borstkanker kan lymfoedeem zich 
ontwikkelen op de thorax, in de borst en in de arm.  
 Deze thesis beschrijft de huidige kennis over arm- en schouderklachten en 
lymfoedeem, gerelateerd aan de behandeling van borstkanker, en hoe deze klachten 
geëvalueerd kunnen worden. Inzicht in deze problemen helpt de fysiotherapeut in 
het klinisch redeneren gedurende het behandelproces en zal de rol van de 
fysiotherapeutische interventie in het multidisciplinaire proces versterken. De 
belangrijkste onderzoeksvragen voor deze thesis waren: welke risicofactoren voor 
verminderde arm- en schouderfunctie zijn gerelateerd aan elke specifieke medische 
behandelmodaliteit en wat is de beste methode om lymfoedeem te meten voor, 
tijdens en na de medische behandeling? 
 
Hoofdstuk 2 geeft een overzicht van de bijwerkingen van de medische 
behandelmodaliteiten bij patiënten met borstkanker op de arm- en schouderfunctie, 
en identificeert hoog-risico patiënten. Er is een systematische review uitgevoerd 
volgens de PRISMA richtlijnen. Er werden studies van minimaal matige kwaliteit 
geïncludeerd, met minstens 100 deelnemers, bij patiënten met borstkanker in 
stadium I – III. De behandeling bestond uit chirurgie en aanvullende behandelingen 
(radiotherapie, chemotherapie en/of hormonale therapie). Uit de studies werden 
data over mobiliteit van de schouder, spierkracht, pijn, lymfoedeem en beperkingen 
in dagelijkse activiteiten geëxtraheerd. Uitkomsten werden verdeeld in effecten met 
betrekking  tot de eerste 12 maanden postoperatief en in effecten langer dan 12 
maanden post-behandeling. Verminderde schoudermobiliteit, verminderde 
spierkracht, pijn, lymfoedeem en een lager niveau in dagelijkse activiteiten werden 
het meest gerapporteerd in relatie tot okselklierdissectie. Ook radiotherapie op de 
oksel is een risicofactor voor verminderde schoudermobiliteit. Okselklierdissectie, en 
wanneer chemotherapie en radiotherapie binnen een bestek van één maand worden 
gegeven, zijn risicofactoren voor verminderde spierkracht. Radiotherapie en anti-
hormonale therapie waren, naast okselklierdissectie, de belangrijkste risicofactoren 
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voor het ontstaan van pijn. Patiënten met pijn moeten goed gemonitord worden, 
omdat pijn leidt tot een lager activiteitenniveau en een lagere kwaliteit van leven. 
Mastectomie en radiotherapie op de oksel,  gelijktijdige behandeling met 
radiotherapie en chemotherapie en wanneer chemotherapie aansluitend op 
radiotherapie gegeven wordt zijn naast okselklierdissectie risicofactoren voor 
lymfoedeem. Okselklierdissectie, lumpectomie en radiotherapie waren, met een wat 
lagere bewijslast, gerelateerd aan een verminderd niveau van dagelijkse activiteiten. 
Het is aangetoond dat patiënten die zijn behandeld met okselklierdissectie, 
het hoogste risico hebben op het ontwikkelen van een verminderde arm- en 
schouderfunctie. Deze patiënten hebben extra aandacht nodig om verminderde arm- 
en schouderfunctie te onderkennen en, als er functionele problemen ontstaan, ze 
consequent te verwijzen voor fysiotherapeutische behandeling. 
 
Hoofdstuk 3 is een onderdeel van de ontwikkeling van de ICF Core Sets voor 
Lymfoedeem. Dit hoofdstuk onderzoekt welke constructen bevraagd worden in 
lymfoedeem-specifieke vragenlijsten. De constructen zijn beschreven volgens de 
International Classification of Functioning and Health (ICF) als 1) lichaamsfuncties en 
structuren, 2) activiteiten, 3) participatie, 4) omgevingsfactoren en 5) persoonlijke 
factoren. Er werden 136 studies geïncludeerd, waarin 51 verschillende vragenlijsten 
gebruikt werden. Van deze vragenlijsten waren er 12 lymfoedeem-specifiek: negen 
voor de bovenste extremiteit, twee voor de onderste extremiteit en één voor 
lymfoedeem in het algemeen. In totaal werden 301 categorieën uit de vragenlijsten 
geëxtraheerd, en 90% hiervan kon gelinkt worden aan het ICF. De meest genoemde 
categorieën waren ‘Structuur van de bovenste extremiteit’, ‘Functies van het 
immunologische systeem’, ‘Propriocepsis’, ‘Pijngewaarwording’, ‘Aankleden’, 
‘Zelfverzorging’,  en ‘Voorzieningen, systemen en beleid met betrekking tot 
gezondheidszorg’. De ICF bleek een waardevolle bron om items uit de vragenlijsten, 
die belangrijk zijn voor patiënten met lymfoedeem, te classificeren. Onderzoek naar 
lymfoedeem vindt voornamelijk plaats in de bovenste extremiteit en lijkt vooral te 
focussen op pijn en zwelling. Er wordt weinig aandacht besteed aan de functies van 
de huid en onderliggende structuren, waarin het lymfesysteem ruim 
vertegenwoordigd is. 
 
Hoofdstuk 4 beschrijft welke meetinstrumenten het meest geëigend zijn om 
lymfoedeem te meten en te monitoren. Om deze vraag te beantwoorden werden 
klinische studies naar meetinstrumenten voor lymfoedeem geselecteerd. De kwaliteit 
van de studies werd beoordeeld met het Quality Assessment of Diagnostic Accuracy 
Studies-2 scoringsinstrument (QUADAS-2). Data over betrouwbaarheid, concurrente 
validiteit, convergente validiteit, sensitiviteit, specificiteit, toepasbaarheid en kosten 
werden uit de studies geëxtraheerd en samengevoegd. 
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Meeteigenschappen werden voornamelijk gerapporteerd in relatie tot lymfoedeem 
in de bovenste extremiteit. Gepoolde data tonen een goede 
intrabeoordelaarsbetrouwbaarheid aan voor Bio Impedantie Spectroscopie (BIS) in de 
onderste extremiteit, en een hoge intra- en interbeoordelaarsbetrouwbaarheid voor 
de waterbakmeting, het meetlint en perometrie in de bovenste extremiteit. In de 
onderste extremiteit is de interbeoordelaarsbetrouwbaarheid van de MoistureMeter 
hoog en van de tonometer goed. In de bovenste extremiteit was het kleinst 
detecteerbare verschil van de waterbakmeting 3.6% (σ = 0.7%), van de perometrie 
5.6% (σ = 2.1%), en van het meetlint 6.6% (σ = 2.6%). Wanneer verschillende 
afkapwaarden gebruikt werden, met de waterbakmeting als indextest, varieerde de 
sensitiviteit van meting met het meetlint in de bovenste extremiteit van 0.73 tot 0.90 
en de specificiteit van 0.72  tot 0.78.  
Meetinstrumenten met evidentie voor een goede betrouwbaarheid en 
validiteit zijn de BIS, de waterbakmeting, het meetlint en perometrie. Bij lymfoedeem 
in stadium 1 kan betrouwbaar gemeten worden met BIS; vanaf stadium 2 met 
watervolumetrie en meetlint en in stadium 3 met de tonometer. Gebaseerd op 
kosten en bruikbaarheid worden als ‘best practice’ in de eerstelijns setting de 
waterbakmeting en het meetlint aanbevolen om lymfoedeem te meten. Voor 
onderzoeksdoeleinden, gebaseerd op een hoge betrouwbaarheid en lage variantie, 
wordt de waterbakmeting aanbevolen als indextest om lymfoedeem in de bovenste 
extremiteit te meten. 
 
Hoofdstuk 5 onderzoekt of lymfoedeem gedetecteerd kan worden door meting van 
beide armen met het meetlint op één enkele locatie. Op vier meetmomenten voor, 
gedurende en na adjuvante chemotherapie met docetaxel, doxorubicine en 
cyclofosfamide (TAC), werd de omvang van de armen gemeten. Als index tests 
werden volumeverschillen tussen beide armen bepaald met de 10 cm interval 
methode. Als eerste stap in de analyse werd de meest valide enkelvoudige 
meetlocatie bepaald door berekening van Pearson’s correlatie coëfficiënt met de 
index test. Als tweede stap werd op de vier meetmomenten de responsiviteit voor 
verandering geanalyseerd met ‘repeated measurements’ ANOVA. Als derde stap 
werd de ‘area under the curve’ gebruikt om de accuratesse en optimale sensitiviteit 
en specificiteit vast te stellen.  
De relatie tussen lymfoedeem (ja/nee) en zwaar gevoel en zwelling (ja/nee) 
werd geanalyseerd met de Phi-coefficiënt. De accuratesse van het meetpunt 30 cm 
proximaal van de processus styloïdeus is hoog. Dit meetpunt kan gebruikt worden om 
patiënten met risico op lymfoedeem te volgen, waarbij 4% verschil tussen de armen 
het afkappunt is voor verdere diagnose. Subjectief gevoel van zwaarte en zwelling 
heeft een matige correlatie met lymfoedeem. De bevindingen van deze studie 
moeten bevestigd worden in een grotere studie. 
 
153 
 
Hoofdstuk 6 evalueert veranderingen in armvolume en fysiek functioneren tijdens 
adjuvante behandeling met docetaxel, doxorubicine en cyclofosfamide (TAC). Er werd 
een prospectieve studie uitgevoerd met meetmomenten vóór chemotherapie (T0), 
tijdens chemotherapie voor de 2e cyclus (T1), de 4e cyclus (T2), en één maand na 
afronding van de behandeling (T3). Volumeveranderingen werden gemonitord met 
metingen met het meetlint met 10 cm interval, beginnend bij de processus styloïdeus 
ulnae. Lymfoedeem was gedefinieerd als ≥ 10% volumeverschil. Linear Mixed-effect 
Models werden gebruikt om verschillen in armvolume en consequenties voor het 
dagelijks functioneren (totale score en domein scores van de Lymf-ICF vragenlijst) in 
de tijd te analyseren, en om patiënt- en behandelkarakteristieken als voorspellers 
voor verandering in volume te schatten. Het volumeverschil veranderde niet 
gedurende de behandeling met TAC. Één maand na de behandeling was het 
volumeverschil significant verhoogd in vergelijking met T0 – T2, en 12 patiënten 
(25%) hadden lymfoedeem ontwikkeld. Okselklierdissectie was voorspellend voor 
lymfoedeem. Na de behandeling ondervonden alle patiënten problemen in de 
dagelijkse activiteiten, maar patiënten met lymfoedeem ondervonden meer 
problemen. Op T3 werd bij patiënten met lymfoedeem een significante associatie 
geobserveerd tussen volume en de totaal score op de ICF vragenlijst en op fysieke 
functies en activiteiten gerelateerd aan mobiliteit (in de zin van verplaatsen). 
 
Hoofdstuk 7 vat de belangrijkste bevindingen van deze thesis samen. Er wordt 
gereflecteerd met betrekking tot de risicofactoren voor de bijwerkingen van de 
medische behandelmodaliteiten in relatie tot beperkingen in arm- en 
schouderfunctie, om te identificeren welke patiënten naar een fysiotherapeut 
moeten worden verwezen voor advies of behandeling en op welk moment. 
Vervolgens wordt gereflecteerd op de validiteit van de meting van lymfoedeem en op 
patiënt gerapporteerde uitkomsten. Daarna worden de implicaties van de 
bevindingen voor de fysiotherapie praktijk beschreven. Ten slotte worden sterke en 
zwakke punten van deze thesis bediscussieerd en worden aanbevelingen gedaan 
voor toekomstig onderzoek.  
De behandeling voor borstkanker heeft verschillende bijwerkingen op het 
fysiek functioneren. Okselklierdissectie, mastectomie en radiotherapie zijn de 
belangrijkste risicofactoren voor fysieke bijwerkingen. Patiënten, die hiermee 
behandeld worden, moeten worden gemonitord op mobiliteit van de schouder, 
spierkracht, pijn, lymfoedeem en activiteiten in het dagelijks leven. Cytotoxische 
behandeling met TAC leidt tot vermindering van fysiek functioneren bij alle patiënten 
met borstkanker en is, een maand na beëindiging van de behandeling, een 
risicofactor voor ontstaan van lymfoedeem. Een maand na de cytotoxische 
behandeling verhoogt okselklierdissectie het risico op het ontstaan van lymfoedeem.  
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De rol van de fysiotherapeut bij patiënten met borstkanker bestaat uit 1) informatie 
en advies, 2) diagnose, 3) behandeling en 4) monitoren en preventie. 
 Informatie en advies wordt idealiter in eerste instantie gegeven door de 
verpleegkundig specialist, die de patiënt informeert over de risico’s op bijwerkingen 
van elke medische behandelmodaliteit en welke problemen deze bijwerkingen 
kunnen geven in het dagelijks leven. Zowel de verpleegkundig specialist als de 
fysiotherapeut hebben een coachende rol om preventieve strategieën, waaronder 
zelfmanagement en een positieve houding ten aanzien van eigen effectiviteit, aan te 
leren en gezondheidsproblemen in een vroeg stadium te detecteren. Voor alle 
patiënten met borstkanker, met en zonder lymfoedeem, is advies over leefstijl 
belangrijk, bestaande uit dagelijks 30 minuten matig intensief bewegen, 
krachttraining en gewichtsbeheersing. Tijdens chemotherapie draagt voldoende 
fysieke activiteit bij aan preventie van afname van de conditie en spierkracht, en 
ondersteunt dit het volhouden van de cytotoxische behandeling. 
Wat betreft diagnose, is het raadzaam alle patiënten met borstkanker te 
monitoren tijdens en na de medische behandelingen, om vroegtijdig problemen met 
fysiek functioneren, pijn en activiteiten in het dagelijks leven te identificeren. Als het 
activiteitenniveau van de patiënt tijdens of na de behandeling daalt, is het raadzaam 
een oncologiefysiotherapeut te consulteren. Objectieve meetuitkomsten en door de 
patiënt gerapporteerde problemen zijn het uitgangspunt voor individuele 
behandeldoelen en behandelmogelijkheden.  
De medische behandeling ontwikkelt zich constant. Daarom wordt 
geadviseerd de literatuur over bijwerkingen van de medische behandeling te blijven 
volgen. Nieuwe evidentie zal moeten worden vertaald naar implicaties voor de 
fysiotherapie praktijk. In toekomstig onderzoek zal meer aandacht besteed moeten 
worden aan de gevolgen van de medische behandeling in relatie tot activiteiten in 
het dagelijks leven en participatie in werk en sociale omgeving. Toekomstig 
onderzoek zal idealiter een grote populatie omvatten, met gebruik making van 
betrouwbare en valide meetinstrumenten, en zal risicofactoren moeten stratificeren 
naar behandelmodaliteit. Aangezien borstreconstructie veelvuldig aangeboden 
wordt, is er een dringende behoefte aan meer informatie over de bijwerkingen van 
deze behandeling. 
 Inmiddels is de multidisciplinaire richtlijn lymfoedeem herzien, waarbij de 
aanbevelingen ten aanzien van het gebruik van meetinstrumenten uit onze 
systematische review zijn overgenomen. Er wordt geadviseerd om de richtlijn 
mammacarcinoom en de Evidence Statement Borstkanker ook te reviseren. Uniforme 
adviezen ten aanzien van de behandeling van lymfoedeem zijn vooral voor de patiënt 
van belang. Daarom wordt ten sterkste geadviseerd, dat de beroepsorganisaties voor 
fysiotherapeuten en huidtherapeuten samenwerken in alle rollen (informatie en 
advies, diagnose, behandeling en preventie). 
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Op dit moment kan de Lymf-ICF vragenlijst worden gebruikt om inzicht te krijgen in 
de patiënt gerapporteerde uitkomsten. Echter, naast klachten in de arm, zullen de 
vragen moeten worden uitgebreid naar klachten in de borst. De vragenlijst zal in de 
toekomst doorontwikkeld moeten worden, zodat deze kan worden gebruikt bij alle 
patiënten met borstkanker als diagnostisch en als evaluatief meetinstrument tijdens 
alle fases van de fysiotherapeutische behandeling. In relatie tot de diagnose en 
behandeling van oedeem in de borst wordt geadviseerd meer aandacht te besteden 
aan onderzoek ten aanzien van de incidentie en de factoren die het ontstaan van 
oedeem in de borst beïnvloeden.  
Er wordt geadviseerd om een database te ontwikkelen met een standaard set 
meetinstrumenten in de fysiotherapie- en huidtherapie praktijk. Deze database kan 
toekomstig onderzoek naar de effectiviteit van behandelmogelijkheden in relatie tot 
lymfoedeem ondersteunen. Als preventieve strategie voor lymfoedeem zal 
krachttraining van grote spiergroepen in combinatie met coördinatietraining en 
weerstandstraining voor arm- en schouderspieren moeten worden onderzocht. 
Het is aan te bevelen meer onderzoek te doen naar een betrouwbare 
diagnose en effectiviteit van de mogelijke behandelvormen bij borstoedeem, waarbij 
inzicht in de incidentie van borstoedeem en in factoren, die ontstaan van 
lymfoedeem beïnvloeden prioriteit hebben. Tot op heden is er geen eenvoudig 
meetinstrument voor midline lymfoedeem. Als er een betrouwbaar, valide en 
bruikbaar meetinstrument onderzocht is, wordt aangeraden om behandelstrategieën 
voor midline lymfoedeem te ontwikkelen. 
 
  
157156
156 
 
Dankwoord 
 
Allereerst wil ik mijn begeleiders bedanken voor hun vertrouwen, dit promotietraject 
met mij te zijn ingaan, na afronding van de Evidence Statement voor Borstkanker. Zo 
kreeg ik de gelegenheid gebruik te maken van de expertise, gastvrijheid en 
collegialiteit van de collega’s van de afdelingen IQ Healthcare en Fysiotherapie 
Centraal. De inzet van Carien en Peter bij het lezen en beoordelen van de vele 
artikelen voor de systematische reviews is van onschatbare waarde geweest. Wilmy 
en collega’s van de afdeling Medische Oncologie ben ik veel dank verschuldigd voor 
het rekruteren van patiënten voor de TAC-studie, en Carien en Riet voor de metingen 
voor deze studie. Dank aan, en respect voor alle patiënten, die aan de studie 
meegewerkt hebben en 4 x extra tijd aan ons gegeven hebben tijdens hun intensieve 
chemotherapie. Naast de promotiecommissie wil ik Monique bedanken voor het 
meelezen en corrigeren van het Engels, en de ondersteuning bij het Engels spreken 
tijdens het ILF congres in Rotterdam. Tot slot wil ik Marijke bedanken voor haar out-
of-the-box idee om patiënten met lymfoedeem op één punt te meten en je hulp bij 
het invoeren van data in SPSS. Een speciaal woord van dank is er voor Marjon, die in 
haar atelier heeft geholpen mijn illustratie vorm te geven. 
Promotieteam, zonder jullie input en feedback was dit proefschrift er niet 
gekomen. Voor mij was het, zeker de laatste jaren, puzzelen om de 
onderzoeksactiviteiten te combineren met het onderwijs en mijn patiëntgebonden 
activiteiten, waardoor het soms lastig was me te blijven focussen. Heel veel dank 
voor alle tijd en feedback. Carien, je was er altijd voor mij, las zo ongeveer elke versie 
van mijn artikelen en zette letterlijk de puntjes op de i. Je steunde me in moeilijke 
periodes, was streng voor me als het nodig was. Je was vooral hartelijke en gastvrij. 
Ria, ondanks je drukke werkzaamheden, heb je veel tijd aan de analyse en rapportage 
van onze onderzoeken besteed. Jouw vertrouwen kan ik niet genoeg waarderen. In 
onze discussies stuurde je me soms alle kanten op, om vooral breed en open minded 
te blijven denken. Hanneke, je verhuisde al snel naar Amsterdam, waardoor het 
contact vooral telefonisch en via de mail verliep. Fantastisch dat je zeer regelmatig 
inbelde tijdens onze besprekingen. Jouw motto gestructureerd en snel is bij mij niet 
gelukt. Je heldere vragen, kennis en ondersteuning waren van grote waarde. Jouw 
aanwezigheid in het promotieteam maakte onze publicaties vakoverstijgend. Philip, 
jij kwam wat later in het promotieteam. Door je kennis en gerichte feedback heb je 
me regelmatig een zet in de goede richting gegeven. Je was heerlijk to the point en 
gestructureerd, waardoor ik hoofd- en bijzaken kon onderscheiden. Regelmatig gaf je 
me een zetje in de goede richting, waardoor ik vertrouwen in het promotieproces 
bleef houden. Jullie als promotieteam hebben soms veel geduld moeten hebben, en 
uiteindelijk hebben we samen artikelen gepubliceerd, waar ik trots op ben en die de 
zorg voor patiënten met borstkanker hopelijk nog verder verbeteren. 
157 
 
Een speciaal woord van dank wil ik richten aan de patiënten. De CARE-groep van 
Arcus Fysiotherapie was de eerste groep patiënten, waarbij ik evidence based en 
gericht op de persoonlijke doelen probeerde te handelen. Patiënten hebben mij het 
vertrouwen gegeven, dat ik in de goede richting denk en handel. Ik kreeg de 
gelegenheid, al mijn nieuwsgierige vragen te stellen, mijn theorieën in de praktijk toe 
te passen en te onderzoeken. Na Zutphen, kon ik mijn passie voor de 
oncologiefysiotherapie verder uitbouwen in Maastricht en vooral in Deventer. 
Regelmatig werkten jullie mee aan projecten van deelnemers van de masteropleiding 
oncologiefysiotherapie van Avans+, en hielpen zo mee jullie klachten, ervaringen en 
gedachten beter te doorgronden en de oncologiefysiotherapie verder te 
onderbouwen. Voor wat betreft dit laatste waren de deelnemers van de TAC-studie 
van onschatbare waarde. 
 Avans+ gaf mij de gelegenheid mijn kennis te delen en te discussiëren met de 
deelnemers van zowel de masteropleiding oncologie als geriatrie over 
oncologiefysiotherapie. Docenten, door jullie verscheidenheid aan achtergronden 
voegen jullie veel toe aan de gespecialiseerde fysiotherapie. Gerben, door jou ben ik 
veel creatiever in aanbiedingsvormen van oefentherapie geworden. Hoofddocenten 
en docenten van masterclasses C en D, met jullie heb ik mijn wetenschappelijke skills 
verder uitgebouwd. Bij alle aspecten van het onderwijs (ontwikkelen, coachen, 
activiteiten tijdens bijeenkomsten) heb ik altijd het vertrouwen van de organisatie 
gekregen, waarbij Yvonne en collega’s mij op alle fronten ondersteund hebben.  
Mijn familie heeft mij meer achter de computer gezien dan hun lief was. Na 
een dag Nijmegen heb ik regelmatig de slaap van mijn lieve man Geert verstoord, 
omdat mijn hoofd bleef analyseren. Ik kan niet beloven, dat dit vanaf nu gaat 
stoppen, maar hoop er wel meer voor jullie te zijn. Pap kan de promotie helaas niet 
meer meemaken. In gedachten zie ik hem tijdens de diplomering in Leuven: wat was 
hij trots! De afgelopen jaren heeft mijn moeder in toenemende mate zorg nodig. 
Gelukkig kan die zorg met mijn beide zussen gedeeld worden. Er is een nieuwe 
generatie op komst, zo gaat het leven door. De komende tijd hoop ik meer in de 
gelegenheid te zijn om te genieten van de goede dingen van het leven en er te zijn 
voor mijn naasten. 
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